

Denis Nash, PhD, MPH
Curriculum Vitae

1. DATE OF PREPARATION OF C.V. September 2026

2. PERSONAL DATA:

Office address: CUNY Graduate School of Public Health and Health
Policy
55 West 125th Street, 6th Floor
New York, NY 10027

E-Mail: denis.nash@sph.cuny.edu

3. ACADEMIC TRAINING

8/95-5/99: University of Maryland
Degree: Doctor of Philosophy, Epidemiology and Preventive Medicine
Thesis title: Lead and menopause: Latent re-exposure to lead stored in bone and health
consequences
Advisor: Ellen K. Silbergeld, Ph.D.

6/93-6/95: Johns Hopkins University School of Hygiene and Public Health
Degree: Master of Public Health, Epidemiology
Advisor: Moyses Szklo, MD, DrPH

9/86-6/91: Drexel University, Philadelphia, PA
Degree: Bachelor of Science, Physics and Atmospheric Science - Cum Laude

4. TRAINEESHIP/POSTDOCTORAL TRAINING:

7/99-7/01: Epidemic Intelligence Service (EIS) Officer

Centers for Disease Control and Prevention, U.S. Public Health Service
Assignment location: New York City Department of Health, New York, NY

1997-1998: Heinz Family Foundation Predoctoral Fellow

Program in Human Health and the Environment, University of Maryland School of Medicine,
Baltimore, MD

5. LICENSURE AND CERTIFICATION:

HIPAA
Good Clinical Practice, Epidemiology and Social Behavior
Human Subjects Research

6. MILITARY/UNIFORMED SERVICE

June 1999 – June 2001. US Public Health Service, Centers for Disease Control and Prevention,
Stationed in New York, NY (Honorably discharged. Rank: Lieutenant Commander, O-4)

7. MEMBERSHIP IN SOCIETIES (past and present):

IAPAC International Association of Providers of AIDS Care
CSTE Council of State and Territorial Epidemiologists

Denis Nash
Curriculum Vitae

SER	Society for Epidemiologic Research
APHA	American Public Health Association
ATPM	Association of Teachers of Preventive Medicine
IAS	International AIDS Society

8. ACADEMIC APPOINTMENTS:

2025—2026	Visiting Professor, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, Paris, France
2016—present	Founding Executive Director, Institute for Implementation Science Research in Population Health, City University of New York (CUNY), New York, NY
2018—present	Distinguished Professor of Epidemiology (with tenure), CUNY School of Public Health
2016—2018	Professor of Epidemiology (with tenure), CUNY School of Public Health
2015—present	Adjunct Professor of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY
2010—2022	Adjunct Associate Professor of Epidemiology, Columbia University Mailman School of Public Health, New York, NY
2013—2016	Executive Officer, Doctor of Public Health Programs, CUNY Graduate Center, New York, NY
2012—2016	Professor of Public Health, CUNY Graduate Center, New York, NY
2012—2016	Associate Professor of Epidemiology (with tenure), Hunter College, School of Urban Public Health, New York, NY
2011—2012	Associate Professor of Public Health, CUNY Graduate Center, New York, NY
2010—2012	Associate Professor of Epidemiology (with tenure), Hunter College, School of Urban Public Health, New York, NY
2006—2010	Associate Professor of Epidemiology, Columbia University Mailman School of Public Health, New York, NY
2004—2006	Assistant Professor of Epidemiology, Columbia University Mailman School of Public Health, New York, NY
2003-2004:	Investigator, Center for Urban Epidemiologic Studies, New York Academy of Medicine, New York, NY
1999—2004	Adjunct Assistant Clinical Professor Department of Community Medicine, Mt. Sinai School of Medicine, New York, NY

9. PROFESSIONAL POSITIONS AND ADMINISTRATIVE RESPONSIBILITIES

2021-present	Founder and CEO, Epidemic Intelligence, LLC, New York, NY
2017-present	Associate Director-Einstein, Rockefeller-CUNY Center for AIDS Research (CFAR)
2016-present	Executive Director, CUNY Institute of Implementation Science in Population Health
2013—present	Dean's Cabinet, CUNY School of Public Health
2025—present	Co-Chair, Implementation Science Working Group, International Epidemiologic Databases to Evaluate AIDS (IeDEA) network
2009—2025	Chair, Global Site Assessment Working Group, International Epidemiologic Databases to Evaluate AIDS (IeDEA) network

Denis Nash, PhD, MPH
Curriculum Vitae

2013—2022	Director, Public Health Policy and Practice Core, HIV Center for Clinical and Behavioral Studies, Columbia University
2008 – 2022	Member, Statistics, Epidemiology, and Data Management (SED) Core, HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University
2016 – 2017	Chair, Faculty Search Committee for Associate Director of the CUNY Institute for Implementation Science in Population Health
2013 – 2016	Executive Officer, Doctor of Public Health Programs, CUNY SPH, New York, NY
2005 – 2015	Editor, Surveillance Section, Journal of HIV/AIDS Surveillance and Epidemiology
2008 – 2015	Member, New York City Department of Health and Mental Hygiene General Preventive Medicine Residency Advisory Committee
2000 - 2015	Member, Mt. Sinai School of Medicine General Preventive Medicine Residency Advisory Committee
2013	Member, Search Committee for Hunter College Associate Provost for Research
2013	Member, Search Committee for Hunter College Center for HIV Educational Studies and Training (CHEST), Faculty Search Committee
2012—2013	Chair, Admissions Committee, CUNY SPH Doctoral Program, CUNY School of Public Health
2011—2012	Chair, Biostatistics Faculty Search Committee, Epidemiology and Biostatistics Program (Hired Xiaowei Yang, PhD, at the Associate Professor level)
2011 – 2013	Track Coordinator, Epidemiology Doctoral Program, CUNY School of Public Health
2007 – 2010	Member, Mailman School of Public Health School-wide Faculty Steering Committee
2007 – 2010	Public Health Reports, ASPH Advisory Committee
2005 – 2010	Member, Mailman School of Public Health, Department of Epidemiology Diversity Committee
2004 – 2010	Leadership Team, International Center for AIDS Care and Treatment Programs (ICAP)
2004 – 2010	Center for Infectious Disease Epidemiologic Research (CIDER) training committee
2004 – 2010	Director, Monitoring, Evaluation, and Research Unit, International Center for AIDS Care and Treatment Programs (ICAP), Columbia University, MSPH.
2002 – 2004	Steering Committee Member, Global AIDS Technical Assistance Program, National Alliance of State and Territorial AIDS Directors (NASTAD)
2001-2003:	Director, HIV/AIDS Surveillance Unit, HIV/AIDS Surveillance and Epidemiology Program, NYC Department of Health and Mental Hygiene, New York, NY.

Advisory Boards

April 2026	Scientific Advisory Board, Long COVID, Pfizer, Inc., Munich, Germany
April 2023	Scientific Advisory Board, Long COVID, AbbVie
December 2022	Scientific Advisory Board, Long Acting Injectable ART, Gilead Sciences
2020-2025	Scientific Advisory Board, NYC Contact Tracing Program Evaluation
2020-2025	Scientific Advisory Board, NYC Transit Worker Pandemic Preparedness Study
2019-present	Scientific Advisory Board, District of Columbia HIV Cohort Study (DC Cohort)

Denis Nash

Curriculum Vitae

- 2016-2023 Co-Chair, Surveillance and Metrics Committee: New York State Hepatitis C Elimination Steering Committee (appointed by Governor and State Health Commissioner)
- 2014-2015 Member of Governor Cuomo's Task Force to End the AIDS Epidemic in New York State (appointed by Governor and State Health Commissioner)

National Institutes of Health Service

- 2022 – 2024: Chair, Time-sensitive Opportunities for Health Research Study Section
- 2020 – 2024: Population Health Approaches to HIV/AIDS (PPAH) Study Section (ad hoc member)
- 2018 – 2020: Population Health Approaches to HIV/AIDS (PPAH) Study Section (standing member)
- 2015 – 2018: Behavioral and Social Science Approaches to Preventing HIV/AIDS Study Section
- 2010 – 2015: trans-NIH Natural History and Epidemiology Research Planning Group
- 2015: Behavioral and Social Science Approaches to Preventing HIV/AIDS Study Section – Ad hoc reviewer;
- 2014: Behavioral and Social Consequences of HIV/AIDS Study Section - Ad hoc reviewer
- 2013: RFA Panel: Methodologies and Formative Work for Combination HIV Prevention Approaches
- 2011: NIDA-PEPFAR Study Section (November, 2011)

Centers for Disease Control Service

- 2010: Special Emphasis Panel, National HIV Behavioral Surveillance (NHBS)
- 2010: Special Emphasis Panel, Kenya Medical Research Institute (KMRI)

Other Service

- 2023 Chair, State of California AIDS grant proposal review panel (January, 2023)
- 2022 Chair, State of California AIDS grant proposal review panel (June, 2022)
- 2011 Grant proposal reviewer, PSC-CUNY Research Award Program
- 2010 Grant proposal reviewer, Alfred P. Sloan Foundation

Editorial

- 2018-present: Editorial Board, Journal of the International AIDS Society (JIAS)
- 2018: Guest Editor, Journal of Virus Eradication, Special issue on Identifying Research Priorities to Inform HIV Treat All Policy Implementation in sub-Saharan Africa
- 2007-2012: Editor, Surveillance Section, Journal of HIV/AIDS Surveillance and Epidemiology
- 2006-2010: ASPH Advisory Committee, Public Health Reports

10. HONORS AND AWARDS:

- 2025-26: Fulbright Scholarship: Fulbright-Tocqueville Distinguished Chair Award, Institut Pierre Louis d'Epidémiologie et de Santé Publique Sorbonne Université, Paris, France
- 2010-17: City University of New York, Salute to Scholars
- 2002: James H. Nagano Citation for an outstanding CDC scientific publication in 2001, National Center for Infectious Diseases, CDC
- 2002: CDC, Charles C. Shephard award finalist, for CDC's best epidemiologic publication in 2001: The outbreak of West Nile virus infection in the New York City area in 1999. **Nash D**, Mostashari F, Fine A, et al. N Engl J Med. Jun 14 2001;344(24):1807-1814.

Denis Nash, PhD, MPH
Curriculum Vitae

- 2001: Secretary's Award for Distinguished Service (West Nile outbreak response): U.S. Department of Health and Human Services
- 2001: Honor Award: Centers for Disease Control, National Center for Infectious Diseases
- 2001: Outstanding Unit Citation: U.S. Public Health Service for work on the 1999 West Nile outbreak
- 1995: John C. Hume Award: Johns Hopkins School of Public Health (nominated)
- 1995: Delta Omega: National Public Health Honor Society (nominated)
- 1991: Sigma Pi Sigma: National Physics Honor Society
- 1988: Dean's List, Drexel University 88-89 and 89-90

11. FELLOWSHIP AND GRANT SUPPORT:


I have been continuously funded as a research investigator since 2002. Over my career I have served as principal investigator, multiple principal investigator, or co-principal investigator on 31 research grants, representing more than \$68 million in total awards (approximately \$40 million as an NIH PI or MPI). This externally funded portfolio spans five NIH institutes (NIAID, NIMH, NIDA, NHLBI, and NIEHS) as well as the CDC, industry, and private foundations, and has grown from a foundation in HIV/AIDS epidemiology and the global scale-up of HIV care and treatment into the epidemiology of COVID-19 and other respiratory viruses (from 2020) and, most recently, the population-health impacts of climate change and extreme weather events (from 2023).

Denis Nash

Curriculum Vitae

Two decades of continuous NIH-led research funding, expanding across domains

Denis Nash — grants held as PI, MPI, or co-PI (n=30 with dated awards). Bars show award periods; dollar figures mark awards ≥\$1M.



Source: CV grants database reconciled with NIH RePORTER (Jul 2026). HIV core funding sustained since 2002; COVID/respiratory from 2020; climate & extreme weather from 2023.

Figure. Two decades of continuous NIH-led research funding, expanding across domains (see grants database for detail).

Fellowship

- 2025-2026: **Fulbright Scholar** - Fulbright-Tocqueville Distinguished Chair, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, Paris, France
- 2004-2008: **National Health Disparities Research Fellow**, National Institute of Health, Competitive Loan Repayment and student loan forgiveness program
- 1999-2001: **Epidemic Intelligence Service Officer**, Epidemiology Program Office, Centers for Disease Control and Prevention. Based at the New York City Department of Health, HIV/AIDS Surveillance Program, New York, NY

Pending grants

#	Period	Award #	Title	Role	Sponsor	Total
1	Submitted Feb 2025	None	Large-scale, hospital-based wastewater surveillance (WWS) as a strategy for early pandemic detection: Baseline and beyond	PI	NIH/NIAID	

Denis Nash, PhD, MPH
Curriculum Vitae

2	Submitted Feb 2025	None	Causal Effects of Extreme Weather on Mental Health: A Multi-Method Study	PI	NIH/NIEHS	
----------	--------------------	------	--	----	-----------	--

Current grants

#	Period	Award #	Title	Role	Sponsor	Total
1	03/2026–12/2027	(no number)	Sustaining Independent Public Health Surveillance: The C3 Cohort as a National Platform for Vaccine Behavior, Long COVID, and Emerging Public Health Threats	PI	Schmidt Initiative for Long COVID	\$300,000
2	08/2023–07/2027	R01 AI179420	Understanding and Mitigating the Influence of Extreme Weather Events on HIV Outcomes: A Global Investigation	MPI	NIH/NIAID	\$3,282,156
3	04/2023–02/2025	R21AI177008	Developing Statistical Methods on Event History Data Subject to Data Complexities for HIV Disease Progression and Policy Evaluation	MPI	NIH/NIAID	\$458,212
4	09/2022–08/2025	R01MH132360	Brief digital intervention to increase COVID-19 vaccination among individuals with anxiety or depression	MPI	NIH/NIMH	\$3,324,957
5	12/2021–06/2027	Pfizer (industry)	Acute and post-acute sequelae of COVID-19 and other major respiratory infections	PI	Pfizer Inc.	\$19,716,913
6	07/2021–06/2026	R01MH125735	Strengthening the Safety Net: Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program	MPI	NIH/NIMH	\$3,299,564
7	05/2023–04/2024	R01MH125735S1	Developing Informed-consent Standards through a COMMunity-driven deliberative democracy process (DISCO) for Data to Suppression (D2S)	MPI	NIH/NIMH	\$264,855
8	07/2021–04/2028	U01AI096299	Central Africa International Epidemiology databases to Evaluate AIDS (CA-IeDEA)	MPI	NIH/NIAID	\$20,500,000
9	07/2023–04/2024	U01AI096299S	Catalyzing a research agenda around climate and HIV care outcomes: A supplement proposal for the IeDEA Network	PI	NIH/NIAID	\$555,404
10	05/2023–04/2027	P30 AI124414	The Einstein, Rockefeller, CUNY Center for AIDS Research (CFAR)	Co-I	NIH/NIAID	\$18,740,615
11	04/2021–04/2026	R24 AI124872-07	A Scalable Toolkit for Standardizing and Coordinating Data Sharing Across International Research Networks	Co-I	NIH/NIAID	\$8,275,232
12	04/2021–09/2024	R34 MH126809	Assessing Perceptions and Preferences around Long-acting Injectables (APLI) in the Ryan White HIV/AIDS Program	MPI	NIH/NIMH	\$618,939
13	03/2022–02/2027	UG3AI69652	Optimizing HIV prevention for highly vulnerable	Co-I	NIH/NIAID	\$12,612,524

Denis Nash Curriculum Vitae

			methamphetamine-using sexual minority men			
14	09/2022–09/2025	R01DA057654	Expansion of Mail-Delivered Harm Reduction Services in the U.S.	Co-I	NIH/NIDA	\$3,250,307
15	08/2018–06/2028	R01HL143788	A longitudinal cohort study to evaluate cardiovascular disease (CVD) risk factors and disease in Haiti	Co-I	NIH/NHLBI	\$5,460,789

Completed grants

#	Period	Award #	Title	Role	Sponsor	Total
1	02/2021–01/2024	R21 AI147933	Obtaining population-based estimates of the timing of antiretroviral therapy initiation using HIV surveillance data: Change-point model development, validation, and dissemination	MPI	NIH/NIAID	\$446,204
2	09/2019–07/2024	R01DA027379	Feasibility and Acceptability of HIV, HCV, and Opioid Use Disorder Services in Syringe Service Programs	Co-I	NIH/NIDA	\$3,445,000
3	02/2018–01/2023	R01 MH117793	HIV care coordination intervention: comparative effectiveness of a revised vs. original intervention and usual care	PI	NIH/NIMH	\$2,790,000
4	06/2020–05/2022	UH3 AI133675	The CHASING COVID Cohort Study (COVID supplement)	PI	NIH/NIAID	\$3,400,000
5	07/2017–06/2018	R13AI134393	Conference Grant: All-Africa IeDEA meeting on universal testing and treatment (Kigali, Rwanda)	PI	NIH/NIAID	
6	07/2017–06/2018	UG3AI133675	Together 5000 (T5000)	Co-I	NIH/NIAID	
7	05/2017–04/2022	P30 AI124414	Einstein Rockefeller CUNY Center for AIDS Research (ERC-CFAR)	Co-I	NIH/NIAID	
8	07/2016–06/2022	5U01AI096299	Central Africa International Epidemiologic Databases to Evaluate AIDS (CA-IeDEA)	PI	NIH/NIAID	\$1,927,944
9	02/2013–01/2018	P30 MH043520	HIV Center for Clinical and Behavioral Studies	Co-I	NIH/NIMH	\$186,249
10	09/2013–06/2018	5 R01 MH101028-02	HIV care coordination: comparative effectiveness, outcome determinants, and costs	PI	NIH/NIMH	\$2,506,127
11	10/2014–03/2018	4895-01	End of the Epidemic Data Center	PI	Health Research, Inc. (New York State DOH)	\$1,530,754
12	07/2018–06/2023	PAR-17-470	The Haiti Cardiovascular Disease Cohort Study	Co-I	NIH (CUNY subaward)	\$374,430
13	05/2010–04/2015	1R01MH089831-01A1	Multi-level determinants of late ART initiation in sub-Saharan Africa	PI	NIH/NIMH	\$2,499,000

Denis Nash, PhD, MPH
Curriculum Vitae

14	10/2013–09/2016	PCORI (no number)	Impact of patient navigators on health education and quality of life among formerly incarcerated persons	Co-I	PCORI	\$130,467
15	10/2010–09/2013	R01 MH089831-01A1S1	Retention and engagement in care of patients prior to ART initiation (PEPFAR Administrative Supplement)	Co-PI	NIH/NIMH	\$287,000
16	01/2014–12/2015	P30-MH43520 (pilot)	Barriers to linkage/re-linkage to HIV care among STD clinic attendees in NYC	PI	NIH/NIMH	\$19,000
17	12/2012–11/2013	1 R49 CE002096	Incidence and risk factors for injuries among firefighters at the Fire Department of New York (FDNY)	PI	CDC / Center for Injury Epidemiology and Prevention, Columbia University	\$10,000
18	02/2007–01/2012	2P30 MH043520-20	HIV Center for Clinical and Behavioral Studies	Co-I	NIH/NIMH	
19	09/2011–08/2015	1 H97 HA2269301-00	Systems Linkages and Access to Care for Populations at High Risk of HIV Infection Initiative - Demonstration States	Co-I	HRSA	\$900,000
20	09/2012–08/2015	Canadian NIH (no number)	Determinants of late initiation and treatment interruption in the context of HAART expansion in British Columbia, Canada	Co-I	Canadian NIH	
21	12/2011–11/2015	1U62PS003692-01	Positive Pathways Project	Co-I	CDC	\$60,000
22	09/2013–08/2015	CDC Cooperative Agreement (EDC subcontract)	Maximizing Online Dissemination and E-Learning of HIV Care Strategies (MODEL HIV Care Strategies)	Co-I	CDC	
23	07/2011–06/2013	U01AI069911-01	International Epidemiological Databases to Evaluate AIDS (IeDEA), Eastern Africa Region	Co-I	NIH/NIAID	\$15,000
24	07/2009–06/2011	U01AI069927	International Epidemiological Databases to Evaluate AIDS (IeDEA), Central Africa Region	Co-I	NIH/NIAID	
25	09/2010–09/2015	U2GPS0033031	Technical Assistance for HIV-related Strategic Information in the Central Asian Republics (Kazakhstan, Kyrgyzstan, Uzbekistan, Tajikistan, Turkmenistan)	PI	CDC	\$2,000,000
26	09/2010–09/2015	U2GPS002828-01	Technical Assistance for HIV-related Strategic Information in Mozambique	PI	CDC	\$240,000
27	09/2001–09/2010	1 T32 AI49821-01	Training in the Epidemiology of Infectious Diseases	Co-I	NIH/NIAID	
28	02/2004–09/2010	U62/CCU223540	President's Emergency Plan for AIDS Relief (PEPFAR) - expand HIV Care and Treatment	Co-I	CDC	
29	07/2003–09/2010	GPO-A-00-03-00001	Expansion of the MTCT-Plus Initiative	Co-I	USAID	
30	09/2002–09/2010	U62 CCU222407	Global AIDS Project, University Technical Assistance Program	Co-I	CDC	

Denis Nash
Curriculum Vitae

31	01/2002–09/2010	The MTCT Plus Initiative (no number)	The MTCT-Plus Initiative	Co-I	Multiple Foundations	
32	01/2007–12/2008	(no number)	International Epidemiological Databases to Evaluate AIDS (IeDEA), Southern Africa Region	Co-I	NIH/NIAID	
33	03/2006–12/2009	Operations Research on AIDS Care and Treatment in Africa	Identifying optimal approaches to HIV care and treatment in Africa	PI	Doris Duke Charitable Foundation	\$200,000
34	None–None	ART-LINC (no number)	Anti-retroviral therapy in low-income countries (ART-LINC) Consortium	Co-I	NIH (OAR) and French ANRS	
35	01/2003–12/2003	U62/CCU206208	Core HIV/AIDS Surveillance	PI	CDC	\$3,067,389
36	01/2003–12/2003	U62/CCU206208	HIV Incidence Surveillance	PI	CDC	\$660,906
37	09/2002–09/2004	U62/CCU220961	Evaluation of integrated HIV/AIDS Surveillance	PI	CDC	\$350,000
38	09/2002–09/2003	U62/CCU206208	Sampling for transmission risk	PI	CDC	\$50,000
39	09/2003–08/2004	U62/CCU206208	AIDS Progression Project, Case Control	Co-PI	CDC	\$83,233
40	09/1998–06/1999	TS 288-14/14	Bone and blood lead and toxicity among peri-menopausal women	Co-I	CDC / Association of Teachers of Preventive Medicine	\$100,000

12. TEACHING EXPERIENCE AND RESPONSIBILITIES:

Courses Taught

2025	EPID 897-02 – Independent Study for PhD students: A causal framework for health equity in implementation science
2024	EPID 897-07 – Independent Study for PhD students: A seminar course on implementation science for epidemiologists
2011-Present	EPID 626 – Infectious Disease Epidemiology, CUNY School of Public Health
2011-Present	EPID 643 – Public Health Surveillance, Principles and Practice, CUNY School of Public Health
2013-Present	PUBH 900 – PhD Dissertation Supervision
2017-Present	CFAR Implementation Science Fellowship Program, lecture on implementation outcomes and the role of implementation science in health equity
2012-2015	Dissertation Research Seminar, CUNY Graduate Center
2005-2014:	EPID P6400, Principles of Epidemiology (Lecturer for Infectious Disease Epidemiology, Fundamental Concepts in Epidemiology, Bias and Confounding, Causal Inference), Columbia University Mailman School of Public Health
2012-2014	Public Health Surveillance, Principles and Practice, Epidemiology and Population Summer Institute at Columbia University
2012	Advanced Research Seminar 1, CUNY Graduate Center (co-Instructor)
2010	PH 753 – Principles of Epidemiology, CUNY School of Public Health at Hunter College

Denis Nash, PhD, MPH
Curriculum Vitae

2007-2010	EPID 8430 – Public Health Surveillance: Principles and Practice (Course Director), Columbia University Mailman School of Public Health
2005-2010	P8488 – Research in Developing Countries (Lecturer on Surveillance), Columbia University Mailman School of Public Health
2005-2010:	EPID P8474, Infectious Disease Epidemiology (Lecturer on Surveillance), Columbia University Mailman School of Public Health
2004-2007:	EHS P6300, Environmental Health Sciences (Lecturer on Field Studies), Columbia University Mailman School of Public Health
2001-2005:	Infectious Disease Epidemiology (Course Director), Mount Sinai School of Medicine

Student mentoring and training

Over the past two decades, I have mentored approximately 90 trainees across the graduate and early-career pipeline, including roughly 37 master's students, more than 20 doctoral students, and 7 post-doctoral or clinical fellows. Among these, I have supervised 16 PhD students directly as primary advisor, dissertation sponsor, or committee chair (4 currently in training), and have served on numerous additional doctoral dissertation committees, including students at CUNY, the University of Geneva, and the University of Cape Town. I have also mentored or co-mentored at least 9 NIH K-awardees, including K01, K08, and K23 awardees, and served as a mentor on a mid-career K24 award. Many of these mentees now hold leadership roles in health departments, universities, and research institutes.

PhD students supervised directly (as primary advisor, dissertation sponsor, or committee chair):

#	Name	Program & institution	Period	Dissertation title	Current position
1	Rebecca Zimba	Epidemiology, CUNY SPH	2021-present	<i>In progress</i>	CUNY ISPH
2	Avantika Srivastava	Epidemiology, CUNY SPH	2021-present	<i>In progress</i>	CUNY ISPH
3	Faisal Abdelqader	Epidemiology, CUNY SPH	2021-present	<i>In progress</i>	CUNY / NYC DOHMH
4	Ellen DuPont	Epidemiology, CUNY SPH	present	<i>In progress</i>	[to be added]
5	Yanhan (Jenny) Shen	Epidemiology, CUNY SPH	2020-2025	Understanding Long COVID in a National Community-Based Cohort	CUNY ISPH
6	Saba Qasmieh	Epidemiology, CUNY SPH	2020-2024	Application of methods to population-based surveys to reduce bias in estimates of SARS-CoV-2 infection burden	CDC EIS Officer
7	Sarah Walters	Environmental Health, CUNY SPH	2013-2023	<i>[Dissertation title to add]</i>	NYC DOHMH, Epidemiology Services
8	Matthew Romo	Epidemiology, CUNY SPH	2016-2022	The Global Implementation of Dolutegravir for HIV Treatment	CUNY ISPH
9	Ellen Brazier	Epidemiology, CUNY SPH	2016-2022	Factors Associated with Racial and Ethnic Disparities in Cesarean Delivery among Women with Low-Risk Pregnancies at New York City Hospitals, 2012-2017	CUNY ISPH
10	Ashly Jordan	Epidemiology, CUNY SPH	2013-2020	Novel Hepatitis C Virus (HCV) Community Viral Load Measures, HCV Incidence and Prevalence	Center for Drug Use and HIV Research
11	McKaylee Robertson	Epidemiology, CUNY SPH	2014-2019	Trends in the Timeliness of HIV Diagnosis and Antiretroviral Treatment Initiation Before, During and After the	CUNY ISPH

Denis Nash **Curriculum Vitae**

				'Treat All' Recommendation, New York City, 2006-2015	
12	Olga Tymejczyk	Epidemiology, CUNY SPH	2013-2019	Hypertension and HIV in an Urban Slum Setting, Port-au-Prince, Haiti	CUNY / Nash research team
13	Amanda Farr	Epidemiology, CUNY SPH	2011-2018	<i>[Dissertation title to add]</i>	Thomson Reuters
14	Eduard Eduardo	Epidemiology, Columbia (CU MSPH)	2006-2014	Programmatic and Individual-level Factors Associated with CD4 Cell Count at HAART Initiation and Survival Among Treatment-naïve Patients Initiating HAART in sub-Saharan Africa	Bristol-Myers Squibb
15	Matthew Lamb	Epidemiology, Columbia (CU MSPH)	2006-2010	Ecologic and patient-level approaches to identifying the association between adherence support and outreach services and non-retention, loss to follow-up, and ascertained death among ART patients in sub-Saharan Africa	Columbia Mailman (faculty)
16	Sarah Braunstein	Epidemiology, Columbia (CU MSPH)	2005-2009	The added value of data on HIV incidence rates and risk factors, and the promise of new methodologies	NYC DOHMH

Name	Level of Learner	Role in training and Setting	Inclusive dates of training	Trainee's current position and Institution employed
1. Sophia Arabadjis, PhD	Post-doctoral fellow (epidemiology)	Supervisor/mentor	2023-present	CUNY ISPH
2. McKaylee Robertson, PhD, MPH	Doctoral student (Epidemiology), post-doc	Primary Mentor, PhD dissertation and funded K01	2014-present	CUNY – Nash research team
3. Angela Parcesepe, PhD, MPH	Post-doctoral fellow	Mentor, primary mentor on funded K01	2015-2025	Assistant Professor, UNC (fall 2017)
4. Faisal Abdelqader, MPH	Epidemiology PhD student	Mentor	2021-present	NYC DOHMH
5. Daniella Pierre, MD, MPH	MPH student (epidemiology)	Mentor	2023-2025	
6. Juan Diego Lecona Garcia, MD, MPH	MPH student (epidemiology)	Mentor	2023-2025	NYC Health and Hospitals
7. Lindsay Reif, DrPH	Post-doctoral fellow (epidemiology)	co-mentor on funded K01	2022-present	Weill Cornell
8. Katey Walsh, MD, MPH	Faculty	co-mentor on funded K01	2022-present	Weill Cornell
9. Justin Knox, PhD	Faculty	Co-mentor on funded K01	2020-2025	Columbia
10. Rebecca Zimba	Epidemiology PhD student	Advisor	2021-present	CUNY ISPH
11. Saba Qasmieh	Epidemiology PhD student	Advisor/mentor	2020-2025	CDC EIS Officer/UN consultant
12. Avantika Srivastava	Epidemiology PhD student	Advisor/mentor	2021-present	CUNY ISPH
13. Jenny Shen	Epidemiology PhD student	Advisor/mentor	2020-present	CUNY ISPH

Denis Nash, PhD, MPH
Curriculum Vitae

Name	Level of Learner	Role in training and Setting	Inclusive dates of training	Trainee's current position and Institution employed
14. Madhura Rane	Post-doctoral fellow (epidemiology), Research Faculty	Supervisor/mentor	2020-2022	California State Department of Health, CUNY ISPH
15. Joanna Starrels	Associate Professor	Mentor on a funded mid-career K24 award	2018-2020	Faculty, Einstein College of Medicine, Montefiore Medical Center
16. Abigail Baim-Lance	Assistant Professor	Mentor, K01 proposal preparation	2017-2020	VA/Mt. Sinai faculty
17. Matthew Romo, PhD	Epidemiology PhD student	Mentor	2016-2021	CUNY ISPH
18. Ellen Brazier, PhD	Epidemiology PhD student	Mentor	2016-2021	CUNY ISPH
19. Rodrigo Cardozo	MPH student	Mentor	2016-2017	Weill Cornell
20. Jonathan Ross, MD, MS	Assistant Professor	Co-Mentor on a funded K	2016-2020	Faculty, Albert Einstein/Montefiore
21. Angela Parcesepe, PhD, MPH	Post-doctoral fellow	Mentor, primary mentor on K01 application	2015-present	Assistant Professor, UNC (fall 2017)
22. Marcus Bacchuber, MD, MS	Assistant Professor at Albert Einstein/Montefiore	Co-Mentor on funded K08	2015-2018	Assistant Professor at Albert Einstein/Montefiore
23. Yusuf Ransome, DrPH, MPH	Columbia University Doctoral Student (Sociomedical Sciences)	Post-doc mentor, and mentor on funded K01	2011-2017	Faculty at Yale SPH
24. Uriel Felson, MD, MPH	Assistant Professor at Albert Einstein/Montefiore	Co-Mentor on a funded K23	2015-2019	Assistant Professor at Albert Einstein/Montefiore
25. Kristina Rodriguez, DrPH	Doctoral student (Epidemiology)	Committee Member	2015-2018	CUNY SPH
26. Olga Tymejczyk, PhD, MPH	Doctoral student (Epidemiology)	Mentor/Sponsor	2013-2019	CUNY – Nash research team
27. Justin Knox, MPH	Doctoral student (Epidemiology) Columbia University	Career mentor	2013-2017	Fulbright scholar
28. Ashly Jordan, PhD, MPH	Doctoral student (Epidemiology)	Mentor/Sponsor	2013-2019	Center for Drug Use and HIV Research
29. Emily D'Agostino, DrPH	Doctoral student (Epidemiology)	Dissertation Committee Chair	2013-2016	
30. Sarah Walters, DrPH	Doctoral Student (Environmental)	Mentor/Sponsor	2013-2023	DOHMH - Epidemiology Services
31. Carol-Ann Swain, PhD	Doctoral Student in Epidemiology (SUNY Albany SPH)	Committee member	2013-2016	NYS DOH HIV Surveillance

Denis Nash
Curriculum Vitae

Name	Level of Learner	Role in training and Setting	Inclusive dates of training	Trainee's current position and Institution employed
32. Bisrat Abraham, MD, MPH	Weill Cornell Medical College, Infectious Disease Fellow	Research mentor	2013-2015	ID Fellow, 2 nd year, Weill Cornell Medical College
33. Sheila Vaidya, PhD	Columbia University MPH Student	Primary thesis reader	2011-2013	MSPH (Epidemiology PhD Program)
34. Christopher Philippou	Columbia University MPH Student	Primary thesis reader	2011-2013	NYC Health and Hospitals Corp.
35. Zoe Edelstein, PhD, MPH	Post-doctoral fellow	Mentor	2011-2014	HIV Center for Clinical and Behavioral Studies, Columbia University
36. Sungwoo Lim, PhD	Doctoral Student (Epidemiology)	Dissertation committee member	2009-2014	NYC DOHMH
37. Amanda Farr, DrPH, MPH	Doctoral Student (Epidemiology)	Academic Advisor and Dissertation Sponsor	2011-2018	Thompson-Reuters
38. Bianca Malcome	Columbia University Doctoral Student (Epidemiology)	Dissertation committee member	2009-2012	
39. Brianne Oliveri	MPH Student	Thesis advisor	2010-2012	NYU
40. Perry Halkitis, PhD	MPH Student	Thesis advisor	2010-2012	Professor and Associate Dean for Research, NYU
41. Kavita Misra, PhD	MPH Student	Thesis advisor	2012-2013	
42. Sonia Gonzalez-Gladstein, DrPH, MPH	Doctoral Student (Community, Society, and Health)	Advisor and Sponsor on NIMH F31	2012-2014	
43. Lucretia Jones, DrPH, MPH	Doctoral student (Community, Society, and Health)	Committee member	2010-2012	NYCDOHMH
44. Ragheed Fadhil, MD, MPH	MPH Student (Epidemiology) and Fulbright Scholar (Iraq)	Thesis Adviser, practicum supervisor, mentor	2011-2012	
45. Kate Fahy	MPH Student (Health Policy and Management)	Thesis Adviser	2011-2012	Director of Development, Institute for Family Health
46. Tracy Garber	MPH Student (Health Policy and Management)	Thesis Adviser and practicum supervisor	2011-2012	Packard Foundation
47. Mark Friedman	MPH Student (Epidemiology)	Thesis Adviser	2011-2012	
48. Lucy Almers	MPH Student (Epidemiology)	Thesis Adviser	2010-2011	CU-MSPH

Denis Nash, PhD, MPH
Curriculum Vitae

Name	Level of Learner	Role in training and Setting	Inclusive dates of training	Trainee's current position and Institution employed
49. Ellen Stiefvater	Doctoral student (Sociomedical Sciences)	Dissertation Committee Member	2010-2014	CU MSPH
50. Ed Kim, MPH	MPH Student (Epidemiology)	Thesis Adviser	2009-2010	US FDA
51. Peter Manyang, MPH	MPH Student (Epidemiology)	Academic Adviser and Thesis Adviser	2009-2010	Carter Center, Guinea Worm Eradication Program
52. Rituparna Pati, MD, MS	MPH Student (Epidemiology) and Cornell University PMR	Thesis and practicum adviser	2009-2011	Weill Cornell Medical College
53. Josephine Tsai, MD, MPH	MPH Student (Epidemiology) and NYCDOHMH PMR	Academic Adviser and Thesis Adviser	2009-2011	NYCDOHMH
54. Rahela Bursac	MPH Student (Epidemiology), MSPH-DOHMH Surveillance Scholar	MSPH-DOHMH Surveillance Scholar Program Director	2009-2011	CU MSPH
55. Katie Lane	MPH Student (Epidemiology), MSPH-DOHMH Surveillance Scholar	Thesis Adviser, MSPH-DOHMH Surveillance Scholar Program Director	2009-2011	CU MSPH
56. Laura Stadelman	MPH Student (Epidemiology), MSPH-DOHMH Surveillance Scholar	Thesis Adviser, MSPH-DOHMH Surveillance Scholar Program Director	2009-2011	CU MSPH
57. Nicole Espinoza	MPH Student (Epidemiology)	Thesis Adviser	2009-2011	CU MSPH
58. Merideth Rossi, MPH	MPH Student (Epidemiology)	Academic Adviser and Thesis Adviser	2008-2009	NYCDOHMH
59. Amanda Farr, MPH	MPH Student (Epidemiology), MSPH-DOHMH Surveillance Scholar	Academic Adviser and Thesis Adviser, MSPH-DOHMH Surveillance Scholar Program Director	2009-2010	CU MSPH
60. Jung-Eun Ha, MPH	MPH Student (Epidemiology), MSPH-DOHMH Surveillance Scholar	MSPH-DOHMH Surveillance Scholar Program Director	2009-2010	Epidemiology Doctoral student, UNC
61. Christina Parinello, MPH	MPH Student (Epidemiology), MSPH-DOHMH Surveillance Scholar	MSPH-DOHMH Surveillance Scholar Program Director	2009-2010	CU MSPH
62. Gretchen Nelson, PhD	Post-doctoral fellow	Academic Adviser and Thesis Adviser	2008-2010	CDC EIS Program
63. Victoria Nankabirwa, MD, MPH	Doctoral Student (Epidemiology)	Dissertation Committee member, CU MSPH	2008-2012	CU MSPH

Denis Nash
Curriculum Vitae

Name	Level of Learner	Role in training and Setting	Inclusive dates of training	Trainee's current position and Institution employed
64. Eduard Eduardo, PhD, MPH	Doctoral Student (Epidemiology)	Dissertation Sponsor, CU MSPH	2006-2014	HIV Regional Advocacy Manager with Bristol-Myers Squibb (BMS)
65. Matthew Lamb, PhD, MPH	Doctoral Student (Epidemiology)	Dissertation Sponsor, CU MSPH	2006-2010	CU MSPH
66. Sarah Braunstein, PhD, MPH	Doctoral student (Epidemiology)	Dissertation Sponsor, CU MSPH	2005-2009	NYCDOHMH
67. Amber Featherstone, MD	MPH Student (Epidemiology) and NYCDOHMH PMR	Academic Adviser and Thesis Adviser	2007-2008	NYCDOHMH
68. Heather McKay, MPH	MPH Student (Epidemiology)	Academic Adviser and Thesis Adviser	2007-2008	Doctoral Student, JHU SPH
69. Soniya Gandhi, MD, MPH	MPH Student (Epidemiology) and CIDER Fellow	Thesis adviser	2008-2009	CUMC
70. Shean Wang, PhD	Doctoral Student (Biostatistics)	Dissertation committee member	2006-2010	Johnson and Johnson Pharma
71. William LaRock, PhD, RN	Doctoral student (School of Nursing)	Dissertation committee member	2007-2009	CU School of Nursing
72. Brandon Aden, MD, MPH	MPH Student (Epidemiology) and NYCDOHMH PMR	Academic Adviser	2007-2008	NYCDOHMH
73. Hannah Jordan, MD, MPH	MPH Student (Epidemiology) and NYCDOHMH PMR	Academic Advisor	2007-2009	NYCDOHMH Preventive Medicine Residency
74. Folake Eniola, MPH	MPH Student (Epidemiology)	Thesis adviser, CU MSPH	2006-2007	NYCDOHMH
75. Judith Austin, MPH	Doctoral student (Epidemiology)	GRA supervisor, CU MSPH	2004-2006	CU MSPH
76. Peter Young, MPH	MPH student	Practicum adviser, thesis adviser, CU MSPH	2004-2006	Allan Rosenfield Global Health Fellow, CDC Mozambique
77. Carolyn Korves, PhD	Post doctoral fellow	Mentor, CU MSPH	2004-2006	Epidemiologist, CU MSPH ICAP
78. Abby Rudolph, PhD, MPH	MPH Student	Academic Adviser, CU MSPH	2005-2006	Doctoral student in epidemiology, Johns Hopkins University
79. Firas Ahmed, MD, MPH	MPH Student and Fulbright Scholar (Iraq)	Academic Adviser, CU MSPH	2005-2007	CU MSPH
80. Aisha Aiebert, MPH	MPH Student	Academic Adviser, CU MSPH	2005-2006	CU MSPH
81. Ema Kulwa, MPH	MD, MPH student	Practicum adviser, CU MSPH	2005-2006	CU Medical School and MSPH

Denis Nash, PhD, MPH
Curriculum Vitae

Name	Level of Learner	Role in training and Setting	Inclusive dates of training	Trainee's current position and Institution employed
82. Tenuja Gengiah, PharmD, MPH	MPH student (Epidemiology) and Fogarty Fellow (South Africa)	Practicum adviser, CU MSPH	Sep 2005-2009	CU MSPH
83. Susan Manning, MD, MPH	Fellow/EIS Officer	Immediate supervisor, NYCDOHMH	June 2002-2004	Epidemiologist, Maine State Department of Health
84. Sarita Shah, MD, MPH	Resident, Internal Medicine	Epidemiology elective preceptor, NYCDOHMH	September-October, 2003	Assistant Professor, Albert Einstein Medical College
85. Ben Harder	CDC Knight Journalism Fellow	Field practicum preceptor, NYCDOHMH	October-November 2003	Reporter, Science Magazine
86. Sarju Patel, Msc	Medical Student, 3 rd year	MPH Program field practicum advisor, NYCDOHMH	January 2003-2005	3 rd year Medical Student, Mt. Sinai School of Medicine
87. Anju Goel, MD, MPH	Preventive Medicine Resident	Epidemiology practicum preceptor, NYCDOHMH	September 2002-2003	PMR, NYCDOH
88. Nisha Khanna	Medical student, 2 nd year	Mentor and supervisor: Health Research Training Program (H RTP), NYCDOHMH	Summer 2002	Medical student, 4 th year, University of Texas
89. Marla Shu	MPH student, 1 st year	Mentor and supervisor, H RTP, NYCDOHMH	Summer 2003	MPH Student, 2 nd year, University of Michigan
90. Anne Labowitz, PhD	PhD student	Dissertation committee member	2000-2001	Clinical Psychologist, Yale University

13. OTHER PROFESSIONAL ACTIVITIES:

Manuscript Reviewer

American Journal of Epidemiology (AJE), Epidemiology, Journal of the American Medical Association (JAMA), Emerging Infectious Diseases, Journal of Urban Health, Environmental Research, Clinical Infectious Diseases (CID), AIDS, Journal of Acquired Immune Deficiency Syndrome (JAIDS), Drug and Alcohol Reviews, American Journal of Industrial Medicine, Journal of the National Medical Association, Annals of Internal Medicine, Archives of Internal Medicine, Bulletin of the World Health Organization, Journal of Occupational and Environmental Medicine, Open AIDS Journal, Population Studies, Public Health Reports, PLOS Medicine, PLOS One, Journal of Healthcare for the Poor and Underserved, Journal of the American College of Nutrition, American Journal of Public Health, Health Affairs, BMC Medicine.

Media appearances (for a full list, visit: <https://www.clippings.me/denisnash>)

Denis Nash Curriculum Vitae

I have appeared in more than 370 media items across over 120 distinct outlets, including 63 mentions in The New York Times. The coverage extends across the national press, including NPR, the Associated Press, CBS News, The Atlantic, ProPublica, STAT, Bloomberg, WIRED, and Rolling Stone, and around the world, with features in The Guardian, the BBC, Al Jazeera, Germany's Die Zeit, Canada's La Presse, Argentina's La Nacion, Japan's TBS and NHK, and South Korea's Arirang. The coverage has included front-line interpretation of the COVID-19 pandemic, spanning testing and data quality, vaccines and mandates, variants and successive waves, schools and children, and masking and reopening. This runs alongside a sustained body of work on HIV/AIDS, emerging threats such as bird flu (H5N1) and mpox, pioneering wastewater surveillance, the health impacts of climate change, Long COVID, and, most recently, the politics of science funding and the public-health workforce.

14. PUBLICATIONS:

I have authored or co-authored 375 peer-reviewed publications (387 including preprints) since 1995, appearing in 125 journals, among them the Journal of Acquired Immune Deficiency Syndromes, the Journal of the International AIDS Society, AIDS, Clinical Infectious Diseases, the American Journal of Epidemiology, PLOS Medicine, and Health Affairs. I am first or senior author on 167 of these. In addition, research conducted under my funded projects has generated a further 161 publications on which I was not an author, reflecting the broader scientific output and impact of the studies and teams I have led.

Original Peer-Reviewed Articles (* indicates senior authored papers)

For a full list of publications, see:

- My NCBI: <https://www.ncbi.nlm.nih.gov/myncbi/denis.nash.1/bibliography/public/>
- Google Scholar: <https://scholar.google.com/citations?user=4jSjQRUAAAAJ&hl=en>

1. **PREPRINT:** [Documenting HIV service delivery and adoption of evidence-based practices in HIV care programs: A protocol for a cross-sectional survey of HIV clinics participating in the International epidemiology Databases to Evaluate AIDS \(IeDEA\)](#) Brazier E, Maruri F, Duda SN, Wools-Kaloustian K, Freeman A, Musick B, Arabadjis S, Ballif M, Villalobos NVF, Kuniholm MH, Lancaster KE, Lujintanon S, Parcesepe AM, Pellegrino RA, Menchelli AFR, Ross J, Ross J, Semeere A, **Nash D**.medRxiv [Preprint]. 2026 Sep 17:2026.09.16.26363245. doi: 10.64898/2026.09.16.26363245.PMID: 42780201
2. [Food insecurity inequities among US adults: An application of intersectional multilevel analysis of individual heterogeneity and discriminatory accuracy \(I-MAIHDA\) with random effects](#) Robertson M, Sanborn J, Parcesepe A, Penrose K, Fleary S, **Nash D**, Borrell LN. Ann Epidemiol. 2026 Sep 11;123:110274. doi: 10.1016/j.annepidem.2026.110274.PMID: 42727658
3. [Gaps between willingness and uptake of influenza and COVID-19 vaccines during the 2025-26 respiratory virus season in a U.S. adult cohort](#) Sanborn J, Robertson MM, Penrose K, Rane M, Pilch-Loeb R, Parcesepe AM, **Nash D**. Vaccine. 2026 Oct 24;92:129126. doi: 10.1016/j.vaccine.2026.129126. Epub 2026 Sep 6.PMID: 42702142
4. [Evolution of ART Medication Adherence Support and Monitoring Across IeDEA Sites: Results From Three Waves of Consortium-Wide Site Assessment Surveys, 2017, 2020 and 2023](#) Brazier E, Odhiambo F, Edwards JK, Zalla L, Kasozi C, Messou E, Schreuder C, Chaiwarith R, Rodriguez MF, Ayakaka I, Zannou M, Freeman A, Ebasone PV, Muktiarti D, Semeere A, Khol V, Mensah E, Cesar C, Tanser F, Sang E, Do CD, Poda A, Niyongabo A, Vega YC, Colasanti JA, Rafael I, Lelo P,

Denis Nash, PhD, MPH
Curriculum Vitae

- Murenzi G, **Nash D**, International Epidemiology Databases to Evaluate AIDS (IeDEA).J Int AIDS Soc. 2026 Sep;29(9):e70197. doi: 10.1002/jia2.70197.PMID: 42693737
5. [Individual and contextual characteristics of blood lead level among adults in Port-au-Prince, Haiti: A cross-sectional analysis](#) Rasul R, Sufra R, Yan LD, Pierre DM, St Sauveur R, Celestin K, Rouzier V, Apollon A, Deschamps MM, Pape JW, McNairy ML, **Nash D**.Environ Epidemiol. 2026 Oct;10(5):e521. doi: 10.1097/EE9.0000000000000521. eCollection 2026 Oct.PMID: 42662637
6. [Depressive symptoms and association with prevalent cardiovascular disease: A cross-sectional analysis in Port-au-Prince, Haiti](#) Pierre DM, Rasul R, St Sauveur R, Celestin K, Rouzier V, Hilaire E, Deschamps MM, Pape JW, Yan LD, Ogyu A, Bennett C, McNairy ML, Sufra R, **Nash D**.PLOS Ment Health. 2026;3(8):e0000693. doi: 10.1371/journal.pmen.0000693. eCollection 2026.PMID: 42658819
7. [COVIDTests.gov Test Kits Associated With Expanded SARS-CoV-2 Testing Among Recipients](#) Sanborn J, Robertson M, **Nash D**, Penrose K, Srivastava A, Parcesepe AM, Shahn Z.Am J Public Health. 2026 Aug 20;:e1-e5. doi: 10.2105/AJPH.2026.308527. [Epub ahead of print]PMID: 42623582
8. **PREPRINT:** [Service disruptions and stockouts: Ongoing impacts of U.S. funding freezes on HIV care across clinics in 38 low- and middle-income countries in late 2025](#) Brazier E, Kludze M, Maruri F, Niyongabo A, Kreniske P, Duda SN, **Nash D**.medRxiv [Preprint]. 2026 Aug 6:2026.08.04.26359701. doi: 10.64898/2026.08.04.26359701.PMID: 42620340
9. **PREPRINT:** [Prevalence of anxiety and depression symptoms under population-level alcohol reduction to low-risk drinking: A parametric g-computation analysis in a U.S. nationwide cohort](#) Sanborn J, **Nash D**, Robertson M, Parcesepe A, Shahn Z.medRxiv [Preprint]. 2026 Aug 3:2026.07.31.26359417. doi: 10.64898/2026.07.31.26359417.PMID: 42620077
10. **PREPRINT:** [The Role of Sick-Quitter Bias in the Association Between Alcohol Use and Anxiety and Depression Symptoms: A Causal Analysis in a U.S. National Cohort](#) Sanborn J, **Nash D**, Robertson M, Parcesepe A, Shahn Z.medRxiv [Preprint]. 2026 Jul 29:2026.07.25.26358931. doi: 10.64898/2026.07.25.26358931.PMID: 42619911
11. **PREPRINT:** [The role of physical activity in shaping the relationship between alcohol use and anxiety and depression symptoms: Findings from a U.S. nationwide cohort](#) Sanborn J, **Nash D**, Robertson M, Parcesepe A, Shahn Z.medRxiv [Preprint]. 2026 Aug 2:2026.07.30.26359355. doi: 10.64898/2026.07.30.26359355.PMID: 42619831
12. [High Motivation but Low Access to PrEP: Social Determinants Undermine HIV Prevention Among Sexual and Gender Minority People Who Use Methamphetamine](#) Grov C, D'Angelo AB, Mirzayi C, Dearolf M, Hoepfner E, Guo Y, Richards N, Ehsan R, **Nash D**, Patel VV, Duncan DT, Ray M, Bartholomew T, Manuzak JA, Manuel JK, McCollister K, Westmoreland D, Carrico AW.AIDS Behav. 2026 Aug 11. doi: 10.1007/s10461-026-05265-5. [Epub ahead of print]PMID: 42579030
13. [GLP-1 receptor agonist medications for weight loss: Sociodemographic patterns of awareness, use, and access in a U.S. national cohort](#) Sanborn J, Fleary SA, **Nash D**, Penrose K, Parcesepe AM, Piltch-Loeb R, Nuñez J, Shen Y, Robertson MM.Ann Epidemiol. 2026 Oct;122:110151. doi: 10.1016/j.annepidem.2026.110151. Epub 2026 Jun 25.PMID: 42349695
14. [Variability in HIV viral load quantification in real-world service delivery settings: findings from an observational cohort study in Rwanda](#) Murenzi G, Brazier E, Rutwaza MG, Mivumbi JP, Barthel R, Ingabire J, Kanyabwisha F, Yotebieng M, **Nash D**.BMC Infect Dis. 2026 Jun 12. doi: 10.1186/s12879-026-13790-w. Online ahead of print.PMID: 42286495
15. [How low-income gay and bisexual men who have sex with men navigate financial challenges to](#)

- [HIV pre-exposure prophylaxis use: a qualitative study](#) Bleasdale J, D'Angelo A, Murrill PE, Cohen N, **Nash D**, Grov C, Westmoreland DA. *AIDS Care*. 2026 May 28;1-12. doi: 10.1080/09540121.2026.2649875. Online ahead of print. PMID: 42206820
16. [Long COVID longitudinal symptoms burden clusters within a national community-based cohort](#) Shen Y, Shahn Z, Robertson MM, Gebo K, **Nash D**. *BMC Infect Dis*. 2026 May 21. doi: 10.1186/s12879-026-13590-2. Online ahead of print. PMID: 42168930
17. [Impact of an HIV Care Coordination Program on All-cause, HIV-related, and Non-HIV-related Mortality in Younger and Older Adults With HIV in New York City, 2018-2022](#) Robertson MM, Avoundjian T, Abdelqader F, Braunstein SL, **Nash D**, Irvine MK. *Open Forum Infect Dis*. 2026 Apr 23;13(5):ofag206. doi: 10.1093/ofid/ofag206. eCollection 2026 May. PMID: 42131623
18. [Effect of a third COVID-19 vaccine dose on the incidence of Long COVID among adults who completed a primary vaccine series: a target trial emulation in a community-based cohort](#) Shen Y, Shahn Z, Robertson MM, Gebo K, **Nash D**; CHASING COVID Cohort Study Team. *Vaccine*. 2026 Jun 20;84:128666. doi: 10.1016/j.vaccine.2026.128666. Epub 2026 May 8. PMID: 42102594
19. **PREPRINT:** [Exploring provider preferences in the design of HIV treatment packages integrating long-acting injectable antiretroviral therapy in New York Ryan White Part A medical case management programs: A discrete choice experiment](#) Zimba R, Kelvin EA, Kulkarni S, Carmona J, Avoundjian T, Emmert C, Peterson M, Irvine M, **Nash D**. *medRxiv* [Preprint]. 2026 Apr 23:2026.04.22.26351494. doi: 10.64898/2026.04.22.26351494. PMID: 42078344
20. [Prospective Respiratory Outcomes from Tracking and Evaluating Community-based TeSting \(Project PROTECTS\): a community-based, prospective study of acute respiratory infections among adults across the USA - cohort profile](#) Rane MS, Penrose K, Robertson MM, Balasubramanian S, Berry A, Kulkarni SG, Allen KE, Puzniak L, Ernst FR, Zamparo J, Srivastava A, Ganzhorn S, Shen Y, Castillo PW, Berger E, Chan BXJ, Sanborn J, **Nash D**. *BMJ Open*. 2026 Apr 27;16(4):e114530. doi: 10.1136/bmjopen-2025-114530. PMID: 42044959
21. [Non-fatal GHB overdose among sexual and gender minorities: A syndemic perspective](#) Chavez JV, Guo Y, Larson ME, Westmoreland DA, D'Angelo AB, Tsai AC, Bartholomew TS, **Nash D**, Grov C, Carrico AW. *Drug Alcohol Depend*. 2026 Apr 15;283:113161. doi: 10.1016/j.drugalcdep.2026.113161. Online ahead of print. PMID: 42013580
22. [Inferring the Timing of Antiretroviral Therapy by Zero-Inflated Random Change Point Models Using Longitudinal Data Subject to Left-Censoring](#) Zhang H, Robertson M, Braunstein SL, Hanna DB, Felsen UR, Waldron L, **Nash D**. *Algorithms*. 2025 Jun;18(6):346. doi: 10.3390/a18060346. Epub 2025 Jun 5. PMID: 41907302
23. [Lingering sex and age disparities in dolutegravir uptake among adults with HIV: a multicountry observational cohort study](#) Brazier E, Romo ML, Ciaranello AL, Odhiambo F, Pujari S, Murenzi G, Kasozi C, Kiertiburanakul S, Nsonde DM, Muyindike W, Khol V, Lelo P, Lyamuya R, Lee MP, **Nash D**. *BMJ Glob Health*. 2026 Mar 13;11(3):e020159. doi: 10.1136/bmjgh-2025-020159. PMID: 41825914
24. [Effect of COVID-19 pandemic on ART access and timely initiation in people living with HIV in 31 countries: a regression discontinuity design study](#) Ben Farhat J, Messou E, Borse R, Varela Bustillo D, Madimabe M, **Nash D**, Byakwaga H, Shah NS, Ezechi O, Pujari S, Veloso VG, Hobbins M, Murenzi G, Mkwashapi D, Hogan B, Choi JY, Minga A, Crabtree-Ramírez B, Twizere C, Diero L, Haw J, Bolton-Moore C, Cortes CP, Lee MP, Mbewe S, Brazier E, Humphrey JM, Althoff KN, Bonnet F, Barger D, Jaquet A; IeDEA International epidemiology Databases to Evaluate AIDS. *BMJ Open*. 2026 Mar 10;16(3):e112903. doi: 10.1136/bmjopen-2025-112903. PMID: 41807002

Denis Nash, PhD, MPH
Curriculum Vitae

25. [HIV disease progression following WHO treat all guideline adoption among people enrolled in HIV care in Central Africa: A multistate analysis](#) Zhang H, Zhu J, Brazier E, Tymejczyk O, Yotebieng M, Kimmel AD, Anastos K, Ross J, Hoover DR, Shi Q, Murenzi G, Nsonde D, Dzudie A, Lelo P, Twizere C, **Nash D**.Ann Epidemiol. 2026 May;117:110063. doi: 10.1016/j.annepidem.2026.110063. Epub 2026 Mar 5.PMID: 41794156
26. **PREPRINT:** [HIV Treatment and Program Preferences Among Ryan White Clients in New York City in the Era of Long-Acting Injectable ART: A Discrete Choice Experiment](#). Zimba R, Kelvin EA, Kulkarni S, Carmona J, Avoundjian T, Emmert C, Peterson M, Irvine M, **Nash D**.medRxiv [Preprint]. 2026 Feb 16:2026.02.13.26346257. doi: 10.64898/2026.02.13.26346257.PMID: 41757214
27. [Impact of US government funding freezes on the HIV response: findings from a rapid survey in 32 countries](#). Brazier E, Duda SN, Ross J, Semeere AS, Tiendrebeogo T, Chimbetete C, **Nash D**.Health Aff Sch. 2026 Feb 23;4(2):qxag020. doi: 10.1093/haschl/qxag020. eCollection 2026 Feb.PMID: 41732341
28. [Sustaining Rwanda's HIV response after elimination of PEPFAR funding: a modelling analysis of HIV epidemic and care continuum outcomes](#). Kimmel AD, Pan Z, Murenzi G, Brazier E, Elul B, Muhoza B, Yotebieng M, Anastos K, **Nash D**; Central Africa International epidemiology Databases to Evaluate AIDS (CA-IeDEA).J Int AIDS Soc. 2026 Feb;29(2):e70078. doi: 10.1002/jia2.70078.PMID: 41674109
29. [Magnitude of potential biases in COVID-19 vaccine effectiveness studies due to differential healthcare seeking following home testing: implications for test negative design studies](#). Qasmieh SA, Ferdinands JM, Chung JR, Wiegand RE, Flannery B, Rane MS, **Nash D**.Am J Epidemiol. 2026 Feb 2:kwag021. doi: 10.1093/aje/kwag021. Online ahead of print.PMID: 41626716
30. [Natural history of self-reported symptoms following SARS-CoV-2 infection: A target trial emulation in a prospective community-recruited cohort](#). Shen Y, Shahn Z, Robertson MM, Gebo K, **Nash D**; CHASING COVID Cohort Study Team.Int J Infect Dis. 2026 Jan 23;164:108422. doi: 10.1016/j.ijid.2026.108422. Online ahead of print.PMID: 41581648
31. [The role of institutional trust in shaping the relationship between vaccine concerns and ongoing COVID-19 vaccination in a U.S. National Cohort](#). Sanborn J, Parcesepe A, Piltch-Loeb R, Penrose K, Shen Y, Maroko A, **Nash D**, Robertson MK.Am J Epidemiol. 2026 Jan 20:kwag012. doi: 10.1093/aje/kwag012. Online ahead of print.PMID: 41555696
32. [Gender, mental health symptoms, loss to clinic, and viral non-suppression 6 months after HIV care initiation among a cohort of people with HIV in Cameroon](#). Parcesepe AM, Filiatreau LM, Ebasone PV, Dzudie A, Yotebieng M, Anastos K, Pefura-Yone E, Nyenti A, **Nash D**.BMC Public Health. 2025 Dec 30;25(1):4374. doi: 10.1186/s12889-025-24668-y.PMID: 41469597
33. [Impact of a Revised Ryan White Part A HIV Care Coordination Program on Viral Suppression and Durable Viral Suppression](#). Avoundjian T, Robertson MM, Abdelqader F, Braunstein SL, **Nash D**, Irvine MK.J Acquir Immune Defic Syndr. 2026 Jan 1;101(1):77-85. doi: 10.1097/QAI.0000000000003768.
34. [SARS-CoV-2 testing behavior in symptomatic adults in a U.S. national cohort, 2020-2023: influence of exposure risk, susceptibility and healthcare access](#). Sanborn J, Qasmieh S, Penrose K, Parcesepe A, Shen Y, Piltch-Loeb R, Nuñez J, **Nash D**, Robertson M.BMC Public Health. 2025 Dec 8. doi: 10.1186/s12889-025-25516-9. Online ahead of print.PMID: 41354779
35. **PREPRINT:** [The development of IeDEA's Treat All Dashboard on HIV care outcomes at participating clinics in Sub-Saharan Africa](#). Brazier E, Berry A, Katz B, Lewis JT, Duda SN,

Denis Nash
Curriculum Vitae

- Semeere A, Huwa J, Jaquet A, Twizere C, Diero LO, Rafael I, Dabis F, Muhoza B, **Nash D**.medRxiv [Preprint]. 2025 Nov 20:2025.11.20.25340413. doi: 10.1101/2025.11.20.25340413.PMID: 41332857
36. [Implementing and retaining a large-scale technology-mediated cohort to study HIV incidence and PrEP uptake among vulnerable cisgender men as well as transgender individuals in the U.S., the Together 5,000 cohort](#). Westmoreland DA, Ray MA, Sultana S, Bleasdale J, Robertson MK, Mirzayi C, D'Angelo AB, Stief M, Hoover D, Hirshfield S, Patel VV, Pantalone DW, Carrico A, Golub SA, **Nash D**, Grov C, Together Team OBOT.Am J Epidemiol. 2025 Nov 12:kwaf250. doi: 10.1093/aje/kwaf250. Online ahead of print.PMID: 41222262
37. [COMBINE EBIs: A novel COLlaborative Method for Building Interventions from Existing Evidence-Based Interventions](#). Knox J, Portier K, Magana C, Denning M, Ferraris CM, Dove-Medows E, Shrader CH, Poku O, Kreniske P, Remien R, Aharonovich E, Elliott JC, **Nash D**, Lancaster K, Baernighausen T, Fujimoto K, Carrico A, Schneider JA, Bouris A, Batey DS, Schwartz SR, Bauermeister J, Sullivan PS, Rosen JG, Wingood G, Wainberg M, Hasin D, Geng E, Wilson PA, Baral SD.Ann Epidemiol. 2025 Dec;112:64-75. doi: 10.1016/j.annepidem.2025.10.018. Epub 2025 Nov 6.PMID: 41205688
38. [Modeling the Burden of Extreme Weather Events in a Large Network of International HIV Care Cohorts](#). Arabadjis SD, Davenport F, Vecedo Cabrera AM, Shahn Z, Brazier E, Maroko A, Srivastava A, Murenzi G, Dizon TJ, Althoff KN, Jaquet A, Semeere AS, Caro Vega Y, Pasayan MKU, Weiser SD, **Nash D**. Geohealth. 2025 Nov 3;9(11):e2025GH001514. doi: 10.1029/2025GH001514. eCollection 2025 Nov.PMID: 41195258
39. [Factors associated with HIV status non-disclosure among people entering care at IeDEA sites in Cameroon: a cross-sectional study](#). Mabou GT, Brazier E, Ebasone P, Dzudie A, Hoover D, Shi Q, Barthel R, Ajeh R, Nfornuwe DN, Nyenti A, Nkodo JM, **Nash D**, Adedimeji A, Yotebieng M, Anastos K.AIDS Res Ther. 2025 Oct 8;22(1):100. doi: 10.1186/s12981-025-00765-1.
40. [Testing Theory-Enhanced Messaging to Promote COVID-19 Vaccination Among Adults: Randomized Controlled Trial](#). Piltch-Loeb R, Shen Y, Fleary S, Robertson M, Nuñez Sahr J, Penrose K, Sanborn J, Yadav S, Srivastava A, **Nash D**, Parcesepe A.J Med Internet Res. 2025 Oct 7;27:e79228. doi: 10.2196/79228.
41. [HIV-related mortality time trends among children and young adolescents on antiretroviral therapy by age, treatment duration, and region: a systematic review and meta-regression analysis](#). He J, Brewer E, Novotney A, Carter A, Paul H, Walters MK, Sherefa Oumer K, Kassanjee R, Dame J, Desmonde S, Eley B, Kariminia A, **Nash D**, Rebeiro PF, Rouzier V, Sudjaritruk T, Wools-Kaloustian K, Yiannoutsos CT, Yotebieng M, Sorensen RJD, Murray CJL, Hay SI, Aravkin A, Flaxman A, Zheng P, Kyu HH.Lancet HIV. 2025 Nov;12(11):e774-e788. doi: 10.1016/S2352-3018(25)00168-7. Epub 2025 Sep 2.
42. [Intravenous Methamphetamine Use, HIV Status and PrEP Uptake Among a U.S. Sample of 29,880 Gender and Sexual Minorities, 2022-2023](#). Bartholomew TS, Plesons M, Westmoreland DA, D'Angelo AB, Mirzayi CA, Dearolf M, Guo Y, Hoepfner E, Richards NS, Patel VV, **Nash D**, Carrico AW, Grov C.AIDS Behav. 2025 Aug 11:10.1007/s10461-025-04846-0. doi: 10.1007/s10461-025-04846-0. Online ahead of print.
43. [Provider Perspectives on the Data-to-Suppression Initiative in Ryan White Part A Housing and Behavioral Health Programs](#).Peterson M, Emmert C, You W, Irvine M, Avoundjian T, **Nash D**, Guarino H.AIDS Patient Care STDS. 2025 Aug;39(8):316-322. doi: 10.1177/10872914251361088. Epub 2025

Denis Nash, PhD, MPH
Curriculum Vitae

44. [Recommendation on the use of viral load tests and exclusion of CD4 tests as proxies for HIV medical visits.](#) Xia Q, Irvine MK, Manandhar-Sasaki P, Bertolino D, Abdelqader F, Peterson M, **Nash D**, Torian LV. *Ann Epidemiol.* 2025 Sep;109:46-51. doi: 10.1016/j.annepidem.2025.06.017. Epub 2025 Jul 3. PMID: 40617368
45. [Are client and provider preferences for HIV care coordination programme features concordant? Discrete choice experiments in Ryan White part A-funded New York City care coordination programmes.](#) Zimba R, Fong C, Conte M, Guarino H, Avoundjian T, Carmona J, Herndon G, Gambone G, Irvine MK, **Nash D**. *BMJ Open.* 2025 Jun 24;15(6):e097918. doi: 10.1136/bmjopen-2024-097918.
46. ["We're Going to Be Here": Providers' Perspectives on Implementing a Revised HIV Care Coordination Program.](#) Emmert C, Avoundjian T, Irvine M, Tapia-Munoz T, Schenkel R, Hernandez M, Kozlowski S, **Nash D**, Guarino H. *AIDS Patient Care STDS.* 2025 Sep;39(9):363-370. doi: 10.1089/apc.2025.0047. Epub 2025 Jun 12. PMID: 40501225 **Free PMC article.**
47. [The American Transformative HIV Study: Protocol for a US National Cohort of Sexual and Gender Minority Individuals With HIV.](#) Grov C, D'Angelo AB, Mirzayi C, Dearolf M, Hoepfner E, Guo Y, Richards N, Ehsan R, Kulkarni S, **Nash D**, Patel VV, Duncan DT, Ray M, Bartholomew T, Manuzak J, Manuel J, McCollister K, Westmoreland D, Carrico AW. *JMIR Public Health Surveill.* 2025 May 22;11:e66921. doi: 10.2196/66921.
48. [Mental health-related help-seeking and the role of HIV care providers: A qualitative study with people with HIV in Cameroon.](#) Parcesepe AM, Grimes KEL, Ebasone PV, Dzudie A, Wainberg ML, Pefura E, Yotebieng M, Anastos K, Nsame D, Nyenti A, **Nash D**. *PLOS Glob Public Health.* 2025 May 15;5(5):e0004597. doi: 10.1371/journal.pgph.0004597. eCollection 2025.
49. [HOME protocol for a national online survey of people who inject drugs.](#) Luhur WE, Chin CL, Li JM, Marsh G, Coello D, Fox A, Guarino H, **Nash D**, Patel VV, Behrends CN. *Harm Reduct J.* 2025 Jul 18;22(Suppl 1):125. doi:10.1186/s12954-025-01260-6
50. [The Current and Future Burden of Long COVID in the United States.](#) Bartsch SM, Chin KL, Strych U, John DC, Shah TD, Bottazzi ME, O'Shea KJ, Robertson M, Weatherwax C, Heneghan J, Martinez MF, Ciciriello A, Kulkarni S, Velmurugan K, Dibbs A, Scannell SA, Shen Y, **Nash D**, Hotez PJ, Lee BY. *J Infect Dis.* 2025;231(6):1581-1590. doi:10.1093/infdis/jiaf030
51. [Preferences for HIV preexposure prophylaxis care among gay, bisexual, and other MSM: a large discrete choice experiment.](#) Patel VV, Andrade EA, Zimba R, Mirzayi C, Zhang C, Kharfen M, Freeman A, Edelstein Z, Doshi R, **Nash D**, Grov C. *AIDS.* 2025;39(7):905-911. doi:10.1097/QAD.0000000000004124
52. [Barriers to initial COVID-19 booster among US adults who completed a primary vaccine series in the CHASING COVID cohort, September 2021-October 2022.](#) Rane MS, Shen Y, Robertson MK, Penrose K, Srivastava A, Puzniak L, Allen KE, Porter TM, Kulkarni S, You W, Berry A, Parcesepe AM, Grov C, Zimba R, **Nash D**. *Am J Epidemiol.* 2025;194(5):1341-1351. doi:10.1093/aje/kwae209
53. [Testing Theory-Enhanced Messaging to Promote COVID-19 Vaccination: Results from a Randomized Controlled Trial.](#) Piltch-Loeb R, Shen Y, Fleary S, Robertson M, Nunez J, Penrose K, Sanborn J, Yadav S, Srivastava A, **Nash D**, Parcesepe A. Published online May 2, 2025. doi:10.21203/rs.3.rs-6472442/v1
54. [Pregnancy Outcomes and All-Cause Mortality After Pregnancy Among US-Born Women With Perinatally Acquired HIV.](#) Abraham BK, Vogler M, Talati A, Suresh P, Gill B, Ravikumar S, Shepard C, Gulick R, **Nash D**, Peters V. *J Acquir Immune Defic Syndr.* 2025;98(1):20-28.

doi:10.1097/QAI.00000000000003535

55. [Prevalence of Cooking with Polluting Fuels and Association with Elevated Blood Pressure Among Adults in Port au Prince, Haiti: A Cross-Sectional Analysis](#). Rasul R, Sufra R, Pierre MCJ, St Sauveur R, Rouzier V, Inddy J, Hilaire E, Preval F, Yan LD, Mourra N, Ogyu A, Pierre DM, Pape JW, **Nash D**, McNairy ML. *Glob Heart*. 2025;20(1):22. doi:10.5334/gh.1405
56. [Factors associated with viral load suppression in pregnant and postpartum women living with HIV in Rwanda: an open-observational cohort study](#). Munyaneza A, Kim HY, Shi Q, Brazier E, Ross J, Muhoza B, Kanyabwisha F, Kubwimana G, Murenzi G, **Nash D**, Anastos K, Yotebieng M. *Front Public Health*. 2025;13:1544165. doi:10.3389/fpubh.2025.1544165
57. [Development and calibration of a mathematical model of HIV outcomes among Rwandan adults: Informing achievement of global targets across sub- populations in Rwanda](#). Kimmel AD, Pan Z, Brazier E, Murenzi G, Mujwara D, Muhoza B, Yotebieng M, Anastos K, **Nash D**. *PLoS One*. 2025;20(5):e0310662. doi:10.1371/journal.pone.0310662
58. [Heterogeneity of provider preferences for HIV Care Coordination Program features: latent class analysis of a discrete choice experiment](#). Fong C, Conte M, Zimba R, Carmona J, Gambone G, Baim-Lance A, Robertson M, Irvine M, **Nash D**. *HIV Res Clin Pract*. 2024;25(1):2300923.
59. [Persistence of anxiety and depression symptoms and their impact on the COVID-19 vaccine uptake](#). Shen Y, Penrose K, Robertson M, Piltch-Loeb R, Fleary S, Kulkarni S, Teasdale C, Balasubramanian S, Yadav S, Chan BXJ, Sanborn J, Sahr JN, Srivastava A, **Nash D**, Parcesepe A. *Epidemiol Psychiatr Sci*. 2024;33:e74. doi:10.1017/S2045796024000763
60. [Gay and Bisexual Men’s Perceptions about a Potential HIV Vaccine within a Post-COVID-19 Era: A Qualitative Study](#). D’Angelo AB, Dearolf MH, MacMartin J, Elder M, **Nash D**, Golub SA, Grov C. *AIDS Behav*. 2024;28(11):3787-3800. doi:10.1007/s10461-024-04450-8
61. [Exploring COVID-19 Vaccine Decision Making: Insights from “One-Shot Wonders” and “Booster Enthusiasts](#). Nunez Sahr J, Parcesepe AM, You W, **Nash D**, Penrose K, Wainberg ML, Balasubramanian S, Chan BXJ, Piltch-Loeb R. ”. *Int J Environ Res Public Health*. 2024;21(8):1054. doi:10.3390/ijerph21081054
62. [Neighborhood Social Vulnerability and Premature Cardiovascular Disease in Haiti](#). Roberts NLS, Sufra R, Yan LD, St Sauveur R, Inddy J, Macius Y, Theard M, Lee MH, Mourra N, Rasul R, **Nash D**, Deschamps MM, Safford MM, Pape JW, Rouzier V, McNairy ML. *JAMA Cardiol*. 2024;9(8):692-701. doi:10.1001/jamacardio.2024.1286
63. [Perceived Risk for Severe COVID-19 and Oral Antiviral Use Among Antiviral-Eligible US Adults](#). Penrose K, Srivastava A, Shen Y, Robertson MM, Kulkarni SG, Allen KE, Porter TM, Puzniak L, McLaughlin JM, **Nash D**. *Infect Dis Ther*. 2024;13(8):1743-1757. doi:10.1007/s40121-024-01003-3
64. [The association between emotional and physical intimate partner violence and COVID-19 vaccine uptake in a community-based U.S. Cohort](#). Penrose K, Abraham A, Robertson M, Berry A, Xi Jasmine Chan B, Shen Y, Srivastava A, Balasubramanian S, Yadav S, Piltch-Loeb R, **Nash D**, Parcesepe AM. *Prev Med Rep*. 2024;43:102784. doi:10.1016/j.pmedr.2024.102784
65. [Copevalence and associations of diabetes mellitus and hypertension among people living with HIV/AIDS in Cameroon](#). Ebasone PV, Dzudie A, Peer N, Hoover D, Shi Q, Kim HY, Brazier E, Ajeh R, Yotebieng M, **Nash D**, Anastos K, Kengne AP. *AIDS Res Ther*. 2024;21(1):36. doi:10.1186/s12981-024-00624-5
66. [PrEP Uptake and Methamphetamine Use Patterns in a 4-Year U.S. National Prospective Cohort Study of Sexual and Gender Minority People, 2017-2022](#). Guo Y, Westmoreland DA, D’Angelo AB, Mirzayi C, Dearolf M, Ray M, Carneiro PB, Pantalone DW, Carrico AW, Patel VV, Golub SA,

Denis Nash, PhD, MPH
Curriculum Vitae

- Hirshfield S, Hoover DR, **Nash D**, Grov C. *AIDS Behav.* 2024;28(6):2078-2086. doi:10.1007/s10461-024-04306-1
67. [Factors associated with PrEP-era HIV seroconversion in a 4-year U.S. national cohort of n = 6059 sexual and gender minority individuals who have sex with men, 2017-2022.](#) Grov C, Guo Y, Westmoreland DA, D'Angelo AB, Mirzayi C, Dearolf M, Carneiro P, Ray M, Pantalone D, Carrico AW, Patel VV, Golub SA, Hirshfield S, Hoover DR, **Nash D**. *J Int AIDS Soc.* 2024;27(6):e26312. doi:10.1002/jia2.26312
68. [Spectrum of prevalent cardiovascular diseases in urban Port-au-Prince, Haiti: a population-based cross-sectional study.](#) Yan LD, Sufra R, St Sauveur R, Jean-Pierre MC, Apollon A, Malebranche R, Theard M, Pierre G, Devieux J, Lau J, Mourra N, Roberts NLS, Rasul R, **Nash D**, Pirmohamed AM, Devereux RB, Lee MH, Kwan GF, Safford MM, Adrien L, Alfred JP, Deschamps M, Severe P, Fitzgerald DW, Pape JW, Rouzier V, McNairy ML. *Lancet Reg Health Am.* 2024;33:100729. doi:10.1016/j.lana.2024.100729
69. [Reducing time to differentiated service delivery for newly-diagnosed people living with HIV in Kigali, Rwanda: a pilot, unblinded, randomized controlled trial.](#) Ross J, Anastos K, Hill S, Remera E, Rwibasira GN, Ingabire C, Umwiza F, Munyaneza A, Muhoza B, Zhang C, **Nash D**, Yotebieng M, Murenzi G. *BMC Health Serv Res.* 2024;24(1):555. doi:10.1186/s12913-024-10950-z
70. [Factors influencing integration of mental health screening and treatment at HIV clinic settings in Cameroon: a qualitative study of health providers' perspectives.](#) Grimes KEL, Ebasone PV, Dzudie A, **Nash D**, Wainberg ML, Pence BW, Barrington C, Pefura E, Yotebieng M, Anastos K, Nsame D, Ajeh R, Nyenti A, Parcesepe AM. *BMC Health Serv Res.* 2024;24(1):519. doi:10.1186/s12913-024-10775-w
71. [Patient Education and Decision Support for Long-Acting Injectable HIV Antiretroviral Therapy: Protocol for Tool Development and Pilot Testing with Ryan White HIV/AIDS Program Medical Case Management Programs in New York.](#) Irvine MK, Zimba R, Avoundjian T, Peterson M, Emmert C, Kulkarni SG, Philbin MM, Kelvin EA, **Nash D**. *JMIR Res Protoc.* 2024;13:e56892. doi:10.2196/56892
72. [Addressing Mental Health Barriers in HIV Care Coordination Is Crucial to Providing Optimal HIV/AIDS Care.](#) Hernandez M, Guarino H, Kozlowski S, Srivastava A, Schenkel R, Tapia T, Seabrook TB, **Nash D**, Irvine MK. *AIDS Patient Care STDS.* 2024;38(3):107-114. doi:10.1089/apc.2023.0240
73. [PrEP Discontinuation In A US National Cohort Of Sexual And Gender Minority Populations, 2017-22.](#) Guo Y, Westmoreland DA, D'Angelo A, Mirzayi C, Dearolf M, Carneiro PB, Ray M, Pantalone DW, Carrico AW, Patel VV, Golub SA, Hirshfield S, Hoover D, **Nash D**, Grov C. *Health Aff (Millwood).* 2024;43(3):443-451. doi:10.1377/hlthaff.2023.00867
74. [Long-term HIV care outcomes under universal HIV treatment guidelines: A retrospective cohort study in 25 countries.](#) Brazier E, Tymejczyk O, Wools-Kaloustian K, Jiamsakul A, Torres MTL, Lee JS, Abuogi L, Khol V, Mejia Cordero F, Althoff KN, Law MG, **Nash D**. *PLoS Med.* 2024;21(3):e1004367. doi:10.1371/journal.pmed.1004367
75. [Oral COVID-19 Antiviral Uptake Among a Highly Vaccinated US Cohort of Adults With SARS-CoV-2 Infection Between December 2021 and October 2022.](#) Shen Y, Robertson MM, Kulkarni SG, Puzniak L, Zamparo JM, Allen KE, Porter TM, Qasmieh SA, Grov C, Srivastava A, Zimba R, McLaughlin JM, **Nash D**. *Open Forum Infect Dis.* 2024;11(2):ofad674. doi:10.1093/ofid/ofad674
76. [Availability of substance use screening and treatment within HIV clinical sites across seven geographic regions within the IeDEA consortium.](#) Lancaster KE, Stockton M, Remch M, Wester

Denis Nash
Curriculum Vitae

- CW, **Nash D**, Brazier E, Adedimeji A, Finlayson R, Freeman A, Hogan B, Kasozi C, Kwobah EK, Kulzer JL, Merati T, Tine J, Poda A, Succi R, Twizere C, Tlali M, Groote P von, Edelman EJ, Parcesepe AM. *Int J Drug Policy*. 2024;124:104309. doi:10.1016/j.drugpo.2023.104309
77. [Underestimation of potentially traumatic events resulting from underreporting of physical and sexual violence among people entering care for HIV in Cameroon](#). Filiatreau LM, Ebasone PV, Dzudie A, Ajeh R, Pence BW, Wainberg M, Yotebieng M, **Nash D**, Anastos K, Parcesepe AM. *Psychol Trauma*. 2024;16(2):347-352. doi:10.1037/tra0001175
78. [Sexual and Gender Minorities' Vaccine Uptake and Behavioral Change in Response to the Mpox Outbreak in the United States: August 2022 Through November 2022](#). Grov C, Zohra F, Mirzayi C, Stief M, D'Angelo AB, Dearolf M, Westmoreland DA, Carneiro P, **Nash D**, Carrico AW. *Clin Infect Dis*. Published online January 23, 2024:ciad793. doi:10.1093/cid/ciad793
79. [Seroincidence of SARS-CoV-2 infection prior to and during the rollout of vaccines in a community-based prospective cohort of U.S. adults](#). **Nash D**, Srivastava A, Shen Y, Penrose K, Kulkarni SG, Zimba R, You W, Berry A, Mirzayi C, Maroko A, Parcesepe AM, Grov C, Robertson MM. *Sci Rep*. 2024;14(1):644. doi:10.1038/s41598-023-51029-9
80. [The Impact of COVID-19 Vaccination on Symptoms of Anxiety and Depression before and after COVID-19 Vaccines Were Universally Available for Adults in the United States](#). Parcesepe AM, **Nash D**, Shen J, Kulkarni SG, Zimba R, You W, Berry A, Piltch-Loeb R, Fleary SA, Stanton E, Grov C, Robertson MM. *Depress Anxiety*. 2024;2024:9682710. doi:10.1155/2024/9682710
81. [Intimate partner violence, depression, hazardous alcohol use, and social support among people with HIV initiating HIV care in Cameroon](#). Grimes KEL, Ebasone PV, Dzudie A, **Nash D**, Pence BW, Wainberg M, Yotebieng M, Ajeh R, Parcesepe AM. *PLoS One*. 2024;19(5):e0304114. doi:10.1371/journal.pone.0304114
82. [Integrating a Resilience Framework to Assess Implementation of a Novel HIV Care Re-Engagement Model in NYC](#). Baim-Lance A, Addison D, Archer N, Gordon P, Duke S, Shubert V, **Nash D**, Robertson M. *J Acquir Immune Defic Syndr*. 2023;94(4):308-316. doi:10.1097/QAI.00000000000003285
83. [Safety, Efficacy, and Ill Intent: Examining COVID-19 Vaccine Perceptions among the New Undervaccinated Moveable Middle in a U.S. Cohort, October 2022](#). Piltch-Loeb R, Penrose K, Stanton E, Parcesepe AM, Shen Y, Fleary SA, **Nash D**. *Vaccines (Basel)*. 2023;11(11):1665. doi:10.3390/vaccines11111665
84. [Boosting" Surveillance for a More Impactful Public Health Response During Protracted and Evolving Infectious Disease Threats: Insights From the COVID-19 Pandemic](#). Qasmieh SA, Robertson MM, **Nash D**. *Health Secur*. 2023;21(S1):S47-S55. doi:10.1089/hs.2023.0046
85. [Proposing the observational-implementation hybrid approach: designing observational research for rapid translation](#). Knox J, Schwartz S, Duncan DT, Curran G, Schneider J, Stephenson R, Wilson P, **Nash D**, Sullivan P, Geng E. *Ann Epidemiol*. 2023;85:45-50. doi:10.1016/j.annepidem.2023.03.008
86. [Availability of screening and treatment for common mental disorders in HIV clinic settings: data from the global International epidemiology Databases to Evaluate AIDS \(IeDEA\) Consortium, 2016-2017 and 2020](#). Parcesepe AM, Stockton M, Remch M, Wester CW, Bernard C, Ross J, Haas AD, Ajeh R, Althoff KN, Enane L, Pape W, Minga A, Kwobah E, Tlali M, Tanuma J, Nsonde D, Freeman A, Duda SN, **Nash D**, Lancaster K. *J Int AIDS Soc*. 2023;26(8):e26147. doi:10.1002/jia2.26147
87. [Food Insecurity During the First Year of COVID-19: Employment and Sociodemographic Factors Among Participants in the CHASING COVID Cohort Study](#). Ng Y, Chang M, Robertson M, Grov

Denis Nash, PhD, MPH
Curriculum Vitae

- C, Maroko A, Zimba R, Westmoreland D, Rane M, Mirzayi C, Parcesepe AM, Kulkarni S, Salgado-You W, Cohen N, **Nash D**. *Public Health Rep*. 2023;138(4):671-680. doi:10.1177/00333549231170203
88. [Client preferences for HIV Care Coordination Program features in New York City: latent class analysis of a discrete choice experiment](#). Conte M, Zimba R, Fong C, Carmona J, Gambone G, Robertson M, Kozlowski S, Abdelqader F, **Nash D**, Irvine M. *J Int AIDS Soc*. 2023;26(8):e26162. doi:10.1002/jia2.26162
 89. [Study protocol for data to suppression \(D2S\): a cluster-randomised, stepped-wedge effectiveness trial of a reporting and capacity-building intervention to improve HIV viral suppression in housing and behavioural health programmes in New York City](#). Irvine MK, Abdelqader F, Levin B, Thomas J, Avoundjian T, Peterson M, Zimba R, Braunstein SL, Robertson MM, **Nash D**. *BMJ Open*. 2023;13(7):e076716. doi:10.1136/bmjopen-2023-076716
 90. [Coping Strategies and Symptoms of Mental Health Disorders Among People with HIV Initiating HIV Care in Cameroon](#). Parcesepe AM, Filiatreau LM, Gomez A, Ebasone PV, Dzudie A, Pence BW, Wainberg M, Yotebieng M, Anastos K, Pefura-Yone E, Nsame D, Ajeh R, **Nash D**. *AIDS Behav*. 2023;27(7):2360-2369. doi:10.1007/s10461-022-03963-4
 91. [Age-varying Associations of Depressive Symptoms and Heavy Episodic Drinking Throughout Adulthood Among People with HIV and Receiving care in Cameroon Within a National “treat all” Policy](#). Lancaster KE, Remch M, Edmonds A, Ajeh R, Dzudie A, Adedimeji A, **Nash D**, Anastos K, Yotebieng M, Yone-Pefura EW, Nsame D, Parcesepe AM. *AIDS Behav*. 2023;27(7):2070-2078. doi:10.1007/s10461-022-03939-4
 92. [The YGetIt? Program: A Mobile Application, PEEP, and Digital Comic Intervention to Improve HIV Care Outcomes for Young Adults](#). Aladin B, Thompson M, Addison D, Havens J, McGowan J, **Nash D**, Smith C. *Health Promot Pract*. 2023;24(4):658-668. doi:10.1177/15248399221150789
 93. [The prevalence of SARS-CoV-2 infection and other public health outcomes during the BA.2/BA.2.12.1 surge, New York City, April-May 2022](#). Qasmieh SA, Robertson MM, Teasdale CA, Kulkarni SG, Jones HE, Larsen DA, Dennehy JJ, McNairy M, Borrell LN, **Nash D**. *Commun Med (Lond)*. 2023;3(1):92. doi:10.1038/s43856-023-00321-w
 94. [The Epidemiology of Long Coronavirus Disease in US Adults](#). Robertson MM, Qasmieh SA, Kulkarni SG, Teasdale CA, Jones HE, McNairy M, Borrell LN, **Nash D**. *Clin Infect Dis*. 2023;76(9):1636-1645. doi:10.1093/cid/ciac961
 95. [Association Between Time to Antiretroviral Therapy and Loss to Care Among Newly Diagnosed Rwandan People Living with Human Immunodeficiency Virus](#). Murenzi G, Kim HY, Shi Q, Muhoza B, Munyaneza A, Kubwimana G, Remera E, Nsanzimana S, Yotebieng M, **Nash D**, Anastos K, Ross J. *AIDS Res Hum Retroviruses*. 2023;39(5):253-261. doi:10.1089/AID.2022.0023
 96. [I stretch them out as long as possible:” U.S. women’s experiences of menstrual product insecurity during the COVID-19 pandemic](#). Schmitt ML, Dimond K, Maroko AR, Phillips-Howard PA, Gruer C, Berry A, **Nash D**, Kochhar S, Sommer M. *BMC Womens Health*. 2023;23(1):179. doi:10.1186/s12905-023-02333-z
 97. [Evaluation of the Revised Versus Original Ryan White Part A HIV Care Coordination Program in a Cluster-Randomized, Stepped-Wedge Trial](#). Irvine MK, Levin B, Abdelqader F, Carmona J, Avoundjian T, Thomas J, Braunstein SL, Robertson M, **Nash D**. *J Acquir Immune Defic Syndr*. 2023;92(4):325-333. doi:10.1097/QAI.0000000000003139
 98. [The prevalence of SARS-CoV-2 infection and long COVID in U.S. adults during the BA.4/BA.5 surge, June-July 2022](#). Qasmieh SA, Robertson MM, Teasdale CA, Kulkarni SG, Jones HE,

Denis Nash
Curriculum Vitae

- McNairy M, Borrell LN, **Nash D**. *Prev Med*. 2023;169:107461. doi:10.1016/j.ypmed.2023.107461
99. [Prevalence of potentially traumatic events and symptoms of depression, anxiety, hazardous alcohol use, and post-traumatic stress disorder among people with HIV initiating HIV care in Cameroon](#). Parcesepe AM, Filiatreau LM, Ebasone PV, Dzudie A, Pence BW, Wainberg M, Yotebieng M, Anastos K, Pefura-Yone E, Nsame D, Ajeh R, **Nash D**. *BMC Psychiatry*. 2023;23(1):150. doi:10.1186/s12888-023-04630-1
100. [HIV-Related Stigma, Social Support, and Symptoms of Mental Health Disorders Among People with HIV Initiating HIV Care in Cameroon](#). Parcesepe AM, Filiatreau LM, Gomez A, Ebasone PV, Dzudie A, Pence BW, Wainberg M, Yotebieng M, Anastos K, Pefura-Yone E, Nsame D, Ajeh R, **Nash D**. *AIDS Patient Care STDS*. 2023;37(3):146-154. doi:10.1089/apc.2022.0187
101. [Drought, HIV Testing, and HIV Transmission Risk Behaviors: A Population- Based Study in 10 High HIV Prevalence Countries in Sub-Saharan Africa](#). Epstein A, Nagata JM, Ganson KT, **Nash D**, Saberi P, Tsai AC, Charlebois ED, Weiser SD. *AIDS Behav*. 2023;27(3):855-863. doi:10.1007/s10461-022-03820-4
102. [Impact of new labor management guidelines on Cesarean rates among low- risk births at New York City hospitals: A controlled interrupted time series analysis](#). Brazier E, Borrell LN, Huynh M, Kelly EA, **Nash D**. *Ann Epidemiol*. 2023;79:3-9. doi:10.1016/j.annepidem.2023.01.001
103. [Estimating the Period Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 \(SARS-CoV-2\) Infection During the Omicron \(BA.1\) Surge in New York City \(NYC\), 1 January to 16 March 2022](#). Qasmieh SA, Robertson MM, Teasdale CA, Kulkarni SG, **Nash D**. *Clin Infect Dis*. 2023;76(3):e499-e502. doi:10.1093/cid/ciac644
104. [Severe Acute Respiratory Syndrome Coronavirus 2 Incidence and Risk Factors in a National, Community-Based Prospective Cohort of US Adults](#). **Nash D**, Rane MS, Robertson MM, Chang M, Kulkarni SG, Zimba R, You W, Berry A, Mirzayi C, Kochhar S, Maroko A, Westmoreland DA, Parcesepe AM, Waldron L, Grov C. *Clin Infect Dis*. 2023;76(3):e375-e384. doi:10.1093/cid/ciac423
105. [Psychosocial Stressors and Maternal Mental Health in the U.S. During the First Wave of the COVID-19 Pandemic: A Cross-Sectional Analysis](#). Parcesepe AM, Kulkarni SG, Grov C, Zimba R, You W, Westmoreland DA, Berry A, Kochhar S, Rane MS, Mirzayi C, Maroko AR, **Nash D**. *Matern Child Health J*. 2023;27(2):335-345. doi:10.1007/s10995-022-03578-0
106. [Population-Based Epidemiology of Heart Failure in a Low-Income Country: The Haiti Cardiovascular Disease Cohort](#). Kingery JR, Roberts NL, Lookens Pierre J, Sufrá R, Dade E, Rouzier V, Malebranche R, Theard M, Goyal P, Pirmohamed A, Yan LD, Hee Lee M, **Nash D**, Metz M, Peck RN, Safford MM, Fitzgerald D, Deschamps MM, Pape JW, McNairy M. *Circ Cardiovasc Qual Outcomes*. 2023;16(2):e009093. doi:10.1161/CIRCOUTCOMES.122.009093
107. [Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting](#). Rane MS, Robertson MM, Kulkarni SG, Frogel D, Gainus C, **Nash D**. *Vaccine*. 2023;41(4):989-998. doi:10.1016/j.vaccine.2022.12.039
108. [Same-Day Antiretroviral Therapy Initiation as a Predictor of Loss to Follow-up and Viral Suppression Among People With Human Immunodeficiency Virus in Sub-Saharan Africa](#). Ross J, Brazier E, Fatti G, Jaquet A, Tanon A, Haas AD, Diero L, Castelnovo B, Yiannoutsos CT, **Nash D**, Anastos KM, Yotebieng M. *Clin Infect Dis*. 2023;76(1):39-47. doi:10.1093/cid/ciac759
109. [Reducing Opioid Analgesic Prescribing in Dentistry Through Prescribing Defaults: A Cluster-Randomized Controlled Trial](#). Bachhuber MA, **Nash D**, Southern WN, Heo M, Berger M, Schepis M, Sugarman OK, Cunningham CO. *Pain Med*. 2023;24(1):1-10. doi:10.1093/pm/pnac106
110. [Design and implementation of a global site assessment survey among HIV clinics participating in](#)

- [the International epidemiology Databases to Evaluate AIDS \(IeDEA\) research consortium](#). Brazier E, Maruri F, Wester CW, Musick B, Freeman A, Parcesepe A, Hossmann S, Christ B, Kimmel A, Humphrey J, Freeman E, Enane LA, Lancaster KE, Ballif M, Golub JE, **Nash D**, Duda SN. *PLoS One*. 2023;18(3):e0268167. doi:10.1371/journal.pone.0268167
111. **PREPRINT:** [Parental COVID-19 vaccine hesitancy and vaccine uptake among children and adolescents in the US: Findings from a prospective national cohort](#) Rane MS, Robertson MS, Westmoreland DA, Zimba R, Kulkarni SG, Shen Y, Berry A, Chang M, You W, Grov C, **Nash D**, CHASING COVID Cohort Team.medRxiv. Published online October 17, 2022:2022.10.16.22281135. doi:10.1101/2022.10.16.22281135
112. [The Importance of Incorporating At-Home Testing Into SARS-CoV-2 Point Prevalence Estimates: Findings From a US National Cohort, February 2022](#). Qasmieh SA, Robertson MM, Rane MS, Shen Y, Zimba R, Picchio CA, Parcesepe AM, Chang M, Kulkarni SG, Grov C, **Nash D**. *JMIR Public Health Surveill*. 2022;8(12):e38196. doi:10.2196/38196
113. [Service delivery challenges in HIV care during the first year of the COVID-19 pandemic: results from a site assessment survey across the global IeDEA consortium](#). Brazier E, Ajeh R, Maruri F, Musick B, Freeman A, Wester CW, Lee MP, Shamu T, Crabtree Ramirez B, d'Almeida M, Wools-Kaloustian K, Kumarasamy N, Althoff KN, Twizere C, Grinsztejn B, Tanser F, Messou E, Byakwaga H, Duda SN, **Nash D**. *J Int AIDS Soc*. 2022;25(12):e26036. doi:10.1002/jia2.26036
114. [Extreme Food Insecurity and Malnutrition in Haiti: Findings from a Population-Based Cohort in Port-au-Prince, Haiti](#). Rasul R, Rouzier V, Sufra R, Yan LD, Joseph I, Mourra N, Sabwa S, Deschamps MM, Fitzgerald DW, Pape JW, **Nash D**, McNairy ML. *Nutrients*. 2022;14(22):4854. doi:10.3390/nu14224854
115. [Self-Reported Use of HIV Preexposure Prophylaxis Is Highly Accurate Among Sexual Health Clinic Patients in New York City](#). Qasmieh S, **Nash D**, Gandhi M, Rozen E, Okochi H, Goldstein H, Herold BC, Jamison K, Pathela P. *Sex Transm Dis*. 2022;49(11):790-793. doi:10.1097/OLQ.0000000000001622
116. [Racial/Ethnic Disparities in Exposure, Disease Susceptibility, and Clinical Outcomes during COVID-19 Pandemic in National Cohort of Adults, United States](#). Robertson MM, Shamsunder MG, Brazier E, Mantravadi M, Zimba R, Rane MS, Westmoreland DA, Parcesepe AM, Maroko AR, Kulkarni SG, Grov C, **Nash D**. *Emerg Infect Dis*. 2022;28(11):2171-2180. doi:10.3201/eid2811.220072
117. [SARS-CoV-2 pandemic in New York metropolitan area: the view from a major urgent care provider](#). Rane MS, Profeta A, Poehlein E, Kulkarni S, Robertson M, Gainus C, Parikh A, LeBenger K, Frogel D, **Nash D**. *Ann Epidemiol*. 2022;74:31-40. doi:10.1016/j.annepidem.2022.05.006
118. [Viral Load Status Before Switching to Dolutegravir-Containing Antiretroviral Therapy and Associations With Human Immunodeficiency Virus Treatment Outcomes in Sub-Saharan Africa](#). Romo ML, Edwards JK, Semeere AS, Musick BS, Urassa M, Odhiambo F, Diero L, Kasozi C, Murenzi G, Lelo P, Wyka K, Kelvin EA, Sohn AH, Wools-Kaloustian KK, **Nash D**. *Clin Infect Dis*. 2022;75(4):630-637. doi:10.1093/cid/ciab1006
119. [Analysis of Heavy Rainfall in Sub-Saharan Africa and HIV Transmission Risk, HIV Prevalence, and Sexually Transmitted Infections, 2005-2017](#). Nagata JM, Hampshire K, Epstein A, Lin F, Zakaras J, Murnane P, Charlebois ED, Tsai AC, **Nash D**, Weiser SD. *JAMA Netw Open*. 2022;5(9):e2230282. doi:10.1001/jamanetworkopen.2022.30282
120. [Site-Level Comprehensiveness of Care Is Associated with Individual Clinical Retention Among Adults Living with HIV in International Epidemiology Databases to Evaluate AIDS, a Global HIV](#)

Denis Nash
Curriculum Vitae

- [Cohort Collaboration, 2000-2016](#). Wada PY, Kim A, Jayathilake K, Duda SN, Abo Y, Althoff KN, Cornell M, Musick B, Brown S, Sohn AH, Chan YJ, Wools-Kaloustian KK, **Nash D**, Yiannoutsos CT, Cesar C, McGowan CC, Rebeiro PF. *AIDS Patient Care STDS*. 2022;36(9):343-355. doi:10.1089/apc.2022.0042
121. [Racial disparity in ART adherence is closed in states with high social trust: Results from the Medical Monitoring Project \(MMP\), 2015](#). Ransome Y, Kershaw T, Kawachi I, **Nash D**, Mayer KH. *J Community Psychol*. 2022;50(8):3659-3680. doi:10.1002/jcop.22862
122. [Variation and racial/ethnic disparities in Cesarean delivery at New York City hospitals: the contribution of hospital-level factors](#). Brazier E, Borrell LN, Huynh M, Kelly EA, **Nash D**. *Ann Epidemiol*. 2022;73:1-8. doi:10.1016/j.annepidem.2022.06.003
123. [Brief Report: Use of Remnant Specimens to Assess Use of HIV PrEP Among Populations With Risk of HIV Infection: A Novel Approach](#). Pathela P, Qasmieh S, Gandhi M, Rozen E, Okochi H, Goldstein H, Herold BC, Jamison K, Schillinger JA, **Nash D**. *J Acquir Immune Defic Syndr*. 2022;90(4):382-387. doi:10.1097/QAI.0000000000002992
124. [Presence of SARS-CoV-2 antibodies following COVID-19 diagnosis: a longitudinal study of patients at a major urgent care provider in New York](#). Poehlein E, Rane MS, Frogel D, Kulkarni S, Gainus C, Profeta A, Robertson M, **Nash D**. *Diagn Microbiol Infect Dis*. 2022;103(4):115720. doi:10.1016/j.diagmicrobio.2022.115720
125. [Prevalence of stressful life events and associations with symptoms of depression, anxiety, and post-traumatic stress disorder among people entering care for HIV in Cameroon](#). Filiatreau LM, Ebasone PV, Dzudie A, Ajeh R, Pence BW, Wainberg M, **Nash D**, Yotebieng M, Anastos K, Pefura-Yone E, Nsame D, Parcesepe AM. *J Affect Disord*. 2022;308:421-431. doi:10.1016/j.jad.2022.04.061
126. [Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa](#). Romo ML, Brazier E, Mahambou-Nsonde D, De Waal R, Sekaggya-Wiltshire C, Chimbetete C, Muyindike WR, Murenzi G, Kunzekwenyika C, Tiendrebeogo T, Muhairwe JA, Lelo P, Dzudie A, Twizere C, Rafael I, Ezechi OC, Diero L, Yotebieng M, Fenner L, Wools-Kaloustian KK, Shah NS, **Nash D**. *J Int AIDS Soc*. 2022;25(7):e25961. doi:10.1002/jia2.25961
127. [A Method for Generating Dashboard Aggregations in an International HIV Consortium](#). Lewis JT, Brazier E, Katz B, **Nash D**, Duda SN. *Stud Health Technol Inform*. 2022;290:1048-1049. doi:10.3233/SHTI220261
128. [Missed routine pediatric care and vaccinations in US children during the first year of the COVID-19 pandemic](#). Teasdale CA, Borrell LN, Shen Y, Kimball S, Zimba R, Kulkarni S, Rane M, Rinke ML, Fleary SA, **Nash D**. *Prev Med*. 2022;158:107025. doi:10.1016/j.ypmed.2022.107025
129. [COVID-19 Testing Among US Children, Parental Preferences for Testing Venues, and Acceptability of School-Based Testing](#). Teasdale CA, Borrell LN, Shen Y, Kimball S, Rinke ML, Rane MS, Kulkarni S, Fleary SA, **Nash D**. *Public Health Rep*. 2022;137(2):362-369. doi:10.1177/00333549211065518
130. [Menstrual Product Insecurity Resulting From COVID-19Related Income Loss, United States, 2020](#). Sommer M, Phillips-Howard PA, Gruer C, Schmitt ML, Nguyen AM, Berry A, Kochhar S, Gorrell Kulkarni S, **Nash D**, Maroko AR. *Am J Public Health*. 2022;112(4):675-684. doi:10.2105/AJPH.2021.306674
131. [Delayed presentation of HIV among older individuals: a growing problem](#). Justice AC, Goetz MB, Stewart CN, Hogan BC, Humes E, Luz PM, Castilho JL, **Nash D**, Brazier E, Musick B, Yiannoutsos C, Malateste K, Jaquet A, Cornell M, Shamu T, Rajasuriar R, Jiamsakul A, Althoff KN. *Lancet HIV*.

Denis Nash, PhD, MPH
Curriculum Vitae

- 2022;9(4):e269-e280. doi:10.1016/S2352-3018(22)00003-0
132. [The question of the question: impactful implementation science to address the HIV epidemic](#). Geng EH, **Nash D**, Phanuphak N, Green K, Solomon S, Grimsrud A, Sohn AH, Mayer KH, Barnighausen T, Bekker LG. *J Int AIDS Soc*. 2022;25(4):e25898. doi:10.1002/jia2.25898
133. [Author Correction: Self-reported COVID-19 vaccine hesitancy and uptake among participants from different racial and ethnic groups in the United States and United Kingdom](#). Nguyen LH, Joshi AD, Drew DA, Merino J, Ma W, Lo CH, Kwon S, Wang K, Graham MS, Polidori L, Menni C, Sudre CH, Anyane-Yeboah A, Astley CM, Warner ET, Hu CY, Selvachandran S, Davies R, **Nash D**, Franks PW, Wolf J, Ourselin S, Steves CJ, Spector TD, Chan AT. *Nat Commun*. 2022;13(1):1715. doi:10.1038/s41467-022-29100-2
134. [Determinants and Trends of COVID-19 Vaccine Hesitancy and Vaccine Uptake in a National Cohort of US Adults: A Longitudinal Study](#). Rane MS, Kochhar S, Poehlein E, You W, Robertson MM, Zimba R, Westmoreland DA, Romo ML, Kulkarni SG, Chang M, Berry A, Parcesepe AM, Maroko AR, Grov C, **Nash D**. *Am J Epidemiol*. 2022;191(4):570-583. doi:10.1093/aje/kwab293
135. [Provider preferences for delivery of HIV care coordination services: results from a discrete choice experiment](#). Zimba R, Fong C, Conte M, Baim-Lance A, Robertson M, Carmona J, Gambone G, **Nash D**, Irvine M. *J Int AIDS Soc*. 2022;25(3):e25887. doi:10.1002/jia2.25887
136. [Estimated blood pressure trajectories and hypertension patterns among pregnant women living with HIV, Haiti, 2007-2017](#). Tymejczyk O, Deschamps MM, Rouzier V, McNairy ML, Peck RN, Malha L, Macius Y, Fitzgerald DW, Pape JW, **Nash D**. *J Clin Hypertens (Greenwich)*. 2022;24(3):237-245. doi:10.1111/jch.14432
137. [Depressive Symptoms, Gender, Disclosure, and HIV Care Stage Among People Living with HIV in Cameroon](#). Parcesepe AM, Remch M, Dzudie A, Ajeh R, **Nash D**, Anastos K, Yotebieng M, Adedimeji A, Pefura-Yone E, Lancaster K. *AIDS Behav*. 2022;26(3):651-661. doi:10.1007/s10461-021-03425-3
138. [Intention to Vaccinate Children Against COVID-19 Among Vaccinated and Unvaccinated US Parents](#). Rane MS, Robertson MM, Westmoreland DA, Teasdale CA, Grov C, **Nash D**. *JAMA Pediatr*. 2022;176(2):201-203. doi:10.1001/jamapediatrics.2021.5153
139. [Self-reported COVID-19 vaccine hesitancy and uptake among participants from different racial and ethnic groups in the United States and United Kingdom](#). Nguyen LH, Joshi AD, Drew DA, Merino J, Ma W, Lo CH, Kwon S, Wang K, Graham MS, Polidori L, Menni C, Sudre CH, Anyane-Yeboah A, Astley CM, Warner ET, Hu CY, Selvachandran S, Davies R, **Nash D**, Franks PW, Wolf J, Ourselin S, Steves CJ, Spector TD, Chan AT. *Nat Commun*. 2022;13(1):636. doi:10.1038/s41467-022-28200-3
140. [High Lead Exposure Associated With Higher Blood Pressure in Haiti: a Warning Sign for Low-Income Countries](#). Yan LD, Rouzier V, Pierre JL, Lee MH, Muntner P, Parsons PJ, Apollon A, St-Preux S, Malebranche R, Pierre G, Emmanuel E, **Nash D**, Kingery J, Walsh KF, Smith CE, Metz M, Tymejczyk O, Deschamps M, Pape JW, Fitzgerald DW, McNairy ML. *Hypertension*. 2022;79(1):283-290. doi:10.1161/HYPERTENSIONAHA.121.18250
141. [Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity : An Observational Study](#). Romo ML, Patel RC, Edwards JK, Humphrey JM, Musick BS, Bernard C, Maina MW, Brazier E, Castelnuovo B, Penner J, Wyka K, Cardoso SW, Ly PS, Kunzekwenyika C, Cortés CP, Panczak R, Kelvin EA, Wools-Kaloustian KK, and **Nash D** for the International epidemiology Databases to Evaluate AIDS (IeDEA). *Ann Intern Med*. 2022 Jan;175(1):84-94. doi: 10.7326/M21-3037. Epub

Denis Nash
Curriculum Vitae

2021 Nov 30.

142. [Sex in the Era of COVID-19 in a U.S. National Cohort of Cisgender Men, Transgender Women, and Transgender Men Who Have Sex with Men: April-May 2020](#). Grov C, Zohra F, Westmoreland DA, Mirzayi C, D'Angelo A, Stief M, Kulkarni S, **Nash D**, Carrico AW. *Arch Sex Behav*. 2022;51(1):343-354. doi:10.1007/s10508-021-02121-6
143. [The relationship between perceived stress and support with blood pressure in urban Haiti: A cross-sectional analysis](#). Yan LD, Devieux JG, Pierre JL, Dade E, Sufra R, St Preux S, Tymejczyk O, **Nash D**, Metz M, Lee MH, Fitzgerald DW, Deschamps M, Pape JW, McNairy ML, Rouzier V. *PLOS Glob Public Health*. 2022;2(5):e0000263. doi:10.1371/journal.pgph.0000263
144. [Diabetes Epidemiology Among Adults in Port-au-Prince, Haiti: A Cross-Sectional Study](#). Sufra R, Lookens Pierre J, Dade E, Rouzier V, Apollon A, St Preux S, Preval F, Inddy J, Metz M, Tymejczyk O, **Nash D**, Malebranche R, Deschamps M, Pape JW, Goncalves MD, McNairy ML, Yan LD. *Front Endocrinol (Lausanne)*. 2022;13:841675. doi:10.3389/fendo.2022.841675
145. [COVID-19 associated changes in HIV service delivery over time in Central Africa: Results from facility surveys during the first and second waves of the pandemic](#). Rogers A, Brazier E, Dzudie A, Adedimeji A, Yotebieng M, Muhoza B, Twizere C, Lelo P, Nsonde D, Mafoua A, Munyaneza A, Gateretse P, Diafouka M, Murenzi G, Niyongabo T, Anastos K, **Nash D**. *PLoS One*. 2022;17(11):e0275429. doi:10.1371/journal.pone.0275429
146. [Psychiatric comorbidity and psychosocial stressors among people initiating HIV care in Cameroon](#). Parcesepe AM, Filiatreau LM, Ebasone PV, Dzudie A, Pence BW, Wainberg M, Yotebieng M, Anastos K, Pefura-Yone E, Nsame D, Ajeh R, **Nash D**. *PLoS One*. 2022;17(6):e0270042. doi:10.1371/journal.pone.0270042
147. [Household factors and the risk of severe COVID-like illness early in the U.S. pandemic](#). **Nash D**, Qasmieh S, Robertson M, Rane M, Zimba R, Kulkarni SG, Berry A, You W, Mirzayi C, Westmoreland D, Parcesepe A, Waldron L, Kochhar S, Maroko AR, Grov C. *PLoS One*. 2022;17(7):e0271786. doi:10.1371/journal.pone.0271786
148. [A cross sectional study to examine factors influencing COVID-19 vaccine acceptance, hesitancy and refusal in urban and rural settings in Tamil Nadu, India](#). Joshi A, Surapaneni KM, Kaur M, Bhatt A, **Nash D**, El-Mohandes A. *PLoS One*. 2022;17(6):e0269299. doi:10.1371/journal.pone.0269299
149. [Patterns of SARS-CoV-2 Testing Preferences in a National Cohort in the United States: Latent Class Analysis of a Discrete Choice Experiment](#). Zimba R, Romo ML, Kulkarni SG, Berry A, You W, Mirzayi C, Westmoreland DA, Parcesepe AM, Waldron L, Rane MS, Kochhar S, Robertson MM, Maroko AR, Grov C, **Nash D**. *JMIR Public Health Surveill*. 2021;7(12):e32846. doi:10.2196/32846
150. [Regression discontinuity analysis demonstrated varied effect of Treat-All on CD4 testing among Southern African countries](#). Zaniewski E, Brazier E, Ostinelli CHD, Wood R, Osler M, Technau KG, van Oosterhout JJ, Maxwell N, van Dijk J, Prozesky H, Fox MP, Bor J, **Nash D**, Egger M. *J Clin Epidemiol*. 2021;140:101-110. doi:10.1016/j.jclinepi.2021.09.001
151. [Mortality among clients in the New York city HIV Care Coordination Program \(CCP\): incidence and associated clinical factors](#). Robertson MM, Irvine MK, Penrose K, Harriman G, Braunstein SL, **Nash D**. *Ann Epidemiol*. 2021;64:161-166. doi:10.1016/j.annepidem.2021.10.001
152. [Gender, Mental Health, and Entry Into Care with Advanced HIV Among People Living with HIV in Cameroon Under a National "Treat All" Policy](#). Parcesepe AM, Filiatreau LM, Ebasone PV, Dzudie A, Ajeh R, Wainberg M, Pence B, Pefura-Yone E, Yotebieng M, Nsame D, Anastos K, **Nash D**. *AIDS Behav*. 2021;25(12):4018-4028. doi:10.1007/s10461-021-03328-3
153. [Heavy episodic drinking and HIV disclosure by HIV treatment status among People with HIV in](#)

- [IeDEA Cameroon](#). Lancaster KE, Remch M, Dzudie A, Ajeh R, Adedimeji A, **Nash D**, Anastos K, Yotebieng M, Yone-Pefura EW, Nsame D, Parcesepe A. *Int J Drug Policy*. 2021;98:103431. doi:10.1016/j.drugpo.2021.103431
154. [Estimated number of N95 respirators needed for healthcare workers in acute-care hospitals during the coronavirus disease 2019 \(COVID-19\) pandemic](#). Wedlock PT, O'Shea KJ, Conte M, Bartsch SM, Randall SL, Ferguson MC, Cox SN, Siegmund SS, Kulkarni S, **Nash D**, Lin MY, Lee BY. *Infect Control Hosp Epidemiol*. 2021;42(11):1318-1326. doi:10.1017/ice.2020.1418
155. [Mental health and initiation of antiretroviral treatment at enrolment into HIV care in Cameroon under a national "treat all" policy: a cross-sectional analysis](#). Parcesepe AM, Filiatreau LM, Ebasone PV, Dzudie A, Pence BW, Wainberg M, Yotebieng M, Anastos K, Pefura-Yone E, Ajeh R, **Nash D**. *J Int AIDS Soc*. 2021;24(11):e25842. doi:10.1002/jia2.25842
156. [HIV Care Coordination promotes care re-engagement and viral suppression among people who have been out of HIV medical care: an observational effectiveness study using a surveillance-based contemporaneous comparison group](#). Irvine MK, Robertson MM, **Nash D**, Kulkarni SG, Braunstein SL, Levin B. *AIDS Res Ther*. 2021;18(1):70. doi:10.1186/s12981-021-00398-0
157. [Plans to Vaccinate Children for Coronavirus Disease 2019: A Survey of United States Parents](#). Teasdale CA, Borrell LN, Kimball S, Rinke ML, Rane M, Fleary SA, **Nash D**. *J Pediatr*. 2021;237:292-297. doi:10.1016/j.jpeds.2021.07.021
158. [Global Disparities in Skin Cancer Services at HIV Treatment Centers across 29 Countries](#). McMahon DE, Semeere A, Laker-Oketta M, Byakwaga H, Mugglin C, Duda SN, Azwa I, Jaquet A, Cardoso SW, **Nash D**, Wester CW, Freeman EE. *J Invest Dermatol*. 2021;141(10):2533-2536.e2. doi:10.1016/j.jid.2021.02.758
159. [Cohort profile: a national, community-based prospective cohort study of SARS-CoV-2 pandemic outcomes in the USA-the CHASING COVID Cohort study](#). Robertson MM, Kulkarni SG, Rane M, Kochhar S, Berry A, Chang M, Mirzayi C, You W, Maroko A, Zimba R, Westmoreland D, Grov C, Parcesepe AM, Waldron L, **Nash D**. *BMJ Open*. 2021;11(9):e048778. doi:10.1136/bmjopen-2021-048778
160. [Effects of National Adoption of Treat-All Guidelines on Pre- Antiretroviral Therapy \(ART\) CD4 Testing and Viral Load Monitoring After ART initiation: A Regression Discontinuity Analysis](#). Brazier E, Tymejczyk O, Zaniewski E, Egger M, Wools-Kaloustian K, Yiannoutsos CT, Jaquet A, Althoff KN, Lee JS, Caro-Vega Y, Luz PM, Tanuma J, Niyongabo T, **Nash D**. *Clin Infect Dis*. 2021;73(6):e1273-e1281. doi:10.1093/cid/ciab222
161. [Parental plans to vaccinate children for COVID-19 in New York city](#). Teasdale CA, Borrell LN, Shen Y, Kimball S, Rinke ML, Fleary SA, **Nash D**. *Vaccine*. 2021;39(36):5082-5086. doi:10.1016/j.vaccine.2021.07.058
162. [Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV](#). Lazarus JV, Safreed-Harmon K, Kamarulzaman A, Anderson J, Leite RB, Behrens G, Bekker LG, Bhagani S, Brown D, Brown G, Buchbinder S, Caceres C, Cahn PE, Carrieri P, Caswell G, Cooke GS, Monforte A d'Arminio, Dedes N, Del Amo J, Elliott R, El-Sadr WM, Fuster-Ruiz de Apodaca MJ, Guaraldi G, Hallett T, Harding R, Hellard M, Jaffar S, Kall M, Klein M, Lewin SR, Mayer K, Perez-Molina JA, Moraa D, Naniche D, **Nash D**, Noori T, Pozniak A, Rajasuriar R, Reiss P, Rizk N, Rockstroh J, Romero D, Sabin C, Serwadda D, Waters L. *Nat Commun*. 2021;12(1):4450. doi:10.1038/s41467-021-24673-w
163. [Stochastic Version of EM Algorithm for Nonlinear Random Change-Point Models](#). Zhang H, Manandhar B. *Proc Int Conf Stat Theory Appl ICSTA*. 2021;2021:119. doi:10.11159/icsta21.119

164. [The effect of the Affordable Care Act dependent coverage provision on HPV vaccine uptake in young adult women, National Health and Nutrition Examination Survey 2007-2016](#). Raymond S, Li L, Taioli E, **Nash D**, Liu B. *Prev Med*. 2021;148:106536. doi:10.1016/j.ypmed.2021.106536
165. [Correlates of self-reported history of mental health help-seeking: a cross-sectional study among individuals with symptoms of a mental or substance use disorder initiating care for HIV in Cameroon](#). Filiatreau LM, Ebasone PV, Dzudie A, Ajeh R, Pence B, Wainberg M, **Nash D**, Yotebieng M, Anastos K, Pefura-Yone E, Nsame D, Parcesepe AM. *BMC Psychiatry*. 2021;21(1):293. doi:10.1186/s12888-021-03306-y
166. [Implementing Implementation Research: Teaching Implementation Research to HIV Researchers](#). Schwartz SR, Smith JD, Hoffmann C, Hansoti B, Mishra S, Means AR, Go V, Sherr K, **Nash D**, Sullivan P, Baral S. *Curr HIV/AIDS Rep*. 2021;18(3):186-197. doi:10.1007/s11904-021-00551-4
167. [Trends in demographic and clinical characteristics and initiation of antiretroviral therapy among adult patients enrolling in HIV care in the Central Africa International epidemiology Database to Evaluate AIDS \(CA- IeDEA\) 2004 to 2018](#). Adedimeji AA, Hoover DR, Shi Q, Kim HY, Brazier E, Ross J, Murenzi G, Twizere C, Lelo P, Nsonde D, Ajeh R, Dzudie A, **Nash D**, Yotebieng M, Anastos K. *J Int AIDS Soc*. 2021;24(6):e25672. doi:10.1002/jia2.25672
168. [Comparison of cohort characteristics in Central Africa International Epidemiology Databases to Evaluate AIDS and Demographic Health Surveys: Rwanda and Burundi](#). Mageras A, Brazier E, Niyongabo T, Murenzi G, D'Amour Sinayobye J, Adedimeji AA, Twizere C, Kelvin EA, Anastos K, **Nash D**, Jones HE. *Int J STD AIDS*. 2021;32(6):551-561. doi:10.1177/0956462420983783
169. [Marketing of Tenofovir Disoproxil Fumarate \(TDF\) Lawsuits and Social Media Misinformation Campaigns' Impact on PrEP Uptake Among Gender and Sexual Minority Individuals](#). Grov C, Westmoreland DA, D'Angelo AB, Johnson J, **Nash D**, Daskalakis DC. *AIDS Behav*. 2021;25(5):1396-1404. doi:10.1007/s10461-020-02977-0
170. [Effect of Changing Electronic Health Record Opioid Analgesic Dispense Quantity Defaults on the Quantity Prescribed: A Cluster Randomized Clinical Trial](#). Bachhuber MA, **Nash D**, Southern WN, Heo M, Berger M, Schepis M, Thakral M, Cunningham CO. *JAMA Netw Open*. 2021;4(4):e217481. doi:10.1001/jamanetworkopen.2021.7481
171. [PrEP Uptake and Discontinuation Among a U.S. National Sample of Transgender Men and Women](#). Zarwell M, John SA, Westmoreland D, Mirzayi C, Pantalone DW, Golub S, **Nash D**, Grov C. *AIDS Behav*. 2021;25(4):1063-1071. doi:10.1007/s10461-020-03064-0
172. [Exploration of the Complex Relationships Among Multilevel Predictors of PrEP Use Among Men Who Have Sex with Men in the United States](#). Rodriguez K, Kelvin EA, Grov C, Meyers K, **Nash D**, Wyka K. *AIDS Behav*. 2021;25(3):798-808. doi:10.1007/s10461-020-03039-1
173. [Tracing-corrected estimates of disengagement from HIV care and mortality among patients enrolling in HIV care without overt immunosuppression in Tanzania](#). Tymejczyk O, Vo Q, Kulkarni SG, Antelman G, Boshe J, Reidy W, Parcesepe A, **Nash D**, Elul B. *AIDS Care*. 2021;33(1):47-53. doi:10.1080/09540121.2019.1699642
174. [Higher and Higher? Drug and Alcohol Use and Misuse among HIV-Vulnerable Men, Trans Men, and Trans Women Who Have Sex with Men in the United States](#). Westmoreland DA, Carrico AW, Goodwin RD, Pantalone DW, **Nash D**, Grov C. *Subst Use Misuse*. 2021;56(1):111-122. doi:10.1080/10826084.2020.1843057
175. [Predictors of COVID-19 Vaccine Acceptance, Intention, and Hesitancy: A Scoping Review](#). Joshi A, Kaur M, Kaur R, Grover A, **Nash D**, El-Mohandes A. *Front Public Health*. 2021;9:698111. doi:10.3389/fpubh.2021.698111

Denis Nash, PhD, MPH
Curriculum Vitae

176. [Hypertension among people living with HIV/AIDS in Cameroon: A cross- sectional analysis from Central Africa International Epidemiology Databases to Evaluate AIDS](#). Dzudie A, Hoover D, Kim HY, Ajeh R, Adedimeji A, Shi Q, Pefura Yone W, Nsame Nforiwe D, Thompson Njie K, Pascal Kengne A, Ebasone PV, Barche B, Bissek Anne Cecile ZK, **Nash D**, Yotebieng M, Anastos K. *PLoS One*. 2021;16(7):e0253742. doi:10.1371/journal.pone.0253742
177. **PREPRINT:** [Risk Profile of Thanksgiving Gatherers and Subsequent SARS-CoV2 Testing and Diagnosis](#) You W, Rane MS, Zimba R, Berry A, Kulkarni SG, Westmoreland DA, Parcesepe A, Chang M, Maroko AR, Kochhar S, Mirzayi C, Grov C, **Nash D**.medRxiv. Published online April 25, 2021:2021.04.22.21255631. doi:10.1101/2021.04.22.21255631
178. **PREPRINT:** [Spread and sources of information and misinformation about COVID-19 early during the pandemic in a U.S. national cohort study](#) Westmoreland DA, Berry A, Zimba R, Kulkarni SG, Parcesepe A, Maroko AR, Poehlein E, You W, Mirzayi C, Kochhar S, Robertson M, Waldron L, Grov C, **Nash D**.medRxiv. Published online March 12, 2021:2021.03.10.21252851. doi:10.1101/2021.03.10.21252851
179. [SARS-CoV-2 Testing Service Preferences of Adults in the United States: Discrete Choice Experiment](#). Zimba R, Kulkarni S, Berry A, You W, Mirzayi C, Westmoreland D, Parcesepe A, Waldron L, Rane M, Kochhar S, Robertson M, Maroko A, Grov C, **Nash D**. *JMIR Public Health Surveill*. 2020;6(4):e25546. doi:10.2196/25546
180. [The HEALing \(Helping to End Addiction Long-term \(SM\)\) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices](#). *Drug Alcohol Depend*. 2020;217:108335. doi:10.1016/j.drugalcdep.2020.108335
181. [Assessing linear CD4 decline quantifying diagnosis delay after HIV seroconversion: assessing the linearity assumption of CD4 decline](#). Robertson MM, Braunstein SL, Hoover DR, Li S, **Nash D**. *Ann Epidemiol*. 2020;52:1-6. doi:10.1016/j.annepidem.2020.08.003
182. [Estimates of the Time From Seroconversion to Antiretroviral Therapy Initiation Among People Newly Diagnosed With Human Immunodeficiency Virus From 2006 to 2015, New York City](#). Robertson MM, Braunstein SL, Hoover DR, Li S, **Nash D**. *Clin Infect Dis*. 2020;71(8):e308-e315. doi:10.1093/cid/ciz1178
183. [Contact Tracing: Essential to the Public Health Response and Our Understanding of the Epidemiology of Coronavirus Disease 2019](#). Althoff KN, Coburn SB, **Nash D**. *Clin Infect Dis*. 2020;71(8):1960-1961. doi:10.1093/cid/ciaa757
184. **PREPRINT:** [The relationship between anxiety, health, and potential stressors among adults in the United States during the COVID-19 pandemic](#). Parcesepe AM, Robertson M, Berry A, Maroko A, Zimba R, Grov C, Westmoreland D, Kulkarni S, Rane M, Salgado-You W, Mirzayi C, Waldron L, **Nash D**. *medRxiv*. Published online November 4, 2020:2020.10.30.20221440. doi:10.1101/2020.10.30.20221440
185. [The Haiti cardiovascular disease cohort: study protocol for a population- based longitudinal cohort](#). Lookens J, Tymejczyk O, Rouzier V, Smith C, Preval F, Joseph I, Baptiste RJ, Victor J, Severe P, Apollon S, Dumont E, Forestal G, St Preux S, Rivera V, Seo G, Charles B, Ariste W, Kingery J, Devieux J, Koenig S, **Nash D**, Fitzgerald D, Safford M, Deschamps MM, Pape J, McNairy M. *BMC Public Health*. 2020;20(1):1633. doi:10.1186/s12889-020-09734-x
186. [The Crisis We Are Not Talking About: One-in-Three Annual HIV Seroconversions Among Sexual and Gender Minorities Were Persistent Methamphetamine Users](#). Grov C, Westmoreland D, Morrison C, Carrico AW, **Nash D**. *J Acquir Immune Defic Syndr*. 2020;85(3):272-279.

Denis Nash
Curriculum Vitae

doi:10.1097/QAI.00000000000002461

187. [Open Letter by Epidemic Intelligence Service Officers Past and Present - in Support of CDC. *Epimonitor*. 2020;41\(10\):12-18.](#)
188. [Individual and Partner Characteristics Associated With Intentions to Use PrEP Among Partnered Men, Trans Men, and Trans Women in Sero-Concordant and -Discordant Relationships in the United States.](#) Westmoreland DA, D'Angelo A, **Nash D**, Grov C. *AIDS Educ Prev*. 2020;32(5):367-377. doi:10.1521/aeap.2020.32.5.367
189. [Implications of COVID-19 for HIV Research: data sources, indicators and longitudinal analyses.](#) Rebeiro PF, Duda SN, Wools-Kaloustian KK, **Nash D**, Althoff KN. *J Int AIDS Soc*. 2020;23(10):e25627. doi:10.1002/jia2.25627
190. [Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City.](#) Jordan AE, Cleland CM, Wyka K, Schackman BR, Perlman DC, **Nash D**. *J Infect Dis*. 2020;222(Suppl 5):S322-S334. doi:10.1093/infdis/jiz659
191. [Hepatitis C Virus \(HCV\) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program.](#) Jordan AE, Cleland CM, Schackman BR, Wyka K, Perlman DC, **Nash D**. *J Infect Dis*. 2020;222(Suppl 5):S335-S345. doi:10.1093/infdis/jiz686
192. [Prior HIV testing behaviour is associated with HIV testing results among men, trans women and trans men who have sex with men in the United States.](#) Grov C, Westmoreland D, Golub SA, **Nash D**. *J Epidemiol Community Health*. 2020;74(9):741-753. doi:10.1136/jech-2019-213493
193. [Impact of Universal Antiretroviral Treatment Eligibility on Rapid Treatment Initiation Among Young Adolescents with Human Immunodeficiency Virus in Sub-Saharan Africa.](#) Tymejczyk O, Brazier E, Wools-Kaloustian K, Davies MA, Dilorenzo M, Edmonds A, Vreeman R, Bolton C, Twizere C, Okoko N, Phiri S, Nakigozi G, Lelo P, von Groote P, Sohn AH, **Nash D**. *J Infect Dis*. 2020;222(5):755-764. doi:10.1093/infdis/jiz547
194. [Goal-Aligned, Epidemic Intelligence for the Public Health Response to the COVID-19 Pandemic.](#) **Nash D**, Geng E. *Am J Public Health*. 2020;110(8):1154-1156. doi:10.2105/AJPH.2020.305794
195. [COVID-19 and Inequity: a Comparative Spatial Analysis of New York City and Chicago Hot Spots.](#) Maroko AR, **Nash D**, Pavilonis BT. *J Urban Health*. 2020;97(4):461-470. doi:10.1007/s11524-020-00468-0
196. [PROMISE \(Program Refinements to Optimize Model Impact and Scalability based on Evidence\): a cluster-randomised, stepped-wedge trial assessing effectiveness of the revised versus original Ryan White Part A HIV Care Coordination Programme for patients with barriers to treatment in the USA.](#) Irvine MK, Levin B, Robertson MM, Penrose K, Carmona J, Harriman G, Braunstein SL, **Nash D**. *BMJ Open*. 2020;10(7):e034624. doi:10.1136/bmjopen-2019-034624
197. [Gone But Not Lost: Implications for Estimating HIV Care Outcomes When Loss to Clinic Is Not Loss to Care.](#) Edwards JK, Lesko CR, Herce ME, Murenzi G, Twizere C, Lelo P, Anastos K, Tymejczyk O, Yotebieng M, **Nash D**, Adedimeji A, Edmonds A. *Epidemiology*. 2020;31(4):570-577. doi:10.1097/EDE.0000000000001201
198. [The COronavirus Pandemic Epidemiology \(COPE\) Consortium: A Call to Action.](#) Chan AT, Drew DA, Nguyen LH, Joshi AD, Ma W, Guo CG, Lo CH, Mehta RS, Kwon S, Sikavi DR, Magicheva-Gupta MV, Fatehi ZS, Flynn JJ, Leonardo BM, Albert CM, Andreotti G, Beane-Freeman LE, Balasubramanian BA, Brownstein JS, Bruinsma F, Cowan AN, Deka A, Ernst ME, Figueiredo JC, Franks PW, Gardner CD, Ghobrial IM, Haiman CA, Hall JE, Deming-Halverson SL, Kirpach B, Lacey JVJ, Marchand LL, Marinac CR, Martinez ME, Milne RL, Murray AM, **Nash D**, Palmer JR, Patel AV, Rosenberg L, Sandler DP, Sharma SV, Schurman SH, Wilkens LR, Chavarro JE, Eliassen

Denis Nash, PhD, MPH
Curriculum Vitae

- AH, Hart JE, Kang JH, Koenen KC, Kubzansky LD, Mucci LA, Ourselin S, Rich-Edwards JW, Song M, Stampfer MJ, Steves CJ, Willett WC, Wolf J, Spector T. *Cancer Epidemiol Biomarkers Prev.* 2020;29(7):1283-1289. doi:10.1158/1055-9965.EPI-20-0606
199. [High levels of viral load monitoring and viral suppression under Treat All in Rwanda - a cross-sectional study](#). Ross J, Ribakare M, Remera E, Murenzi G, Munyaneza A, Hoover DR, Shi Q, Nsanzimana S, Yotebieng M, **Nash D**, Anastos K. *J Int AIDS Soc.* 2020;23(6):e25543. doi:10.1002/jia2.25543
200. [International epidemiology databases to evaluate AIDS \(IeDEA\) in sub-Saharan Africa, 2012-2019](#). Chammartin F, Dao Ostinelli CH, Anastos K, Jaquet A, Brazier E, Brown S, Dabis F, Davies MA, Duda SN, Malateste K, **Nash D**, Wools-Kaloustian K, von Groote PM, Egger M. *BMJ Open.* 2020;10(5):e035246. doi:10.1136/bmjopen-2019-035246
201. [Demographic, Behavioral, and Geographic Differences Between Men, Transmen, and Transwomen Currently on PrEP, Former PrEP Users, and Those Having Never Used PrEP](#). Westmoreland DA, Pantalone DW, Patel VV, Hoover D, **Nash D**, Grov C. *AIDS Behav.* 2020;24(5):1304-1311. doi:10.1007/s10461-019-02722-2
202. [Social Vulnerabilities and Reported Discrimination in Health Care Among HIV-Positive Medical Case Management Clients in New York City](#). Penrose K, Robertson M, **Nash D**, Harriman G, Irvine M. *Stigma Health.* 2020;5(2):179-187. doi:10.1037/sah0000187
203. [Are we on the precipice of a new epidemic? Risk for hepatitis C among HIV-negative men-, trans women-, and trans men- who have sex with men in the United States](#). Grov C, Westmoreland DA, Carrico AW, **Nash D**. *AIDS Care.* 2020;32(sup2):74-82. doi:10.1080/09540121.2020.1739204
204. [Impact of an HIV Care Coordination Program on the Timeliness of Viral Suppression and Immune Recovery Among Clients Newly Diagnosed with HIV](#). Robertson MM, Penrose K, **Nash D**, Harriman G, Braunstein SL, Levin B, Irvine MK. *AIDS Behav.* 2020;24(4):1237-1242. doi:10.1007/s10461-019-02732-0
205. [Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation](#). Jordan AE, Perlman DC, Cleland CM, Wyka K, Schackman BR, **Nash D**. *J Clin Virol.* 2020;124:104285. doi:10.1016/j.jcv.2020.104285
206. [Drought and intimate partner violence towards women in 19 countries in sub-Saharan Africa during 2011-2018: A population-based study](#). Epstein A, Bendavid E, **Nash D**, Charlebois ED, Weiser SD. *PLoS Med.* 2020;17(3):e1003064. doi:10.1371/journal.pmed.1003064
207. [Psychological distress among a population-representative sample of residents of four slum neighborhoods in Port-au-Prince, Haiti](#). Tymejczyk O, Rivera VR, Peck M, Dorelien A, Petion JS, Seo G, Walsh KF, Pape JW, McNairy ML, Fitzgerald DW, **Nash D**, Parcesepe A. *J Affect Disord.* 2020;263:241-245. doi:10.1016/j.jad.2019.11.103
208. [Maximizing Response Rates to Ads for Free At-Home HIV Testing on a Men- for-Men Geosocial Sexual Networking App: Lessons Learned and Implications for Researchers and Providers](#). Grov C, Stief M, Westmoreland DA, MacCrate C, Mirzayi C, **Nash D**. *Health Educ Behav.* 2020;47(1):5-13. doi:10.1177/1090198119893692
209. [Gender, HIV-Related Stigma, and Health-Related Quality of Life Among Adults Enrolling in HIV Care in Tanzania](#). Parcesepe AM, **Nash D**, Tymejczyk O, Reidy W, Kulkarni SG, Elul B. *AIDS Behav.* 2020;24(1):142-150. doi:10.1007/s10461-019-02480-1
210. [Designing and Disseminating Metrics to Support Jurisdictional Efforts to End the Public Health Threat Posed by HIV Epidemics](#). **Nash D**. *Am J Public Health.* 2020;110(1):53-57. doi:10.2105/AJPH.2019.305398

211. [Sociocultural influences on attitudes towards pre-exposure prophylaxis \(PrEP\), history of PrEP use, and future PrEP use in HIV-vulnerable cisgender men who have sex with men across the U.S.](#) Westmoreland DA, Patel VV, D'Angelo AB, **Nash D**, Grov C. *Ann LGBTQ Public Popul Health*. 2020;1(2):128-158. doi:10.1891/lgbtq-2020-0005
212. [Substance use service availability in HIV treatment programs: Data from the global IeDEA consortium, 2014-2015 and 2017.](#) Parcesepe AM, Lancaster K, Edelman EJ, DeBoni R, Ross J, Atwoli L, Tlali M, Althoff K, Tine J, Duda SN, Wester CW, **Nash D**. *PLoS One*. 2020;15(8):e0237772. doi:10.1371/journal.pone.0237772
213. [Global variations in mortality in adults after initiating antiretroviral treatment: an updated analysis of the International epidemiology Databases to Evaluate AIDS cohort collaboration.](#) Johnson LF, Anderegg N, Zaniewski E, Eaton JW, Rebeiro PF, Carriquiry G, **Nash D**, Yotebieng M, Ekouevi DK, Holmes CB, Choi JY, Jiamsakul A, Bakoyannis G, Althoff KN, Sohn AH, Yiannoutsos C, Egger M. *AIDS*. 2019;33 Suppl 3:S283-S294. doi:10.1097/QAD.0000000000002358
214. [Treatment as Prevention: Concepts and Challenges for Reducing HIV Incidence.](#) Brault MA, Spiegelman D, Hargreaves J, **Nash D**, Vermund SH. *J Acquir Immune Defic Syndr*. 2019;82 Suppl 2:S104-S112. doi:10.1097/QAI.0000000000002168
215. [High Burden of Non-communicable Diseases among a Young Slum Population in Haiti.](#) McNairy ML, Tymejczyk O, Rivera V, Seo G, Dorelien A, Peck M, Petion J, Walsh K, Bolgrien A, **Nash D**, Pape J, Fitzgerald DW. *J Urban Health*. 2019;96(6):797-812. doi:10.1007/s11524-019-00368-y
216. [Seeing Is Believing? Unique Capabilities of Internet-Only Studies as a Tool for Implementation Research on HIV Prevention for Men Who Have Sex With Men: A Review of Studies and Methodological Considerations.](#) Grov C, Westmoreland D, Rendina HJ, **Nash D**. *J Acquir Immune Defic Syndr*. 2019;82 Suppl 3:S253-S260. doi:10.1097/QAI.0000000000002217
217. [Public Health Practice-Driven Research to Improve HIV Prevention in the United States.](#) Dombrowski JC, Irvine M, **Nash D**, Harriman G, Golden MR. *J Acquir Immune Defic Syndr*. 2019;82 Suppl 3:S279-S285. doi:10.1097/QAI.0000000000002194
218. [Psychosocial Factors Associated with Food Insufficiency Among People Living with HIV/AIDS \(PLWH\) Initiating ART in Ethiopia.](#) DiLorenzo MA, Parcesepe A, Tymejczyk O, Hoffman S, Elul B, Weiser SD, Remien RH, Kulkarni SG, Gadisa T, Melaku Z, **Nash D**. *AIDS Behav*. 2019;23(11):3052-3057. doi:10.1007/s10461-019-02505-9
219. [A Web-Based Study of HIV Prevention in the Era of Pre-Exposure Prophylaxis Among Vulnerable HIV-Negative Gay and Bisexual Men, Transmen, and Transwomen Who Have Sex With Men: Protocol for an Observational Cohort Study.](#) **Nash D**, Stief M, MacCrate C, Mirzayi C, Patel VV, Hoover D, Pantalone DW, Golub S, Millett G, D'Angelo AB, Westmoreland DA, Grov C. *JMIR Res Protoc*. 2019;8(9):e13715. doi:10.2196/13715
220. [How to Evolve the Response to the Global HIV Epidemic With New Metrics and Targets Based on Pre-Treatment CD4 Counts.](#) **Nash D**, Robertson M. *Curr HIV/AIDS Rep*. 2019;16(4):304-313. doi:10.1007/s11904-019-00452-7
221. [Timeliness of Human Immunodeficiency Virus Diagnosis and Antiretroviral Treatment Initiation in the Era of Universal Testing and Treatment.](#) Robertson MM, Braunstein SL, Hoover DR, Li S, **Nash D**. *J Infect Dis*. 2019;220(4):648-656. doi:10.1093/infdis/jiz148
222. [Factors associated with delayed and late ART initiation among people living with HIV in BC: results from the engage study.](#) Kesselring S, Osborne C, Bever A, Salters K, Cui Z, Chia J, Moore DM, Parashar S, Kaida A, Samji H, Duddy J, Gabler K, Howard T, **Nash D**, McCandless LC, Patterson TL, Corneil T, Montaner JSG, Hogg RS. *AIDS Care*. 2019;31(7):885-892.

Denis Nash, PhD, MPH
Curriculum Vitae

- doi:10.1080/09540121.2018.1549722
223. [Recruiting vulnerable populations to participate in HIV prevention research: findings from the Together 5000 cohort study](#). Grov C, Westmoreland DA, Carneiro PB, Stief M, MacCrate C, Mirzayi C, Pantalone DW, Patel VV, **Nash D**. *Ann Epidemiol*. 2019;35:4-11. doi:10.1016/j.annepidem.2019.05.003
 224. [Implementation of “Treat-all” at adult HIV care and treatment sites in the Global IeDEA Consortium: results from the Site Assessment Survey](#). Brazier E, Maruri F, Duda SN, Tymejczyk O, Wester CW, Somi G, Ross J, Freeman A, Cornell M, Poda A, Musick BS, Zhang F, Althoff KN, Mugglin C, Kimmel AD, Yotebieng M, **Nash D**. *J Int AIDS Soc*. 2019;22(7):e25331. doi:10.1002/jia2.25331
 225. [Changes in rapid HIV treatment initiation after national “treat all” policy adoption in 6 sub-Saharan African countries: Regression discontinuity analysis](#). Tymejczyk O, Brazier E, Yiannoutsos CT, Vinikoor M, van Lettow M, Nalugoda F, Urassa M, Sinayobye J d’Amour, Rebeiro PF, Wools-Kaloustian K, Davies MA, Zaniewski E, Anderegg N, Liu G, Ford N, **Nash D**. *PLoS Med*. 2019;16(6):e1002822. doi:10.1371/journal.pmed.1002822
 226. [Gender Differences and Psychosocial Factors Associated with Problem Drinking Among Adults Enrolling in HIV Care in Tanzania](#). Parcesepe AM, **Nash D**, Tymejczyk O, Reidy W, Kulkarni SG, Elul B. *AIDS Behav*. 2019;23(6):1612-1622. doi:10.1007/s10461-018-2340-x
 227. [Hypertension prevalence and risk factors among residents of four slum communities: population-representative findings from Port-au-Prince, Haiti](#). Tymejczyk O, McNairy ML, Petion JS, Rivera VR, Dorelien A, Peck M, Seo G, Walsh KF, Fitzgerald DW, Peck RN, Joshi A, Pape JW, **Nash D**. *J Hypertens*. 2019;37(4):685-695. doi:10.1097/HJH.0000000000001966
 228. [Early outcomes after implementation of treat all in Rwanda: an interrupted time series study](#). Ross J, Sinayobye J d’Amour, Yotebieng M, Hoover DR, Shi Q, Ribakare M, Remera E, Bachhuber MA, Murenzi G, Sugira V, **Nash D**, Anastos K. *J Int AIDS Soc*. 2019;22(4):e25279. doi:10.1002/jia2.25279
 229. [Non-HIV Comorbid Conditions and Polypharmacy Among People Living with HIV Age 65 or Older Compared with HIV-Negative Individuals Age 65 or Older in the United States: A Retrospective Claims-Based Analysis](#). Kong AM, Pozen A, Anastos K, Kelvin EA, **Nash D**. *AIDS Patient Care STDS*. 2019;33(3):93-103. doi:10.1089/apc.2018.0190
 230. [Impact of an HIV Care Coordination Program on Durable Viral Suppression](#). Robertson MM, Penrose K, Irvine MK, Robbins RS, Kulkarni S, Braunstein SL, Waldron L, Harriman G, **Nash D**. *J Acquir Immune Defic Syndr*. 2019;80(1):46-55. doi:10.1097/QAI.0000000000001877
 231. [Research priorities to inform “Treat All” policy implementation for people living with HIV in sub-Saharan Africa: a consensus statement from the International epidemiology Databases to Evaluate AIDS \(IeDEA\)](#). Yotebieng M, Brazier E, Addison D, Kimmel AD, Cornell M, Keiser O, Parcesepe AM, Onovo A, Lancaster KE, Castelnovo B, Murnane PM, Cohen CR, Vreeman RC, Davies MA, Duda SN, Yiannoutsos CT, Bono RS, Agler R, Bernard C, Syvertsen JL, Sinayobye J d’Amour, Wikramanayake R, Sohn AH, von Groote PM, Wandeler G, Leroy V, Williams CF, Wools-Kaloustian K, **Nash D**. *J Int AIDS Soc*. 2019;22(1):e25218. doi:10.1002/jia2.25218
 232. [An End-User Participatory Approach to Collaboratively Refine HIV Care Data, The New York State Experience](#). Swain CA, Sawicki S, Addison D, Katz B, Piersanti K, Baim-Lance A, Gordon D, Anderson BJ, **Nash D**, Steinbock C, Agins B. *AIDS Behav*. 2019;23(Suppl 1):83-93. doi:10.1007/s10461-018-2104-7
 233. [Factors Influencing the Successful Implementation of HIV Linkage and Retention Interventions in](#)

Denis Nash
Curriculum Vitae

- [Healthcare Agencies Across New York State](#). Addison D, Baim-Lance A, Suchman L, Katz B, Swain CA, Piersanti K, Steinbock C, Sawicki S, Agins B, **Nash D**. *AIDS Behav*. 2019;23(Suppl 1):105-114. doi:10.1007/s10461-018-2060-2
234. [Cost-effectiveness of HIV care coordination scale-up among persons at high risk for sub-optimal HIV care outcomes](#). Stevens ER, Nucifora KA, Irvine MK, Penrose K, Robertson M, Kulkarni S, Robbins R, Abraham B, **Nash D**, Braithwaite RS. *PLoS One*. 2019;14(4):e0215965. doi:10.1371/journal.pone.0215965
235. [HIV-Related Stigma, Social Support, and Psychological Distress Among Individuals Initiating ART in Ethiopia](#). Parcesepe A, Tymejczyk O, Remien R, Gadisa T, Kulkarni SG, Hoffman S, Melaku Z, Elul B, **Nash D**. *AIDS Behav*. 2018;22(12):3815-3825. doi:10.1007/s10461-018-2059-8
236. [IeDEA-WHO Research-Policy Collaboration: contributing real-world evidence to HIV progress reporting and guideline development](#). Zaniewski E, Tymejczyk O, Kariminia A, Desmonde S, Leroy V, Ford N, Sohn AH, **Nash D**, Yotebieng M, Cornell M, Althoff KN, Rebeiro PF, Egger M. *J Virus Erad*. 2018;4(Suppl 2):9-15.
237. [Treating all people living with HIV in sub-Saharan Africa: a new era calling for new approaches](#). **Nash D**, Yotebieng M, Sohn AH. *J Virus Erad*. 2018;4(Suppl 2):1-4.
238. [Mathematical modelling to inform “treat all” implementation in sub-Saharan Africa: a scoping review](#). Kimmel AD, Bono RS, Keiser O, Sinayobye JD, Estill J, Mujwara D, Tymejczyk O, **Nash D**. *J Virus Erad*. 2018;4(Suppl 2):47-54.
239. [The contribution of observational studies in supporting the WHO “treat all” recommendation for HIV/AIDS](#). Ford N, Penazzato M, Vitoria M, Doherty M, Davies MA, Zaniewski E, Tymejczyk O, Egger M, **Nash D**. *J Virus Erad*. 2018;4(Suppl 2):5-8.
240. [Onchocerciasis and epilepsy: a causal relationship?](#) Romo ML, **Nash D**. *Lancet Infect Dis*. 2018;18(11):1172-1174. doi:10.1016/S1473-3099(18)30488-2
241. [HIV Care and Viral Load Suppression After Sexual Health Clinic Visits by Out-of-Care HIV-Positive Persons](#). Tymejczyk O, Jamison K, Pathela P, Braunstein S, Schillinger JA, **Nash D**. *AIDS Patient Care STDS*. 2018;32(10):390-398. doi:10.1089/apc.2018.0097
242. [Active case finding: comparison of the acceptability, feasibility and effectiveness of targeted versus blanket provider-initiated-testing and counseling of HIV among children and adolescents in Cameroon](#). Yumo HA, Kuaban C, Ajeh RA, Nji AM, **Nash D**, Kathryn A, Beissner M, Loescher T. *BMC Pediatr*. 2018;18(1):309. doi:10.1186/s12887-018-1276-7
243. [Using Registry Data to Construct a Comparison Group for Programmatic Effectiveness Evaluation: The New York City HIV Care Coordination Program](#). Robertson MM, Waldron L, Robbins RS, Chamberlin S, Penrose K, Levin B, Kulkarni S, Braunstein SL, Irvine MK, **Nash D**. *Am J Epidemiol*. 2018;187(9):1980-1989. doi:10.1093/aje/kwy103
244. [Gaps Along the HIV Care Continuum: Findings Among a Population Seeking Sexual Health Care Services in New York City](#). Pathela P, Jamison K, Braunstein SL, Schillinger JA, Tymejczyk O, **Nash D**. *J Acquir Immune Defic Syndr*. 2018;78(3):314-321. doi:10.1097/QAI.0000000000001674
245. [Trends in depression prevalence in the USA from 2005 to 2015: widening disparities in vulnerable groups](#). Weinberger AH, Gbedemah M, Martinez AM, **Nash D**, Galea S, Goodwin RD. *Psychol Med*. 2018;48(8):1308-1315. doi:10.1017/S0033291717002781
246. [Reducing the default dispense quantity for new opioid analgesic prescriptions: study protocol for a cluster randomised controlled trial](#). Bachhuber MA, **Nash D**, Southern WN, Heo M, Berger M, Schepis M, Cunningham CO. *BMJ Open*. 2018;8(4):e019559. doi:10.1136/bmjopen-2017-019559
247. [Frequency of Cannabis Use and Medical Cannabis Use Among Persons Living With HIV in the](#)

- [United States: Findings From a Nationally Representative Sample](#). Pacek LR, Towe SL, Hobkirk AL, **Nash D**, Goodwin RD. *AIDS Educ Prev*. 2018;30(2):169-181. doi:10.1521/aeap.2018.30.2.169
248. [Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs](#). *Clin Infect Dis*. 2018;66(6):893-903. doi:10.1093/cid/cix915
249. [HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries](#). Tymejczyk O, Brazier E, Yiannoutsos C, Wools-Kaloustian K, Althoff K, Crabtree-Ramirez B, Van Nguyen K, Zaniewski E, Dabis F, Sinayobye J d'Amour, Anderegg N, Ford N, Wikramanayake R, **Nash D**. *PLoS Med*. 2018;15(3):e1002534. doi:10.1371/journal.pmed.1002534
250. [Psychological distress, health and treatment-related factors among individuals initiating ART in Oromia, Ethiopia](#). Parcesepe AM, Tymejczyk O, Remien R, Gadisa T, Kulkarni SG, Hoffman S, Melaku Z, Elul B, **Nash D**. *AIDS Care*. 2018;30(3):338-342. doi:10.1080/09540121.2017.1363367
251. [Screening and management of mental health and substance use disorders in HIV treatment settings in low- and middle-income countries within the global IeDEA consortium](#). Parcesepe AM, Mugglin C, Nalugoda F, Bernard C, Yuniastuti E, Althoff K, Jaquet A, Haas AD, Duda SN, Wester CW, **Nash D**. *J Int AIDS Soc*. 2018;21(3):e25101. doi:10.1002/jia2.25101
252. [Household decision-making power and the mental health and well-being of women initiating antiretroviral treatment in Oromia, Ethiopia](#). Parcesepe AM, Tymejczyk O, Remien R, Gadisa T, Kulkarni SG, Hoffman S, Melaku Z, Elul B, **Nash D**. *AIDS Care*. 2018;30(2):211-218. doi:10.1080/09540121.2017.1360998
253. [Retention and mortality on antiretroviral therapy in sub-Saharan Africa: collaborative analyses of HIV treatment programmes](#). Haas AD, Zaniewski E, Anderegg N, Ford N, Fox MP, Vinikoor M, Dabis F, **Nash D**, Sinayobye J d'Amour, Niyongabo T, Tanon A, Poda A, Adedimeji AA, Edmonds A, Davies MA, Egger M. *J Int AIDS Soc*. 2018;21(2). doi:10.1002/jia2.25084
254. [Adherence to antiretroviral therapy in a clinical cohort of HIV-infected children in East Africa](#). Vreeman RC, Ayaya SO, Musick BS, Yiannoutsos CT, Cohen CR, **Nash D**, Wabwire D, Wools-Kaloustian K, Wiehe SE. *PLoS One*. 2018;13(2):e0191848. doi:10.1371/journal.pone.0191848
255. [Short-term effectiveness of HIV care coordination among persons with recent HIV diagnosis or history of poor HIV outcomes](#). **Nash D**, Robertson MM, Penrose K, Chamberlin S, Robbins RS, Braunstein SL, Myers JE, Abraham B, Kulkarni S, Waldron L, Levin B, Irvine MK. *PLoS One*. 2018;13(9):e0204017. doi:10.1371/journal.pone.0204017
256. [Implementing parallel spreadsheet models for health policy decisions: The impact of unintentional errors on model projections](#). Bailey SL, Bono RS, **Nash D**, Kimmel AD. *PLoS One*. 2018;13(3):e0194916. doi:10.1371/journal.pone.0194916
257. [A Human-Centered Platform for HIV Infection Reduction in New York: Development and Usage Analysis of the Ending the Epidemic \(ETE\) Dashboard](#). Joshi A, Amadi C, Katz B, Kulkarni S, **Nash D**. *JMIR Public Health Surveill*. 2017;3(4):e95. doi:10.2196/publichealth.8312
258. [Brief Report: Stigma and HIV Care Continuum Outcomes Among Ethiopian Adults Initiating ART](#). Hoffman S, Tymejczyk O, Kulkarni S, Lahuerta M, Gadisa T, Remien RH, Melaku Z, **Nash D**, Elul B. *J Acquir Immune Defic Syndr*. 2017;76(4):382-387. doi:10.1097/QAI.0000000000001530
259. [Testing, Testing?: Multiple HIV-Positive Tests among Patients Initiating Antiretroviral Therapy in Ethiopia](#). Kulkarni S, Tymejczyk O, Gadisa T, Lahuerta M, Remien RH, Melaku Z, El-Sadr W, Elul B, **Nash D**, Hoffman S. *J Int Assoc Provid AIDS Care*. 2017;16(6):546-554. doi:10.1177/2325957417737840
260. [Come as You Are: Improving Care Engagement and Viral Load Suppression Among HIV Care](#)

- [Coordination Clients with Lower Mental Health Functioning, Unstable Housing, and Hard Drug Use.](#) Irvine MK, Chamberlin SA, Robbins RS, Kulkarni SG, Robertson MM, **Nash D.** *AIDS Behav.* 2017;21(6):1572-1579. doi:10.1007/s10461-016-1460-4
261. [HIV prevention resources: time to move toward affordability.](#) Kimmel AD, **Nash D.** *Lancet HIV.* 2017;4(5):e191-e193. doi:10.1016/S2352-3018(17)30022-X
262. [The relationship between higher social trust and lower late HIV diagnosis and mortality differs by race/ethnicity: results from a state-level analysis.](#) Ransome Y, Batson A, Galea S, Kawachi I, **Nash D**, Mayer KH. *J Int AIDS Soc.* 2017;20(1):21442. doi:10.7448/IAS.20.01/21442
263. [Outcomes of HIV-positive patients lost to follow-up in African treatment programmes.](#) Zurcher K, Mooser A, Anderegg N, Tymejczyk O, Couvillon MJ, **Nash D**, Egger M. *Trop Med Int Health.* 2017;22(4):375-387. doi:10.1111/tmi.12843
264. [All-cause mortality in HIV-positive adults starting combination antiretroviral therapy: correcting for loss to follow-up.](#) Anderegg N, Johnson LF, Zaniewski E, Althoff KN, Balestre E, Law M, **Nash D**, Shepherd BE, Yiannoutsos CT, Egger M. *AIDS.* 2017;31 Suppl 1:S31-S40. doi:10.1097/QAD.0000000000001321
265. [Comprehensiveness of HIV care provided at global HIV treatment sites in the IeDEA consortium: 2009 and 2014.](#) Fritz CQ, Blevins M, Lindegren ML, Wools-Kaloutsian K, Musick BS, Cornell M, Goodwin K, Addison D, Dusingize JC, Messou E, Poda A, Duda SN, McGowan CC, Law MG, Moore RD, Freeman A, **Nash D**, Wester CW. *J Int AIDS Soc.* 2017;20(1):20933. doi:10.7448/IAS.20.1.20933
266. [Disclosure History Among Persons Initiating Antiretroviral Treatment at Six HIV Clinics in Oromia, Ethiopia, 2012-2013.](#) Gadisa T, Tymejczyk O, Kulkarni SG, Hoffman S, Lahuerta M, Remien RH, Yigzaw M, Daba S, Elul B, **Nash D**, Melaku Z. *AIDS Behav.* 2017;21(1):70-81. doi:10.1007/s10461-016-1290-4
267. [Characteristics of HIV-Infected Children at Enrollment into Care and at Antiretroviral Therapy Initiation in Central Africa.](#) Adedimeji A, Edmonds A, Hoover D, Shi Q, Sinayobye J d'Amour, Nduwimana M, Lelo P, **Nash D**, Anastos K, Yotebieng M. *PLoS One.* 2017;12(1):e0169871. doi:10.1371/journal.pone.0169871
268. [Increase in CD4+ T-Cell Count at the Time of HIV Diagnosis and Antiretroviral Treatment Initiation Among Persons With HIV in New York City.](#) Braunstein SL, Robertson MM, Myers J, Abraham B, **Nash D.** *J Infect Dis.* 2016;214(11):1682-1686. doi:10.1093/infdis/jiw438
269. [Structural inequalities drive late HIV diagnosis: The role of black racial concentration, income inequality, socioeconomic deprivation, and HIV testing.](#) Ransome Y, Kawachi I, Braunstein S, **Nash D.** *Health Place.* 2016;42:148-158. doi:10.1016/j.healthplace.2016.09.004
270. [Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.](#) *Lancet.* 2016;388(10053):1459-1544. doi:10.1016/S0140-6736(16)31012-1
271. [Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.](#) *Lancet.* 2016;388(10053):1775-1812. doi:10.1016/S0140-6736(16)31470-2
272. [Social Capital is Associated With Late HIV Diagnosis: An Ecological Analysis.](#) Ransome Y, Galea S, Pabayo R, Kawachi I, Braunstein S, **Nash D.** *J Acquir Immune Defic Syndr.* 2016;73(2):213-221. doi:10.1097/QAI.0000000000001043
273. [Using HIV Viral Load From Surveillance to Estimate the Timing of Antiretroviral Therapy Initiation.](#) Braunstein SL, Robertson MM, Myers J, **Nash D.** *J Acquir Immune Defic Syndr.*

Denis Nash, PhD, MPH
Curriculum Vitae

- 2016;73(2):222-227. doi:10.1097/QAI.0000000000001052
274. [Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015](#). *Lancet HIV*. 2016;3(8):e361-e387. doi:10.1016/S2352-3018(16)30087-X
275. [Gender Differences and Psychosocial Factors Associated with Quality of Life Among ART Initiators in Oromia, Ethiopia](#). Vo QT, Hoffman S, **Nash D**, El-Sadr WM, Tymejczyk OA, Gadisa T, Melaku Z, Kulkarni SG, Remien RH, Elul B. *AIDS Behav*. 2016;20(8):1682-1691. doi:10.1007/s10461-016-1396-8
276. [Untangling the Relationship Between Antiretroviral Therapy Use and Incident Pregnancy: A Marginal Structural Model Analysis Using Data From 47,313 HIV-Positive Women in East Africa](#). Elul B, Wools-Kaloustian KK, Wu Y, Musick BS, Nuwagaba-Biribonwoha H, **Nash D**, Ayaya S, Bukusi E, Okong P, Otieno J, Wabwire D, Kambugu A, Yiannoutsos CT. *J Acquir Immune Defic Syndr*. 2016;72(3):324-332. doi:10.1097/QAI.0000000000000963
277. [Postpartum Human Immunodeficiency Virus Care Among Women Diagnosed During Pregnancy](#). Swain CA, Smith LC, **Nash D**, Pulver WP, Gordon D, Bian F, Miranda W, Anderson BJ, Chicoine J, Birkhead GS, McNutt LA. *Obstet Gynecol*. 2016;128(1):44-51. doi:10.1097/AOG.0000000000001454
278. [Identifying Perceived Barriers along the HIV Care Continuum: Findings from Providers, Peer Educators, and Observations of Provider-Patient Interactions in Ethiopia](#). Kulkarni S, Hoffman S, Gadisa T, Melaku Z, Fantahun M, Yigzaw M, El-Sadr W, Remien R, Tymejczyk O, **Nash D**, Elul B. *J Int Assoc Provid AIDS Care*. 2016;15(4):291-300. doi:10.1177/2325957415593635
279. [HIV Care and Treatment Beliefs among Patients Initiating Antiretroviral Treatment \(ART\) in Oromia, Ethiopia](#). Tymejczyk O, Hoffman S, Kulkarni SG, Gadisa T, Lahuerta M, Remien RH, Elul B, El-Sadr W, Melaku Z, **Nash D**. *AIDS Behav*. 2016;20(5):998-1008. doi:10.1007/s10461-015-1184-x
280. [Implementation and Operational Research: Declining Tuberculosis Incidence Among People Receiving HIV Care and Treatment Services in East Africa, 2007-2012](#). Saito S, Mpofu P, Carter EJ, Diero L, Wools-Kaloustian KK, Yiannoutsos CT, Beverly MS, Tsiouris S, Somi GR, Ssali J, **Nash D**, Elul B. *J Acquir Immune Defic Syndr*. 2016;71(4):e96-e106. doi:10.1097/QAI.0000000000000896
281. [Postpartum Loss to HIV Care and HIV Viral Suppression among Previously Diagnosed HIV-Infected Women with a Live Birth in New York State](#). Swain CA, Smith LC, **Nash D**, Pulver WP, Lazariu V, Anderson BJ, Warren BL, Birkhead GS, McNutt LA. *PLoS One*. 2016;11(8):e0160775. doi:10.1371/journal.pone.0160775
282. [Conceptualizing Care Continua: Lessons from HIV, Hepatitis C Virus, Tuberculosis and Implications for the Development of Improved Care and Prevention Continua](#). Perlman DC, Jordan AE, **Nash D**. *Front Public Health*. 2016;4:296. doi:10.3389/fpubh.2016.00296
283. [Factors associated with initiation of antiretroviral therapy in the advanced stages of HIV infection in six Ethiopian HIV clinics, 2012 to 2013](#). **Nash D**, Tymejczyk O, Gadisa T, Kulkarni SG, Hoffman S, Yigzaw M, Elul B, Remien RH, Lahuerta M, Daba S, El Sadr W, Melaku Z. *J Int AIDS Soc*. 2016;19(1):20637. doi:10.7448/IAS.19.1.20637
284. [Towards an integrated primary and secondary HIV prevention continuum for the United States: a cyclical process model](#). Horn T, Sherwood J, Remien RH, **Nash D**, Auerbach JD. *J Int AIDS Soc*. 2016;19(1):21263. doi:10.7448/IAS.19.1.21263
285. [Can TasP Approaches Be Implemented in Correctional Settings?: A review of HIV testing and](#)

- [linkage to community HIV treatment programs](#). Elkington KS, Jaiswal J, Spector AY, Reukauf H, Tesoriero JM, **Nash D**, Remien RH. *J Health Care Poor Underserved*. 2016;27(2A):71-100. doi:10.1353/hpu.2016.0047
286. [Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013](#). Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, Burnett R, Casey D, Coates MM, Cohen A, Delwiche K, Estep K, Frostad JJ, Astha KC, Kyu HH, Moradi-Lakeh M, Ng M, Slepak EL, Thomas BA, Wagner J, Aasvang GM, Abbafati C, Abbasoglu Ozgoren A, Abd-Allah F, Abera SF, Aboyans V, Abraham B, Abraham JP, Abubakar I, Abu-Rmeileh NME, Aburto TC, Achoki T, Adelekan A, Adofo K, Adou AK, Adsuar JC, Afshin A, Agardh EE, Al Khabouri MJ, Al Lami FH, Alam SS, Alasfoor D, Albittar MI, Alegretti MA, Aleman AV, Alemu ZA, Alfonso-Cristancho R, Alhabib S, Ali R, Ali MK, Alla F, Allebeck P, Allen PJ, Alsharif U, Alvarez E, Alvis-Guzman N, Amankwaa AA, Amare AT, Ameh EA, Ameli O, Amini H, Ammar W, Anderson BO, Antonio CAT, Anwari P, Argeseanu Cunningham S, Arnlov J, Arsenijevic VSA, Artaman A, Asghar RJ, Assadi R, Atkins LS, Atkinson C, Avila MA, Awuah B, Badawi A, Bahit MC, Bakfalouni T, Balakrishnan K, Balalla S, Balu RK, Banerjee A, Barber RM, Barker-Collo SL, Barquera S, Barregard L, Barrero LH, Barrientos-Gutierrez T, Basto-Abreu AC, Basu A, Basu S, Basulaiman MO, Batis Ruvalcaba C, Beardsley J, Bedi N, Bekele T, Bell ML, Benjet C, et al. *Lancet*. 2015;386(10010):2287-2323. doi:10.1016/S0140-6736(15)00128-2
287. [Hepatitis C Direct Acting Antiviral Therapies in a New York City HIV/AIDS Special Needs Plan: Uptake and Barriers](#). Kuniholm MH, Leach T, Luniewicz J, Olivo N, Anastos K, Vazquez Y, Brennan-Ing M, Karpiak SE, Alao O, **Nash D**, Ernst J. *AIDS Patient Care STDS*. 2015;29(12):643-645. doi:10.1089/apc.2015.0240
288. [Increasing Trend of Fatal Falls in Older Adults in the United States, 1992 to 2005: Coding Practice or Reporting Quality?](#) Kharrazi RJ, **Nash D**, Mielenz TJ. *J Am Geriatr Soc*. 2015;63(9):1913-1917. doi:10.1111/jgs.13591
289. [Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013](#). *Lancet*. 2015;386(9995):743-800. doi:10.1016/S0140-6736(15)60692-4
290. [Trends in Reporting of Abuse and Neglect to Long Term Care Ombudsmen: Data from the National Ombudsman Reporting System from 2006 to 2013](#). Bloemen EM, Rosen T, Clark S, **Nash D**, Mielenz TJ. *Geriatr Nurs*. 2015;36(4):281-283. doi:10.1016/j.gerinurse.2015.03.002
291. [Expanded HIV testing coverage is associated with decreases in late HIV diagnoses](#). Ransome Y, Terzian A, Addison D, Braunstein S, Myers J, Abraham B, **Nash D**. *AIDS*. 2015;29(11):1369-1378. doi:10.1097/QAD.0000000000000684
292. [Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013](#). Jordan AE, Des Jarlais DC, Arasteh K, McKnight C, **Nash D**, Perlman DC. *Drug Alcohol Depend*. 2015;152:194-200. doi:10.1016/j.drugalcdep.2015.03.039
293. [The Global Burden of Cancer 2013](#). Vol 1.; 2015. doi:10.1001/jamaoncol.2015.0735
294. [Risk factors for loss to follow-up prior to ART initiation among patients enrolling in HIV care with CD4+ cell count >=200 cells/muL in the multi- country MTCT-Plus Initiative](#). Gwynn RC, Fawzy A, Viho I, Wu Y, Abrams EJ, **Nash D**. *BMC Health Serv Res*. 2015;15:247. doi:10.1186/s12913-015-0898-9

Denis Nash, PhD, MPH
Curriculum Vitae

295. [All-cause, drug-related, and HIV-related mortality risk by trajectories of jail incarceration and homelessness among adults in New York City](#). Lim S, Harris TG, **Nash D**, Lennon MC, Thorpe LE. *Am J Epidemiol*. 2015;181(4):261-270. doi:10.1093/aje/kwu313
296. [CD41 T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa](#). Geng EH, Neilands TB, Thiebaut R, Bwana MB, **Nash D**, Moore RD, Wood R, Zannou DM, Althoff KN, Lim PL, Nachega JB, Easterbrook PJ, Kambugu A, Little F, Nakigozi G, Nakanjako D, Kiggundu V, Ki Li PC, Bangsberg DR, Fox MP, Prozesky H, Hunt PW, Davies MA, Reynolds SJ, Egger M, Yiannoutsos CT, Vittinghoff EV, Deeks SG, Martin JN. *Int J Epidemiol*. 2015;44(1):251-263. doi:10.1093/ije/dyu271
297. [Improvements in HIV care engagement and viral load suppression following enrollment in a comprehensive HIV care coordination program](#). Irvine MK, Chamberlin SA, Robbins RS, Myers JE, Braunstein SL, Mitts BJ, Harriman GA, Laraque F, **Nash D**. *Clin Infect Dis*. 2015;60(2):298-310. doi:10.1093/cid/ciu783
298. [Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013](#). *Lancet*. 2015;385(9963):117-171. doi:10.1016/S0140-6736(14)61682-2
299. [Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda](#). Mutimura E, Addison D, Anastos K, Hoover D, Dusingize JC, Karenzie B, Izimukwiye I, Mutesa L, Nsanzimana S, **Nash D**. *AIDS*. 2015;29(1):67-76. doi:10.1097/QAD.0000000000000520
300. [Influence of Jail Incarceration and Homelessness Patterns on Engagement in HIV Care and HIV Viral Suppression among New York City Adults Living with HIV/AIDS](#). Lim S, **Nash D**, Hollod L, Harris TG, Lennon MC, Thorpe LE. *PLoS One*. 2015;10(11):e0141912. doi:10.1371/journal.pone.0141912
301. [Burden of present-on-admission infections and health care-associated infections, by race and ethnicity](#). Jeon CY, Muennig P, Furuya EY, Cohen B, **Nash D**, Larson EL. *Am J Infect Control*. 2014;42(12):1296-1302. doi:10.1016/j.ajic.2014.08.019
302. [Predictors of index patient acceptance of expedited partner therapy for Chlamydia trachomatis infection and reasons for refusal, sexually transmitted disease clinics, New York City, 2011 to 2012](#). Vaidya S, Johnson K, Rogers M, **Nash D**, Schillinger JA. *Sex Transm Dis*. 2014;41(11):690-694. doi:10.1097/OLQ.0000000000000197
303. [Home HIV testing and counselling: answers raising questions](#). Kimmel AD, **Nash D**. *Lancet HIV*. 2014;1(2):e52-53. doi:10.1016/S2352-3018(14)70029-3
304. [Advanced disease at enrollment in HIV care in four sub-Saharan African countries: change from 2006 to 2011 and multilevel predictors in 2011](#). Hoffman S, Wu Y, Lahuerta M, Kulkarni SG, Nuwagaba-Biribonwoha H, Sadr WE, Remien RH, Mugisha V, Hawken M, Chuva E, **Nash D**, Elul B. *AIDS*. 2014;28(16):2429-2438. doi:10.1097/QAD.0000000000000427
305. [Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013](#). Murray CJL, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, Dansereau EA, Graetz N, Barber RM, Brown JC, Wang H, Duber HC, Naghavi M, Dicker D, Dandona L, Salomon JA, Heuton KR, Foreman K, Phillips DE, Fleming TD, Flaxman AD, Phillips BK, Johnson EK, Coggeshall MS, Abd-Allah F, Abera SF, Abraham JP, Abubakar I, Abu-Raddad LJ, Abu-Rmeileh NM, Achoki T, Adeyemo AO, Adou AK, Adsuar JC, Agardh EE, Akena D, Al Khabouri MJ, Alasfoor D, Albittar

- MI, Alcala-Cerra G, Alegretti MA, Alemu ZA, Alfonso-Cristancho R, Alhabib S, Ali R, Alla F, Allen PJ, Alsharif U, Alvarez E, Alvis-Guzman N, Amankwaa AA, Amare AT, Amini H, Ammar W, Anderson BO, Antonio CAT, Anwari P, Arnlov J, Arsenijevic VSA, Artaman A, Asghar RJ, Assadi R, Atkins LS, Badawi A, Balakrishnan K, Banerjee A, Basu S, Beardsley J, Bekele T, Bell ML, Bernabe E, Beyene TJ, Bhala N, Bhalla A, Bhutta ZA, Abdulkhak AB, Binagwaho A, Blore JD, Basara BB, Bose D, Brainin M, Breitborde N, Castaneda-Orjuela CA, Catala-Lopez F, Chadha VK, Chang JC, Chiang PPC, Chuang TW, Colomar M, Cooper LT, Cooper C, Courville KJ, Cowie BC, Criqui MH, Dandona R, Dayama A, De Leo D, Degenhardt L, et al. *Lancet*. 2014;384(9947):1005-1070. doi:10.1016/S0140-6736(14)60844-8
306. [Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013](#). Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, Shackelford KA, Steiner C, Heuton KR, Gonzalez-Medina D, Barber R, Huynh C, Dicker D, Templin T, Wolock TM, Ozgoren AA, Abd-Allah F, Abera SF, Abubakar I, Achoki T, Adelekan A, Ademi Z, Adou AK, Adsuar JC, Agardh EE, Akena D, Alasfoor D, Alemu ZA, Alfonso-Cristancho R, Alhabib S, Ali R, Al Kahbouri MJ, Alla F, Allen PJ, AlMazroa MA, Alsharif U, Alvarez E, Alvis-Guzman N, Amankwaa AA, Amare AT, Amini H, Ammar W, Antonio CAT, Anwari P, Arnlov J, Arsenijevic VSA, Artaman A, Asad MM, Asghar RJ, Assadi R, Atkins LS, Badawi A, Balakrishnan K, Basu A, Basu S, Beardsley J, Bedi N, Bekele T, Bell ML, Bernabe E, Beyene TJ, Bhutta Z, Bin Abdulkhak A, Blore JD, Basara BB, Bose D, Breitborde N, Cardenas R, Castaneda-Orjuela CA, Castro RE, Catala-Lopez F, Cavlin A, Chang JC, Che X, Christophi CA, Chugh SS, Cirillo M, Colquhoun SM, Cooper LT, Cooper C, da Costa Leite I, Dandona L, Dandona R, Davis A, Dayama A, Degenhardt L, De Leo D, del Pozo-Cruz B, Deribe K, Dessalegn M, deVeber GA, Dharmaratne SD, Dilmen U, Ding EL, Dorrington RE, Driscoll TR, Ermakov SP, Esteghamati A, Faraon EJA, Farzadfar F, Felicio MM, et al. *Lancet*. 2014;384(9947):980-1004. doi:10.1016/S0140-6736(14)60696-6
307. [Low risk of attrition among adults on antiretroviral therapy in the Rwandan national program: a retrospective cohort analysis of 6, 12, and 18 month outcomes](#). Nuwagaba-Biribonwoha H, Jakubowski A, Mugisha V, Basinga P, Asiimwe A, **Nash D**, Elul B. *BMC Public Health*. 2014;14:889. doi:10.1186/1471-2458-14-889
308. [Reply to Patten et al.](#) Lahuerta M, **Nash D**. *Clin Infect Dis*. 2014;59(3):457-458. doi:10.1093/cid/ciu290
309. [Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006-2011: findings from four sub-saharan African countries](#). Lahuerta M, Wu Y, Hoffman S, Elul B, Kulkarni SG, Remien RH, Nuwagaba-Biribonwoha H, El-Sadr W, **Nash D**. *Clin Infect Dis*. 2014;58(3):432-441. doi:10.1093/cid/cit724
310. [Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries](#). Avila D, Althoff KN, Mugglin C, Wools-Kaloustian K, Koller M, Dabis F, **Nash D**, Gsponer T, Sungkanuparph S, McGowan C, May M, Cooper D, Chimbetete C, Wolff M, Collier A, McManus H, Davies MA, Costagliola D, Crabtree-Ramirez B, Chaiwarith R, Cescon A, Cornell M, Diero L, Phanuphak P, Sawadogo A, Ehmer J, Eholie SP, Li PCK, Fox MP, Gandhi NR, Gonzalez E, Lee CKC, Hoffmann CJ, Kambugu A, Keiser O, Ditangco R, Prozesky H, Lampe F, Kumarasamy N, Kitahata M, Lugina E, Lyamuya R, Vonthanak S, Fink V, d'Arminio Monforte A, Luz PM, Chen YMA, Minga A, Casabona J, Mwango A, Choi JY, Newell ML, Bukusi EA, Ngonyani K, Merati TP, Otieno J, Bosco MB, Phiri S, Ng OT, Anastos K, Rockstroh J, Santos I, Oka S, Somi G, Stephan C, Teira R, Wabwire D, Wandeler G, Boulle A, Reiss P, Wood R, Chi BH,

Denis Nash, PhD, MPH
Curriculum Vitae

- Williams C, Sterne JA, Egger M. *J Acquir Immune Defic Syndr*. 2014;65(1):e8-16. doi:10.1097/QAI.0b013e3182a39979
311. [Characteristics and comprehensiveness of adult HIV care and treatment programmes in Asia-Pacific, sub-Saharan Africa and the Americas: results of a site assessment conducted by the International epidemiologic Databases to Evaluate AIDS \(IeDEA\) Collaboration](#). Duda SN, Farr AM, Lindegren ML, Blevins M, Wester CW, Wools-Kaloustian K, Ekouevi DK, Egger M, Hemingway-Foday J, Cooper DA, Moore RD, McGowan CC, **Nash D**. *J Int AIDS Soc*. 2014;17:19045. doi:10.7448/IAS.17.1.19045
312. [Factors associated with loss to clinic among HIV patients not yet known to be eligible for antiretroviral therapy \(ART\) in Mozambique](#). Pati R, Lahuerta M, Elul B, Okamura M, Alvim MF, Schackman B, Bang H, Fernandes R, Assan A, Lima J, **Nash D**. *J Int AIDS Soc*. 2013;16:18490. doi:10.7448/IAS.16.1.18490
313. [Association of neighborhood-level factors with hospitalization for community-associated methicillin-resistant Staphylococcus aureus, New York City, 2006: a multilevel observational study](#). Farr AM, Marx MA, Weiss D, **Nash D**. *BMC Infect Dis*. 2013;13:84. doi:10.1186/1471-2334-13-84
314. [The problem of late ART initiation in Sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon?](#) Lahuerta M, Ue F, Hoffman S, Elul B, Kulkarni SG, Wu Y, Nuwagaba-Biribonwoha H, Remien RH, El Sadr W, **Nash D**. *J Health Care Poor Underserved*. 2013;24(1):359-383. doi:10.1353/hpu.2013.0014
315. [High levels of adherence and viral suppression in a nationally representative sample of HIV-infected adults on antiretroviral therapy for 6, 12 and 18 months in Rwanda](#). Elul B, Basinga P, Nuwagaba-Biribonwoha H, Saito S, Horowitz D, **Nash D**, Mugabo J, Mugisha V, Rugigana E, Nkunda R, Asiimwe A. *PLoS One*. 2013;8(1):e53586. doi:10.1371/journal.pone.0053586
316. [Implementation of tuberculosis infection control measures at HIV care and treatment sites in sub-Saharan Africa](#). Reid MJA, Saito S, **Nash D**, Scardigli A, Casalini C, Howard AA. *Int J Tuberc Lung Dis*. 2012;16(12):1605-1612. doi:10.5588/ijtld.12.0033
317. [Adult HIV care resources, management practices and patient characteristics in the Phase 1 IeDEA Central Africa cohort](#). Divaris K, Newman J, Hemingway-Foday J, Akam W, Balimba A, Dusengamungu C, Kalenga L, Mbaya M, Molu BM, Mugisha V, Mukumbi H, Mushingantahe J, **Nash D**, Niyongabo T, Atibu J, Azinyue I, Kiumbu M, Woelk G. *J Int AIDS Soc*. 2012;15(2):17422. doi:10.7448/IAS.15.2.17422
318. [TB diagnostic capacity in sub-Saharan African HIV care settings](#). Saito S, Howard AA, Reid MJA, Elul B, Scardigli A, Verkuijl S, Nyaruhirira AU, **Nash D**. *J Acquir Immune Defic Syndr*. 2012;61(2):216-220. doi:10.1097/QAI.0b013e3182638ec7
319. [Trends in hospitalization for community-associated methicillin-resistant Staphylococcus aureus in New York City, 1997-2006: data from New York State's Statewide Planning and Research Cooperative System](#). Farr AM, Aden B, Weiss D, **Nash D**, Marx MA. *Infect Control Hosp Epidemiol*. 2012;33(7):725-731. doi:10.1086/666329
320. [Healthcare-related correlates of recent HIV testing in New York City](#). Kim EK, Thorpe L, Myers JE, **Nash D**. *Prev Med*. 2012;54(6):440-443. doi:10.1016/j.ypmed.2012.03.006
321. [A causal framework for understanding the effect of losses to follow-up on epidemiologic analyses in clinic-based cohorts: the case of HIV-infected patients on antiretroviral therapy in Africa](#). Geng EH, Glidden DV, Bangsberg DR, Bwana MB, Musunguzi N, **Nash D**, Metcalfe JZ, Yiannoutsos CT, Martin JN, Petersen ML. *Am J Epidemiol*. 2012;175(10):1080-1087. doi:10.1093/aje/kwr444
322. [The contribution of antenatal care to the coverage and correlates of HIV testing among adults in](#)

- [Zimbabwe 2005-06](#). Saito S, Wu Y, Nankabirwa V, **Nash D**. *Int J STD AIDS*. 2012;23(5):308-315. doi:10.1258/ijsa.2011.011274
323. [Availability of nutritional support services in HIV care and treatment sites in sub-Saharan African countries](#). Anema A, Zhang W, Wu Y, Elul B, Weiser SD, Hogg RS, Montaner JSG, El Sadr W, **Nash D**. *Public Health Nutr*. 2012;15(5):938-947. doi:10.1017/S136898001100125X
324. [Association of adherence support and outreach services with total attrition, loss to follow-up, and death among ART patients in sub-Saharan Africa](#). Lamb MR, El-Sadr WM, Geng E, **Nash D**. *PLoS One*. 2012;7(6):e38443. doi:10.1371/journal.pone.0038443
325. [Factors associated with late antiretroviral therapy initiation among adults in Mozambique](#). Lahuerta M, Lima J, Nuwagaba-Biribonwoha H, Okamura M, Alvim MF, Fernandes R, Assan A, Hoos D, Elul B, El-Sadr WM, **Nash D**. *PLoS One*. 2012;7(5):e37125. doi:10.1371/journal.pone.0037125
326. [Metabolic syndrome among adults in New York City, 2004 New York City Health and Nutrition Examination Survey](#). Jordan HT, Tabaei BP, **Nash D**, Angell SY, Chamany S, Kerker B. *Prev Chronic Dis*. 2012;9:E04.
327. [Risk Factor Detection as a Metric of STARHS Performance for HIV Incidence Surveillance Among Female Sex Workers in Kigali, Rwanda](#). Braunstein SL, van de Wijgert JH, Vyankandondera J, Kestelyn E, Ntirushwa J, **Nash D**. *Open AIDS J*. 2012;6:112-121. doi:10.2174/1874613601206010112
328. [Patients enrolled in HIV care in Mozambique: baseline characteristics and follow-up outcomes](#). Lahuerta M, Lima J, Elul B, Okamura M, Alvim MF, Nuwagaba-Biribonwoha H, Horowitz D, Fernandes R, Assan A, Abrams EJ, El-Sadr WM, **Nash D**. *J Acquir Immune Defic Syndr*. 2011;58(3):e75-86. doi:10.1097/QAI.0b013e31822ac0a9
329. [Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009](#). Geng EH, Hunt PW, Diero LO, Kimaiyo S, Somi GR, Okong P, Bangsberg DR, Bwana MB, Cohen CR, Otieno JA, Wabwire D, Elul B, **Nash D**, Easterbrook PJ, Braitstein P, Musick BS, Martin JN, Yiannoutsos CT, Wools-Kaloustian K. *J Int AIDS Soc*. 2011;14:46. doi:10.1186/1758-2652-14-46
330. [HIV diagnosis, linkage to HIV care, and HIV risk behaviors among newly diagnosed HIV-positive female sex workers in Kigali, Rwanda](#). Braunstein SL, Umulisa MM, Veldhuijzen NJ, Kestelyn E, Ingabire CM, Nyinawabega J, van de Wijgert JHHM, **Nash D**. *J Acquir Immune Defic Syndr*. 2011;57(4):e70-76. doi:10.1097/QAI.0b013e3182170fd3
331. [Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries](#). **Nash D**, Wu Y, Elul B, Hoos D, El Sadr W. *AIDS*. 2011;25(12):1523-1533. doi:10.1097/QAD.0b013e32834811b2
332. [High human immunodeficiency virus incidence in a cohort of Rwandan female sex workers](#). Braunstein SL, Ingabire CM, Kestelyn E, Uwizera AU, Mwamarangwe L, Ntirushwa J, **Nash D**, Veldhuijzen NJ, Nel A, Vyankandondera J, van de Wijgert JHHM. *Sex Transm Dis*. 2011;38(5):385-394. doi:10.1097/olq.0b013e31820b8eba
333. [Dual testing algorithm of BED-CEIA and AxSYM Avidity Index assays performs best in identifying recent HIV infection in a sample of Rwandan sex workers](#). Braunstein SL, **Nash D**, Kim AA, Ford K, Mwamarangwe L, Ingabire CM, Vyankandondera J, van de Wijgert JHHM. *PLoS One*. 2011;6(4):e18402. doi:10.1371/journal.pone.0018402
334. [Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa](#). Egger M, Spycher BD, Sidle J, Weigel R, Geng EH, Fox MP, MacPhail P, van Cutsem G, Messou E, Wood R, **Nash D**, Pascoe M, Dickinson D, Etard JF,

Denis Nash, PhD, MPH
Curriculum Vitae

- McIntyre JA, Brinkhof MWG. *PLoS Med.* 2011;8(1):e1000390. doi:10.1371/journal.pmed.1000390
335. [High burden of prevalent and recently acquired HIV among female sex workers and female HIV voluntary testing center clients in Kigali, Rwanda.](#) Braunstein SL, Ingabire CM, Geubbels E, Vyankandondera J, Umulisa MM, Gahiro E, Uwineza M, Tuijn CJ, **Nash D**, van de Wijgert JHHM. *PLoS One.* 2011;6(9):e24321. doi:10.1371/journal.pone.0024321
336. [Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions.](#) Geng EH, **Nash D**, Kambugu A, Zhang Y, Braitstein P, Christopoulos KA, Muyindike W, Bwana MB, Yiannoutsos CT, Petersen ML, Martin JN. *Curr HIV/AIDS Rep.* 2010;7(4):234-244. doi:10.1007/s11904-010-0061-5
337. [Introducing a multi-site program for early diagnosis of HIV infection among HIV-exposed infants in Tanzania.](#) Nuwagaba-Biribonwoha H, Werq-Semo B, Abdallah A, Cunningham A, Gamaliel JG, Mtunga S, Nankabirwa V, Malisa I, Gonzalez LF, Massambu C, **Nash D**, Justman J, Abrams EJ. *BMC Pediatr.* 2010;10:44. doi:10.1186/1471-2431-10-44
338. [Initiation of antiretroviral therapy among pregnant women in resource- limited countries: CD4+ cell count response and program retention.](#) Toro PL, Katyal M, Carter RJ, Myer L, El-Sadr WM, **Nash D**, Abrams EJ. *AIDS.* 2010;24(4):515-524. doi:10.1097/QAD.0b013e3283350ecd
339. [Mortality after failure of antiretroviral therapy in sub-Saharan Africa.](#) Keiser O, Tweya H, Braitstein P, Dabis F, MacPhail P, Boulle A, **Nash D**, Wood R, Luthi R, Brinkhof MWG, Schechter M, Egger M. *Trop Med Int Health.* 2010;15(2):251-258. doi:10.1111/j.1365-3156.2009.02445.x
340. [Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings.](#) Tuboi SH, Pacheco AG, Harrison LH, Stone RA, May M, Brinkhof MWG, Dabis F, Egger M, **Nash D**, Bangsberg D, Braitstein P, Yiannoutsos CT, Wood R, Sprinz E, Schechter M. *J Acquir Immune Defic Syndr.* 2010;53(1):70-77. doi:10.1097/QAI.0b013e3181c22d19
341. [Strategies for more effective monitoring and evaluation systems in HIV programmatic scale-up in resource-limited settings: Implications for health systems strengthening.](#) **Nash D**, Elul B, Rabkin M, Tun M, Saito S, Becker M, Nuwagaba-Biribonwoha H. *J Acquir Immune Defic Syndr.* 2009;52 Suppl 1:S58-62. doi:10.1097/QAI.0b013e3181bbcc45
342. [Pregnancy desires, and contraceptive knowledge and use among prevention of mother-to-child transmission clients in Rwanda.](#) Elul B, Delvaux T, Munyana E, Lahuerta M, Horowitz D, Ndagije F, Roberfroid D, Mugisha V, **Nash D**, Asiimwe A. *AIDS.* 2009;23 Suppl 1:S19-26. doi:10.1097/01.aids.0000363774.91376.dc
343. [Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring.](#) Keiser O, Tweya H, Boulle A, Braitstein P, Schechter M, Brinkhof MWG, Dabis F, Tuboi S, Sprinz E, Pujades-Rodriguez M, Calmy A, Kumarasamy N, **Nash D**, Jahn A, MacPhail P, Luthy R, Wood R, Egger M. *AIDS.* 2009;23(14):1867-1874. doi:10.1097/QAD.0b013e32832e05b2
344. [Adult clinical and immunologic outcomes of the national antiretroviral treatment program in Rwanda during 2004-2005.](#) Lowrance DW, Ndamage F, Kayirangwa E, Ndagije F, Lo W, Hoover DR, Hanson J, Elul B, Ayaba A, Ellerbrock T, Rukundo A, Shumbusho F, **Nash D**, Mugabo J, Assimwe A. *J Acquir Immune Defic Syndr.* 2009;52(1):49-55. doi:10.1097/QAI.0b013e3181b03316
345. [HIV incidence in sub-Saharan Africa: a review of available data with implications for surveillance and prevention planning.](#) Braunstein SL, van de Wijgert JHHM, **Nash D**. *AIDS Rev.* 2009;11(3):140-156.
346. [Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies.](#) **Nash D**, Katyal M, Brinkhof MWG, Keiser O, May M, Hughes R,

Denis Nash
Curriculum Vitae

- Dabis F, Wood R, Sprinz E, Schechter M, Egger M. *AIDS*. 2008;22(17):2291-2302. doi:10.1097/QAD.0b013e3283121ca9
347. [Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America](#). Keiser O, Anastos K, Schechter M, Balestre E, Myer L, Boulle A, Bangsberg D, Toure H, Braitstein P, Sprinz E, **Nash D**, Hosseinipour M, Dabis F, May M, Brinkhof MWG, Egger M. *Trop Med Int Health*. 2008;13(7):870-879. doi:10.1111/j.1365-3156.2008.02078.x
348. [Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries](#). Brinkhof MWG, Dabis F, Myer L, Bangsberg DR, Boulle A, **Nash D**, Schechter M, Laurent C, Keiser O, May M, Sprinz E, Egger M, Anglaret X. *Bull World Health Organ*. 2008;86(7):559-567. doi:10.2471/blt.07.044248
349. [Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration](#). Braitstein P, Boulle A, **Nash D**, Brinkhof MWG, Dabis F, Laurent C, Schechter M, Tuboi SH, Sprinz E, Miotti P, Hosseinipour M, May M, Egger M, Bangsberg DR, Low N. *J Womens Health (Larchmt)*. 2008;17(1):47-55. doi:10.1089/jwh.2007.0353
350. [Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries](#). Brinkhof MWG, Egger M, Boulle A, May M, Hosseinipour M, Sprinz E, Braitstein P, Dabis F, Reiss P, Bangsberg DR, Rickenbach M, Miro JM, Myer L, Mocroft A, **Nash D**, Keiser O, Pascoe M, van der Borgh S, Schechter M. *Clin Infect Dis*. 2007;45(11):1518-1521. doi:10.1086/522986
351. [Incident sexually transmitted infections among persons living with diagnosed HIV/AIDS in New York City, 2001-2002: a population-based assessment](#). Manning SE, Pfeiffer MR, **Nash D**, Blank S, Sackoff J, Schillinger J. *Sex Transm Dis*. 2007;34(12):1008-1015. doi:10.1097/OLQ.0b013e3180eaa243
352. [Differences among U.S. states in estimating the number of people living with HIV/AIDS: impact on allocation of federal Ryan White funding](#). **Nash D**, Andreopoulos E, Horowitz D, Sohler N, Vlahov D. *Public Health Rep*. 2007;122(5):644-656. doi:10.1177/003335490712200512
353. [Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries \(ART-LINC\) collaboration](#). Tuboi SH, Brinkhof MWG, Egger M, Stone RA, Braitstein P, **Nash D**, Sprinz E, Dabis F, Harrison LH, Schechter M. *J Acquir Immune Defic Syndr*. 2007;45(1):52-59. doi:10.1097/QAI.0b013e318042e1c3
354. [Estimation of HIV prevalence, risk factors, and testing frequency among sexually active men who have sex with men, aged 18-64 years--New York City, 2002](#). Manning SE, Thorpe LE, Ramaswamy C, Hajat A, Marx MA, Karpati AM, Mostashari F, Pfeiffer MR, **Nash D**. *J Urban Health*. 2007;84(2):212-225. doi:10.1007/s11524-006-9135-5
355. [Barriers and missed opportunities in breast and cervical cancer screening among women aged 50 and over, New York City, 2002](#). **Nash D**, Chan C, Horowitz D, Vlahov D. *J Womens Health (Larchmt)*. 2007;16(1):46-56. doi:10.1089/jwh.2006.0079
356. [Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries](#). Braitstein P, Brinkhof MWG, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JAC, May M, Egger M. *Lancet*. 2006;367(9513):817-824. doi:10.1016/S0140-6736(06)68337-2
357. [Evaluation of an intervention to increase screening colonoscopy in an urban public hospital setting](#). **Nash D**, Azeez S, Vlahov D, Schori M. *J Urban Health*. 2006;83(2):231-243. doi:10.1007/s11524-006-9029-6

Denis Nash, PhD, MPH
Curriculum Vitae

358. [Trends in predictors of death due to HIV-related causes among persons living with AIDS in New York City: 1993-2001](#). Nash D, Katyal M, Shah S. *J Urban Health*. 2005;82(4):584-600. doi:10.1093/jurban/jti123
359. [Colon cancer screening practices in New York City, 2003: results of a large random-digit dialed telephone survey](#). Thorpe LE, Mostashari F, Hajat A, Nash D, Karpati A, Weber T, Winawer S, Neugut AI, Awad A, Zevallos M, Remy P, Frieden T. *Cancer*. 2005;104(5):1075-1082. doi:10.1002/cncr.21274
360. [Estimates of HIV incidence among persons testing for HIV using the sensitive/less sensitive enzyme immunoassay, New York City, 2001](#). Nash D, Bennani Y, Ramaswamy C, Torian L. *J Acquir Immune Defic Syndr*. 2005;39(1):102-111. doi:10.1097/01.qai.0000144446.52141.4c
361. [A comparison of HIV seropositive and seronegative young adult heroin- and cocaine-using men who have sex with men in New York City, 2000-2003](#). Fuller CM, Absalon J, Ompad DC, Nash D, Koblin B, Blaney S, Galea S, Vlahov D. *J Urban Health*. 2005;82(1 Suppl 1):i51-61. doi:10.1093/jurban/jti024
362. [Racial/ethnic differences in screening for colon cancer: report from the New York Cancer Project](#). Vlahov D, Ahern J, Vazquez T, Johnson S, Philips LA, Nash D, Mitchell MK, Freeman H. *Ethn Dis*. 2005;15(1):76-83.
363. [Bone density-related predictors of blood lead level among peri- and postmenopausal women in the United States: The Third National Health and Nutrition Examination Survey, 1988-1994](#). Nash D, Magder LS, Sherwin R, Rubin RJ, Silbergeld EK. *Am J Epidemiol*. 2004;160(9):901-911. doi:10.1093/aje/kwh296
364. [Long-term prognosis for clinical West Nile virus infection](#). Klee AL, Maidin B, Edwin B, Poshni I, Mostashari F, Fine A, Layton M, Nash D. *Emerg Infect Dis*. 2004;10(8):1405-1411. doi:10.3201/eid1008.030879
365. [Implementation of named HIV reporting--New York City, 2001](#). *MMWR Morb Mortal Wkly Rep*. 2004;52(51-52):1248-1252.
366. [Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women](#). Nash D, Magder L, Lustberg M, Sherwin RW, Rubin RJ, Kaufmann RB, Silbergeld EK. *JAMA*. 2003;289(12):1523-1532. doi:10.1001/jama.289.12.1523
367. [Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases](#). Roehrig JT, Nash D, Maldin B, Labowitz A, Martin DA, Lanciotti RS, Campbell GL. *Emerg Infect Dis*. 2003;9(3):376-379. doi:10.3201/eid0903.020531
368. [Mercury exposure and malaria prevalence among gold miners in Para, Brazil](#). Silbergeld EK, Nash D, Trevant C, Strickland GT, de Souza JM, da Silva RSU. *Rev Soc Bras Med Trop*. 2002;35(5):421-429. doi:10.1590/s0037-86822002000500001
369. [Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings](#). Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC, Cetron M, Cohen M, Doyle T, Fischer M, Greene C, Griffith KS, Guarner J, Hadler JL, Hayslett JA, Meyer R, Petersen LR, Phillips M, Pinner R, Popovic T, Quinn CP, Reefhuis J, Reissman D, Rosenstein N, Schuchat A, Shieh WJ, Siegal L, Swerdlow DL, Tenover FC, Traeger M, Ward JW, Weisfuse I, Wiersma S, Yeskey K, Zaki S, Ashford DA, Perkins BA, Ostroff S, Hughes J, Fleming D, Koplan JP, Gerberding JL. *Emerg Infect Dis*. 2002;8(10):1019-1028. doi:10.3201/eid0810.020353
370. [Laboratory response to anthrax bioterrorism, New York City, 2001](#). Heller MB, Bunning ML, France MEB, Niemeyer DM, Peruski L, Naimi T, Talboy PM, Murray PH, Pietz HW, Kornblum J, Oleszko W, Beatrice ST. *Emerg Infect Dis*. 2002;8(10):1096-1102. doi:10.3201/eid0810.020376

Denis Nash
Curriculum Vitae

371. [Epidemiologic response to anthrax outbreaks: field investigations, 1950-2001](#). Bales ME, Dannenberg AL, Brachman PS, Kaufmann AF, Klatsky PC, Ashford DA. *Emerg Infect Dis*. 2002;8(10):1163-1174. doi:10.3201/eid0810.020223
372. [Survival rates in NYC in the era of combination ART](#). Fordyce EJ, Singh TP, **Nash D**, Gallagher B, Forlenza S. *J Acquir Immune Defic Syndr*. 2002;30(1):111-118. doi:10.1097/00042560-200205010-00015
373. [25 years of HIV in New York City: lessons from surveillance](#). *J Urban Health*. 2001;78(4):669-678. doi:10.1093/jurban/78.4.669
374. [Epidemic West Nile encephalitis, New York, 1999: results of a household- based seroepidemiological survey](#). Mostashari F, Bunning ML, Kitsutani PT, Singer DA, **Nash D**, Cooper MJ, Katz N, Liljebjelke KA, Biggerstaff BJ, Fine AD, Layton MC, Mullin SM, Johnson AJ, Martin DA, Hayes EB, Campbell GL. *Lancet*. 2001;358(9278):261-264. doi:10.1016/S0140-6736(01)05480-0
375. [The outbreak of West Nile virus infection in the New York City area in 1999](#). **Nash D**, Mostashari F, Fine A, Miller J, O'Leary D, Murray K, Huang A, Rosenberg A, Greenberg A, Sherman M, Wong S, Layton M. *N Engl J Med*. 2001;344(24):1807-1814. doi:10.1056/NEJM200106143442401
376. [Testing for West Nile virus](#). Fine A, Mostashari F, **Nash D**, Layton M. *Lancet*. 2000;356(9235):1110-1111. doi:10.1016/S0140-6736(05)74550-5
377. [The role of pathology in an investigation of an outbreak of West Nile encephalitis in New York, 1999](#). Shieh WJ, Guarner J, Layton M, Fine A, Miller J, **Nash D**, Campbell GL, Roehrig JT, Gubler DJ, Zaki SR. *Emerg Infect Dis*. 2000;6(4):370-372. doi:10.3201/eid0604.000407
378. [Repeat victims of violence: report of a large concurrent case-control study](#). Cooper C, Eslinger D, **Nash D**, al-Zawahri J, Stolley P. *Arch Surg*. 2000;135(7):837-843. doi:10.1001/archsurg.135.7.837
379. [From the Centers for Disease Control and Prevention. Update: West Nile- like viral encephalitis-- New York, 1999](#). *JAMA*. 1999;282(18):1714.
380. [Update: West Nile-like viral encephalitis--New York, 1999](#). *MMWR Morb Mortal Wkly Rep*. 1999;48(39):890-892.
381. [Outbreak of West Nile-like viral encephalitis--New York, 1999](#). *MMWR Morb Mortal Wkly Rep*. 1999;48(38):845-849.
382. [The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines](#). Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, **Nash D**, Clark S, Haber P, Stolley PD, Schonberger LB, Chen RT. *N Engl J Med*. 1998;339(25):1797-1802. doi:10.1056/NEJM199812173392501
383. [Guillain-Barre syndrome incidence based on hospital discharge data](#). Ballesteros M, Lasky T, **Nash D**, Magder L, Koski CL, Chehrensa M. *J Infect Dis*. 1998;178(4):1228. doi:10.1086/515703
384. [Health surveillance using an occupational medical database](#). Gowers DS, Carpenter AV, Ellis HM, Best AM, **Nash D**, Holzner CL, Keith JB, Sherrard HG. *J Occup Environ Med*. 1998;40(8):685-696. doi:10.1097/00043764-199808000-00005
385. [An epidemic of lung cancer due to chloromethyl ethers. 30 years of observation](#). Weiss W, **Nash D**. *J Occup Environ Med*. 1997;39(10):1003-1009. doi:10.1097/00043764-199710000-00012
386. [Bone mass and the risk of breast cancer](#). Ballesteros M, **Nash D**, Fix A, Bush T. *N Engl J Med*. 1997;337(3):200. doi:10.1056/NEJM199707173370313
387. **Nash D**. Inappropriate administration of DT/DTP vaccines. *J Fam Pract*. 1995;41(5):437.
388. [Oral temperatures in a group of healthy industrial workers](#). Gowers DS, Carpenter AV, **Nash D**, Ellis HM. *J Occup Environ Med*. 1995;37(11):1259-1260. doi:10.1097/00043764-199511000-00001

Denis Nash, PhD, MPH
Curriculum Vitae

Book Chapters

1. **Nash D**, Cohen N, Layton M. West Nile virus infection in New York City: The public health perspective. In: Hughes J, ed. *Emerging Infections 5*. Washington: ASM Press, 2001.

Editorials in academic journals

1. **Nash D**. [Designing and Disseminating Metrics to Support Jurisdictional Efforts to End the Public Health Threat Posed by HIV Epidemics](#). *Am J Public Health*. 2020;110(1):53-57. doi:10.2105/AJPH.2019.305398
2. **Nash D**, Geng E. [Goal-Aligned, Epidemic Intelligence for the Public Health Response to the COVID-19 Pandemic](#). *Am J Public Health*. 2020;110(8):1154-1156. doi:10.2105/AJPH.2020.305794
3. **Nash D**, Robertson M. [How to Evolve the Response to the Global HIV Epidemic With New Metrics and Targets Based on Pre-Treatment CD4 Counts](#). *Curr HIV/AIDS Rep*. 2019;16(4):304-313. doi:10.1007/s11904-019-00452-7
4. **Nash D**, Yotebieng M, Sohn AH. [Treating all people living with HIV in sub-Saharan Africa: a new era calling for new approaches](#). *J Virus Erad*. 2018;4(Suppl 2):1-4.
5. Romo ML and **Nash D**. [Onchocerciasis and epilepsy: a causal relationship?](#) *Lancet Infectious Diseases*. 2018 18 (11): 1172-1174.
6. Kimmel AD and **Nash D**. [HIV prevention resources: time to move toward affordability](#). *Lancet HIV*. 2017 May;4(5):e191-e193
7. Kimmel A and **Nash D**. Home HIV testing and counselling: answers raising questions. *Lancet HIV*. Volume 1, No. 2, e52–e53, November 2014. DOI: [http://dx.doi.org/10.1016/S2352-3018\(14\)70029-3](http://dx.doi.org/10.1016/S2352-3018(14)70029-3)

Op-eds/commentaries in the lay press

1. [Ending U.S.-global health research partnerships will cost America](#). STAT News, 2025
2. [The ‘disease detectives’ dodged a bullet — but another might be coming](#), STAT News, 2025
3. [From sewage to safety: Hospital wastewater surveillance as a beacon for defense against H5N1 bird flu](#). STAT News 2024
4. [The bird flu outbreak has spread to humans — are we too late to prevent the next pandemic?](#) The Hill, 2024
5. [Is Biden correct that the pandemic is over? Not exactly](#). NBC News Think, 2022
6. [The CDC Got Lost Trying to Follow the Science](#). Barron’s, 2022
7. [To combat COVID, we must have better indicators](#), The New York Daily News, 2022
8. [What we’ve learned from the HIV pandemic](#). CNN, 2020

Books

Letters:

1. Lahuerta, M. and **Nash D**. Reply to Pattern et al. re: “Advanced HIV disease at ART initiation despite implementation of expanded ART eligibility guidelines during 2007-2012 in Khayelitsha, South Africa”. *Clinical Infectious Diseases*, 2014. PMID 3894575
2. **Nash D**, Silbergeld E. Blood lead levels and hypertension (Authors' reply). *JAMA*. 2003;294:461.

Denis Nash
Curriculum Vitae

3. Fine A, Mostashari F, **Nash D**, Layton M. [Testing for West Nile virus](#). *Lancet*. Sep 23 2000;356(9235):1110-1111.
4. Ballesteros M, Lasky T, **Nash D**, Magder L, Koski CL, Chehrenama M. [Guillain-Barre syndrome incidence based on hospital discharge data](#). *J Infect Dis*. Oct 1998;178(4):1228.
5. **Nash D**, Ballesteros M, Fix A, Bush T. [Bone mass and the risk of breast cancer](#). *N Engl J Med*. Jul 17 1997;337(3):200.
6. **Nash D**. Inappropriate administration of DT/DTP vaccines. *J Fam Pract*. Nov 1995;41(5):437.

INVITED PRESENTATIONS:

1. September 2025 – Penn <https://www.med.upenn.edu/cfar/seminar-series/>
2. **August 2025**: Brief digital intervention to increase COVID-19 vaccination among individuals with anxiety or depression, CDC ARise Prevention Research Center Site Visit, New York, NY
3. **February 2025** – [The Beyond TB Lecture: Estimating the Causal Effects of Extreme Weather Events on HIV care outcomes in the IeDEA Cohort Collaboration: Study design and early results](#). The Union Against Tuberculosis and Lung Disease Conference, Vancouver, Canada
4. **December 2024** – [Estimating the Causal Effects of Extreme Weather Events on HIV Care Outcomes](#), University of Memphis, Memphis, TN, USA
5. **October 2024** – *Estimating the Causal Effects of Extreme Weather Events on HIV Care Outcomes*, WHO Philippines, Manila, Philippines
6. **October 2024** – *Estimating the Causal Effects of Extreme Weather Events on HIV Care Outcomes*, Research Institute for Tropical Medicine (Government of the Philippines), Muntinlupa, Philippines
7. **October 2024** – [Estimating the Causal Effects of Extreme Weather Events](#), University of Bordeaux, Bordeaux, France
8. **October 2024** – *New strategies to treat and prevent HIV Infection*, National CFAR Meeting, New York, NY, USA
9. **October 2024** – *Implementation science: Opportunities to apply what we have learned in HIV research to transform program delivery*, TREAT Asia / amfAR Meeting, Bali, Indonesia
10. **September 2024** – [Estimating the Causal Effects of Extreme Weather Events on HIV Care Outcomes](#), McGill University, Montreal, Canada
11. **April 2024** – *Extreme Weather Events and HIV Care Outcomes in the IeDEA Cohort Collaboration*, IeDEA Meeting, Abidjan, Côte d'Ivoire
12. **April 2024** – *Extreme Weather Events and HIV Care Outcomes in the IeDEA Cohort Collaboration*, IeDEA Meeting, Douala, Cameroon
13. **March 2024** – *IWHOD Climate & Health Side Meeting*, International Workshop on HIV and Hepatitis Observational Databases (IWHOD), Toledo, Spain
14. **February 2024**: *Study designs in HIV implementation research: Examples from NYC's Ryan White HIV/AIDS Part A Program*. Presentation to the DC CFAR.
15. **April 2023** – [Novel data collection strategies for today's longitudinal infectious disease research](#), Nature Seminar Series
16. **March 2023** – *IWHOD Climate & Health Side Meeting*, International Workshop on HIV and Hepatitis Observational Databases (IWHOD), Lisbon, Portugal
17. **March 2023**: *Extreme weather and pandemics: Leveraging observational cohorts to assess the influence of large scale exposures on health outcomes (or Everything, Everywhere All at Once)*, NYU Epidemiology Department Seminar.

Denis Nash, PhD, MPH
Curriculum Vitae

18. **October 2022** – *Climate, Extreme Weather Events and HIV/AIDS Outcomes: Investigating Impacts and Mechanisms*, Albert Einstein College of Medicine, ERC CFAR Seminar Series, Bronx, NY, USA
19. **September 2022** – *A Very Quick Primer on Implementation Science*, Memorial Sloan Kettering, New York, NY, USA
20. **June 2022** – *Climate, Extreme Weather Events and HIV/AIDS Outcomes: Investigating Impacts and Mechanisms*, Venue TBD, Paris, France
21. **May 2022** – *Implementation-Science Approaches to Strengthening the HIV Service System*, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA
22. **February 2022** – [Leveraging Observational Cohorts and Surveillance Registries as Platforms for Implementation Research](#), Columbia University Irving Medical Center, New York, NY, USA
23. **May 2020** – *Epidemic intelligence to inform the public health response to the SARS-CoV-2 pandemic: Introducing the CHASING COVID Cohort Study*, The HIV Center for Clinical and Behavioral Studies, Columbia University.
24. **April 2020** – [Epidemic intelligence to inform the public health response to the SARS-CoV-2 pandemic](#), Office of NY State Senator Liz Krueger (Town Hall Meeting), New York, NY, USA
25. **November 2019** – *ERC-CFAR and NYC DOHMH Collaboration (with Sarah Braunstein)*, Emory University CFAR Grand Rounds, Atlanta, GA, USA
26. **October 2019** – *Grant Writing Workshop*, All-Africa IeDEA Meeting, Johannesburg, South Africa
27. **October 2019** – *Rapid ART Initiation Under National Treat-All Policy Implementation*, All-Africa IeDEA Meeting, Johannesburg, South Africa
28. **September 2019** – *Introduction to Implementation Science Research*, NIH HIV-associated Comorbidities, Coinfections, and Complications (H3C) Workshop, Bethesda, MD, USA
29. **September 2019** – [Designing and Disseminating Metrics to Support Jurisdictional Efforts to End the Public Health Threat Posed by HIV Epidemics](#), NYC DOHMH Grand Rounds, New York, NY, USA
30. **June 2019** – *ANRS Talk (title TBD)*, ANRS, Paris, France
31. **April 2019** – *Early Data on ‘Treat All’ Guideline Implementation for HIV/AIDS, and Developing Research Priorities to Inform Future Implementation*, HIV Grand Rounds, University of Pennsylvania, Philadelphia, PA, USA
32. **March 2019** – [Early Data on ‘Treat All’ Guideline Implementation for HIV/AIDS, and Developing Research Priorities to Inform Future Implementation](#), University of California, San Francisco (UCSF), San Francisco, CA, USA
33. **February 2019** – *Using Evidence to Enhance the Effectiveness of an HIV Care Coordination Intervention in NYC*, Einstein/Montefiore ERC CFAR Seminar Series, Bronx, NY, USA
34. **December 2018** – *Early Data on ‘Treat All’ Guideline Implementation for HIV/AIDS, and Developing Research Priorities to Inform Future Implementation*, Northwell Health Grand Rounds, New Hyde Park, NY, USA
35. **November 2018** – *Early Data on ‘Treat All’ Guideline Implementation for HIV/AIDS, and Developing Research Priorities to Inform Future Implementation*, Yale School of Public Health, New Haven, CT, USA
36. **September 2018** – *Assessing the Impact of National ‘Treat All’ Policies on Timely ART Initiation in Six Sub-Saharan African Countries*, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Denis Nash
Curriculum Vitae

37. **May 2018** – *A Global Analysis of the Expansion of HIV Treatment Guidelines, and Research Priorities for ‘Treat-all’ Implementation in Sub-Saharan Africa*, SUNY Downstate Medical Center Grand Rounds, Brooklyn, NY, USA
38. **April 2018** – *A Global Perspective on the Implementation of ‘Treat all’ Guidelines for Antiretroviral Therapy*, HIV Center Grand Rounds, Columbia University Medical Center, New York State Psychiatric Institute
39. **April 2018** – *A Global Analysis of the Expansion of HIV treatment Guidelines, and Research Priorities for ‘Treat-all’ Implementation in Sub-Saharan Africa*, Columbia University, Mailman School of Public Health, Implementation Science Seminar Series
40. **April 2018** – *Has HIV Treatment Guideline Expansion Improved the Timely Uptake of ART?* Northwestern University, Conference on HIV Implementation Science, Chicago, IL
41. **April 2018** – *History and public health burden of infectious diseases*, Lecture in the Infectious Disease Epidemiology course at Mt, Sinai School of Medicine.
42. **April 2018** – *A Global Analysis of the Expansion of HIV Treatment Guidelines, and Research Priorities for ‘Treat-all’ Implementation in Sub-Saharan Africa*, Columbia University HIV Center for Clinical & Behavioral Studies, New York, NY, USA
43. **April 2018** – *A Global Analysis of the Expansion of HIV Treatment Guidelines, and Research Priorities for ‘Treat-all’ Implementation in Sub-Saharan Africa*, Columbia Implementation Science T32 Post-doctoral Fellows Seminar, New York, NY, USA
44. **April 2018** – *Has HIV Treatment Guideline Expansion Improved the Timely Uptake of ART?*, Northwestern University CFAR, Chicago, IL, USA
45. **February 2018** – *A Global Analysis of the Expansion of HIV treatment Guidelines, and Research Priorities for ‘Treat-all’ Implementation in Sub-Saharan Africa*, George Washington University School of Public Health, Epidemiology Seminar Series, Washington, DC
46. **January 2018** – *HIV and Aging Research in the ERC Center for AIDS Research (CFAR)*, New York University Symposium on HIV and Aging, New York, NY
47. **January 2018** – *A Global Analysis of the Expansion of HIV Treatment Guidelines, and Research Priorities for ‘Treat-all’ Implementation in Sub-Saharan Africa*, George Washington University Milken Institute School of Public Health, Washington, DC, USA
48. **November 2017** – *A Global Analysis of the Expansion of HIV treatment Guidelines, and Research Priorities for ‘Treat-all’ Implementation in Sub-Saharan Africa*, New York University, Center for Drug Use and HIV Research (CDUHR), New York, NY
49. **July 2017** – *Ending the HIV Epidemic in New York City: Innovations and Progress; UNAIDS 90-90-90 Targets Workshop*, UNAIDS 90-90-90 Targets Workshop, Paris, France
50. **July 2017 (Panel discussant)** – *Implementation Science, What is it? Example of NIH funded implementation science research*, International AIDS Society Meeting, Paris France
51. **July 2017** – *Tracking and Disseminating Information on Progress Towards Ending the AIDS Epidemic in New York*, New York State AIDS Advisory Committee.
52. **June 2017** – *Lost in Translation: Reducing the Time from Infection to ART Initiation at Scale*, NIH/ERC CFAR Site Visit (Presentation to Anthony Fauci), Bethesda, MD, USA
53. **May 2017** – *Monitoring Population Health*, Ministry of Health Training Workshop, Marrakech, Morocco.
54. **April 2017** – *History and public health burden of infectious diseases*, Lecture in the Infectious Disease Epidemiology course at Mt, Sinai School of Medicine.

Denis Nash, PhD, MPH
Curriculum Vitae

55. **March 2017** – *Implementation Science in Population Health: Conducting Research To Help Optimize The Potential for Impact At Scale*, University of California at San Francisco, Center for AIDS Research.
56. **March 2017** – *Surveillance and Metrics for Hepatitis C elimination*, New York State Hepatitis C Elimination Summit Meeting, Albany, NY
57. **February 2017** – *Epidemiology of HIV/AIDS*, Lecture in the HIV/AIDS Epidemiology course at Columbia University, Mailman School of Public Health
58. **December 2016** – *HIV incidence as a metric for HIV prevention in the United States*, National Webinar, Treatment Action Group and Community Justice Alliance.
59. **December 2016** – *Strategic information for ending HIV epidemics: Comparative effectiveness of evidence-based HIV interventions at scale*, HRSA AETC Webinar delivered at Columbia University, Mailman School of Public Health.
60. **November 2016** – *Epidemiology of HIV/AIDS*, Lecture in the Intro to Public Health course at Mt, Sinai School of Medicine.
61. **July 2016** – *Ending the Epidemic Dashboard System update*, New York State AIDS Advisory Committee.
62. **June 2016** – *Pulling back the lens to contextualize HIV care: Examples from the Global IeDEA Network*, National Institutes of Health, Bethesda, MD
63. **April 2016** – *History and public health burden of infectious diseases*, Lecture in the Infectious Disease Epidemiology course at Mt, Sinai School of Medicine.
64. **April 2016** – *Strategic information for ending HIV epidemics: Comparative effectiveness of evidence-based HIV interventions at scale*, Albert Einstein College of Medicine, Seminar Series in Epidemiology and Population Health.
65. **April 2016** – *Discussant: NYC Department of Health and Mental Hygiene, Epidemiology Grand Rounds on Hepatitis C Virus in NYC*.
66. **February 2016** – *HIV Pre-Exposure Prophylaxis Usage Indicators at the Individual and Population levels*, The New York Academy of Medicine.
67. **December 2015** – *NYC Ryan White Part A Care Coordination and the CHORDS Study*, Columbia University HIV Center Grand Rounds.
68. **November 2015** – *Epidemiology of HIV/AIDS*, Lecture in the Intro to Public Health course at Mt, Sinai School of Medicine.
69. **April 2015** – *History and public health burden of infectious diseases*, Lecture in the Infectious Disease Epidemiology course at Mt, Sinai School of Medicine.
70. **December 2014 (Panel Moderator)** – *Epidemiologists discuss the Ebola Epidemic: Response, Preparedness, Lessons*, CUNY Graduate Center.
71. **December 2014**, *Creating an Implementation Science Research Agenda for HIV Prevention*, Treatment Action Group and AmFAR Summit on Implementation Science
72. **November 2014** – *Epidemiology of HIV/AIDS*, Lecture in the Intro to Public Health course at Mt, Sinai School of Medicine.
73. **May 2014** – *Launching a Cutting Edge Global Health Research Agenda*, Mt, Sinai School of Medicine, Global Health Rounds.
74. **April 2014** – *History and public health burden of infectious diseases*, Lecture in the Infectious Disease Epidemiology course at Mt, Sinai School of Medicine.
75. **December 2013** – *Concepts in Infectious Disease Epidemiology*, Lecture in the Epidemiology course of the Executive MPH Program, Columbia University, Mailman School of Public Health

Denis Nash
Curriculum Vitae

76. **November 2013** – *Epidemiology of HIV/AIDS*, Lecture in the Intro to Public Health course at Mt, Sinai School of Medicine.
77. **October 2013** – *Data Visualization in Infectious Disease Epidemiology*, Lecture in Data Visualization Course, Columbia University, Mailman School of Public Health
78. **September 2013** – *Concepts in Infectious Disease Epidemiology*, Lecture in Epidemiology I course at Columbia University Mailman School of Public Health
79. **November 2012** – *Epidemiology of HIV/AIDS*, Lecture in the Intro to Public Health course at Mt, Sinai School of Medicine.
80. **September 2012** – *Can lessons from HIV scale-up in sub-Saharan Africa help us achieve the National HIV/AIDS Strategy goals here in the US? NYC DOHMH Epidemiology Grand Rounds.*
81. **September 2012** – *Concepts in Infectious Disease Epidemiology*, Lecture in Epidemiology I course at Columbia University Mailman School of Public Health
82. **November 2011** – *Epidemiology of HIV/AIDS*, Lecture in the Intro to Public Health course at Mt, Sinai School of Medicine.
83. **September 2011** – *Concepts in Infectious Disease Epidemiology*, Lecture in Epidemiology I course at Columbia University Mailman School of Public Health
84. **September 2010** – *Columbia University Global Health Track Career Day*
85. **March 2010** – *Operations research in HIV scale-up*, Hunter College Epidemiology Seminar Series
86. **March 2010** – *Columbia University Mailman School of Public Health: Meet the Methodologist panel series*, Focus on Geographic Information Systems
87. **December 2008** – *World AIDS Day Lecture, NYU Doctors of the World*
88. **June 2008** – *Describing facility characteristics and their associations with HIV outcomes, CDC Kenya*
89. **October 2007** – *Operations research in HIV care and treatment scale-up*, HIV Center Grand Rounds.
90. **August 2005** – *National HIV Incidence Surveillance*, International Conference on Infectious Diseases, Kigali, Rwanda
91. **March 2005** – *The emergence and spread of West Nile virus in the US*, Epidemiology Departmental Seminar, Columbia University Mailman School of Public Health
92. **February 2005** – *Invited lecturer on Surveillance and Infectious Diseases, Infectious Disease Epidemiology Course, Columbia University Mailman School of Public Health (course director: Judith Absalon)*
93. **October 2004** – *Discussant on Waterborne diseases, Environmental Health Sciences Core Course, Columbia University Mailman School of Public Health*
94. **April 2004** – *The emergence and spread off West Nile Virus in the US (invited speaker)*, The Conference on Emerging Infections, Mt Sinai Medical School, 2004
95. **October 2003** – *Public health surveillance*, Epidemiology in Action Course (Invited speaker), New York City Department of Health and Mental Hygiene, New York, NY
96. **October 2003** – *Epidemiology of HIV/AIDS*, Epidemiology in Action Course (Invited speaker), New York City Department of Health and Mental Hygiene, New York, NY
97. **May 2003** – *The next generation of public health HIV surveillance: Obtaining population-based estimates of HIV incidence*, HIV Grand Rounds, SUNY Downstate Medical Center, Brooklyn, NY
98. **May 2003** – *The next generation of public health HIV surveillance: Obtaining population-based estimates of HIV incidence*, HIV Grand Rounds, Jacobi Medical Center, Bronx, NY

Denis Nash, PhD, MPH
Curriculum Vitae

99. **April 2003** – *Population-based HIV incidence surveillance in NYC: The sensitive/less sensitive EIA technique*, Physicians' Research Network (PRN) monthly meeting, The 200 5th Club, New York, NY
100. **September 2002** – *Epidemiology of HIV/AIDS*, Invited lecturer in course on Activism in Public Health, Montefiore Medical Center, Bronx, NY
101. **June 2002** – *Using population-based data to inform prevention programs and planning*, American Diabetes Association Annual Meeting, San Francisco, June 2002
102. **May 2002** – *Trends in the predictors of survival among persons living with AIDS in NYC, 1993-2001*, New York City Department of Health, Commissioner's Epidemiology Grand Rounds
103. **May 2001** – *Emerging trends in HIV/AIDS*, Conference of the New York State and County Health Officials (NYSCHO), Cooperstown, NY
104. **April 2001** – *Trends in the predictors of mortality among reported AIDS cases in New York City, 1993-1999*, Annual meeting of the Epidemic Intelligence Service, CDC, Atlanta, GA
105. **April 2001** – *A follow-up study of New York City residents infected during a 1999 outbreak of West Nile viral disease*, Annual meeting of the Epidemic Intelligence Service, CDC, Atlanta, GA
106. **April 2001** – *Guinea worm disease eradication: Experiences in Nigeria*, Annual meeting of the Epidemic Intelligence Service, CDC, Atlanta, GA
107. **December 2000** – *Epidemiologic and clinical aspects of the NYC West Nile outbreak*, Pathology rounds, Albert Einstein College of Medicine.
108. **September 2000** – *Mortality and survival among reported Acquired Immunodeficiency Syndrome (AIDS) cases, New York City, 1990-1999*, Epidemiology Grand Rounds, Centers for Disease Control and Prevention, Atlanta, GA.
109. **September 2000** – *The epidemiology of West Nile Virus in the New York City metropolitan area, 1999*, Invited speaker, Annual meeting of the American College of Epidemiology, Atlanta, GA.
110. **June 2000** – *The public health aspects of West Nile Virus in New York City*, Cornell University Cooperative Extension: West Nile Virus Forum.
111. **June 2000** – *The public health significance of and response to the NYC West Nile outbreak*, Keynote address of the annual meeting of the Mid-Atlantic Biosafety Conference.
112. **April 2000** – *Report of a regional outbreak of West Nile virus in the New York City metropolitan area*, Annual meeting of the Epidemic Intelligence Service, CDC, Atlanta, GA
113. **March 2000** – *The public health significance of and response to the NYC West Nile outbreak*, Annual meeting of the Coalition Against the Misuse of Pesticides.
114. **March 2000** – *Report of an outbreak of West Nile Virus, New York City area, 1999*, Weekly seminar series, Yale School of Medicine.
115. **December 1999** – *Clinical aspects of 43 serologically positive, clinical cases of West Nile Virus (WNV) infection in New York City, 1999*, Annual meeting of the American Society of Tropical Medicine, late breaker session, Washington, DC.
116. **November 1999** – *An outbreak of West Nile Virus, New York City, 1999*, Mt Sinai School of Medicine, Infectious Disease Conference.
117. **March 1999** – *Lead and osteoporosis in peri and post-menopausal women*, Bureau of Environmental Health and Safety Lecture Series, Idaho Department of Health and Welfare, Presented in Coeur d' Alene, Idaho.
118. **June 1997** – *Risk factors for repeat violence-related trauma: report of a large concurrent case control study*, Visiting Lecture Series of the University of Maryland at Baltimore, Department of Epidemiology and Preventive Medicine.

Denis Nash
Curriculum Vitae

119. **May 1997** – *Instructor, Workshop on Molecular Epidemiology*, Women's Health Research Group, University of Maryland at Baltimore, Department of Epidemiology and Preventive Medicine.
120. **September 1996** – *Self-rated health and survival in a sample of community dwelling elderly women*, Visiting Lecture Series of the University of Maryland at Baltimore, Department of Epidemiology and Preventive Medicine.

Conference Abstracts (not up to date):

1. Olga Tymejczyk, Ellen Brazier, Constantin Yiannoutsos, Kara Wools-Kaloustian, Keri Althoff, Brenda Crabtree-Ramirez, Kinh Van Nguyen, Elizabeth Zaniewski, Francois Dabis, Jean d'Amour Sinayobye, Nanina Anderegg, Nathan Ford, Radhika Wikramanayake, and **Denis Nash**, on behalf of IeDEA. The impact of HIV treatment guideline expansion on the timeliness of ART initiation following enrollment in HIV care. International Workshop on HIV and Hepatitis Observational Databases, Lisbon, Portugal, 2017 (Abstract #30, Oral Presentation).
2. Diane Addison, **Denis Nash**, Kathryn Anastos, Qiuhu Shi, Donald Hoover, Jean d'Amour Sinayobye, Patricia Lelo, Marcel Yotebieng, April Kimmel, Andrew Edmonds on behalf of IeDEA Central Africa Cohort Collaboration. A novel implementation cascade for monitoring adults and children receiving HIV care and treatment in resource-limited settings: findings from the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Central Africa. 21st International Workshop on HIV and Hepatitis Observational Databases, Lisbon, Portugal, 2017 (Abstract #9, Oral Presentation).
3. Catrina Mugglin, Matthias Egger, Mark Urassa, Sanjay Pujari, Olivia Keiser, Antoine Jaquet, Stephany Duda, **Denis Nash**, C. William Wester on behalf of IeDEA. HIV care and treatment sites' capacity to manage NCDs: diabetes and hypertension. International Workshop on HIV and Hepatitis Observational Databases, Lisbon, Portugal, 2017 (Abstract #108, Oral Presentation).
4. McKaylee Robertson, Katherine Penrose, Mary Irvine, Rebekkah Robbins, Sarah Kulkarni, Sarah Braunstein, Levi Waldron, and **Denis Nash**. Durable Viral Suppression among HIV Care Coordination Participants and Non-Participants. International Association of Providers of AIDS Care (IAPAC) Conference. Miami, 2017.
5. C. Mugglin, L. Mulenga, A. Mweemba, C. Wyatt, Y. Abo, A. Avihingsanon, K. Wools-Kaloustian, C. McGowan, **D. Nash**, M. Egger, C.W. Wester, on behalf of IeDEA. Site capacity to screen for and manage renal dysfunction among HIV-infected persons receiving care in low- and middle-income countries (LMICs). International AIDS Society Meeting, Paris, France, 2017 (Poster Abstract # WEPEB0549).
6. Parcesepe, C. Mugglin, M. Egger, F. Nalugoda, C. Bernard, E. Yuniastuti, S. Duda, C. William Wester, **D. Nash**, for the IeDEA Network Collaboration. Capacity to screen and manage mental health disorders at HIV treatment sites in low- and middle-income countries. International AIDS Society Meeting, Paris, France, 2017 (Poster Discussion Abstract # MOPDB0105).
7. N. Anderegg, O. Kirk, for the IeDEA (including **D Nash**) & COHERE collaborations. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle- and high-income countries. International AIDS Society Meeting, Paris, France, 2017 (Oral Abstract # MOAB0101).
8. Olga Tymejczyk, Constantin Yiannoutsos, Beverly Musick, Amit Achhra, Carina Cesar, Peter Rebeiro, Kinh Van Nguyen, Matthias Egger, and **Denis Nash** for the IeDEA Collaboration. Loss to clinic prior to ART initiation among patients enrolling in HIV care in the IeDEA network, 2004-2013. International Workshop on HIV and Hepatitis Observational Databases, Budapest, Hungary 2016 (Abstract #139, Oral Presentation).

Denis Nash, PhD, MPH
Curriculum Vitae

9. Olga Tymejczyk, Constantin Yiannoutsos, Kara Wools-Kaloustian, Amit Achhra, Keri Althoff, Brenda Crabtree-Ramirez, Kinh Van Nguyen, Elizabeth Zaniewski, and **Denis Nash** for the IeDEA Collaboration. Cumulative incidence of ART initiation at the original clinic of enrolment: An analysis of IeDEA network data from 195 clinics in 28 countries, 2004-2014. International Workshop on HIV and Hepatitis Observational Databases, Budapest, Hungary 2016 (Abstract #137, Poster Presentation).
10. Olga Tymejczyk; Kelly Jamison; Preeti Pathela; Sarah L. Braunstein; Julia Schillinger; and **Denis Nash**. Evidence of HIV Care Following STD Clinic Visits by Out-of-Care HIV-Positive Persons. Conference on Retroviruses and Opportunistic Infections (CROI). Boston, 2016 (Abstract #1009)
11. Quynh T. Vo; Olga Tymejczyk; Batya Elul; Wafaa M. El-Sadr; Yingfeng Wu; Laurence Ahoua; Sarah Kulkarni; Susie Hoffman; and **Denis Nash**. Late ART Initiation and 12-Month Mortality After ART Initiation in Sub-Saharan Africa. Conference on Retroviruses and Opportunistic Infections (CROI). Boston, 2016 (Abstract #1020)
12. Anne Mooser; Kathrin Zürcher; **Denis Nash**; Olga Tymejczyk; Margaret Couvillon; and Matthias Egger; for the IeDEA and MESH Consortia. Declining Mortality in Patients on ART Lost to Follow-up in Sub-Saharan Africa. Conference on Retroviruses and Opportunistic Infections (CROI). Boston, 2016 (Abstract #1021)
13. **Denis Nash**, Rebekkah Robbins, McKaylee Robertson, Stephanie Chamberlin, Sarah Braunstein, Levi Waldron, Sarah Kulkarni and Mary Irvine. A comparison group analysis aimed at assessing HIV care coordination program effectiveness. International Association of Providers of AIDS Care (IAPAC) Conference. Miami, 2016. (Oral abstract #48)
14. Angela Parcesepe, Batya Elul, Zenebe Melaku, Susie Hoffman, Sarah Gorrell Kulkarni, Tsigereda Gadisa, Robert Remien, Olga Tymejczyk, and **Denis Nash**. Psychological Distress and Recent HIV Diagnosis in Oromia, Ethiopia. International Association of Providers of AIDS Care (IAPAC) Conference. Miami, 2016. (Oral abstract #124)
15. Carol-Ann Swain, Lou Smith, **Denis Nash**, Wendy Pulver, Bridget Anderson, Guthrie S. Birkhead and Louise-Anne McNutt. Postpartum HIV Care among Women Diagnosed during Pregnancy in New York State. American Public Health Association Meeting, 2016 (Poster Abstract #358455)
16. Angela Parcesepe, Olga Tymejczyk, Robert Remien, Tsigereda Gadisa, Sarah Gorrell-Kulkarni, Susie Hoffman, Zenebe Melaku, Batya Elul, and **Denis Nash**. Decision-making power, psychological distress and quality of life among women initiating ART in Oromia, Ethiopia. American Public Health Association Meeting, 2016 (Oral Abstract #359005)
17. Adedimeji, A. Edmonds, D. Hoover, Q. Shi, J.D. Sinayobye, T. Niyongabo, K. Anastos, **D. Nash**, M. Yotebeing. Characteristics of children entering care and at antiretroviral therapy initiation in the Central Africa IeDEA cohort, 2004-2013. Central Africa IeDEA Collaboration. International AIDS Society Meeting, Durban, South Africa, 2016 (Abstract # WEPEE652).
18. H.A. Yumo, R.A. Ajeh, M. Beissner, I. Sieleunou, M.N. Akindeh, P.B. Kuwuh, D. Addison, A.A. Adedimeji, **D. Nash**, K. Anastos, C. Kuaban, T. Loescher, for the ASPA Study Group. Reaching out to children of people living with HIV/AIDS with HIV testing, care and treatment: preliminary results of the Active Search for Pediatric HIV/AIDS (ASPA) study in Cameroon. International AIDS Society Meeting, Durban, South Africa, 2016 (Abstract # TUPEE493).
19. Sarah L. Braunstein, McKaylee Robertson, Julie Myers, Bisrat Abraham, and **Denis Nash**. Reductions in the Time From HIV Infection to ART Initiation in New York City. Conference on Retroviruses and Opportunistic Infections (CROI). Seattle 2015 (Abstract #1001)

Denis Nash
Curriculum Vitae

20. S. Kesselring, S. Parashar, A. Kaida, Z. Cui, N. Oliveira, G. Colley, C. Osborne, H. Samji, M. Kestler, R. Baltzer-Turje, L. McCandless, **D. Nash**, D. Moore, R. Hogg. Socio-economic and clinical factors associated with late initiation of antiretroviral therapy: preliminary results from the ENGAGE cohort study. International AIDS Society Meeting, Vancouver, British Columbia, 2015 (Abstract # WEPED856).
21. Georgina Osorio, Megan Ghiroli, Sylvia Nyamu, Beth Hribar, Mary Johnson, Christopher Beattie, Rituparna Pati, Ana Ventuneac, **Denis Nash**, and Jeffrey T. Parsons. A randomized controlled trial on the use of patient navigators to facilitate health outcomes in formerly incarcerated individuals during community re-entry. American Public Health Association Meeting, 2015 (Roundtable Abstract #331129)
22. Christina Ventura-DiPersia and **Denis Nash**. Using Technology and Faculty-Student Collaboration to Standardize the Teaching of Essential Public Health Concepts: The City University of New York, School of Public Health Epidemiology Glossary Pilot Project. American Public Health Association Meeting, 2015 (Oral Abstract #319658).
23. Ashly Jordan, Don C. Des Jarlais, Kamyar Arasteh, Courtney McKnight, **Denis Nash**, and David C. Perlman. [Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013](#). American Public Health Association Meeting, 2015 (Oral Abstract #316566)
24. Stephanie Chamberlin, Mary Irvine, Rebekkah Robbins, Sarah Gorrell Kulkarni, McKaylee Robertson, and **Denis Nash**. Improved Care Engagement and Viral Load Suppression Among HIV Care Coordination Clients with Poor Mental Health, Unstable Housing, and Substance Use at Baseline. International Association of Providers of AIDS Care (IAPAC) Conference. Miami, 2015. (Oral abstract #109)
25. Irvine MK, Chamberlin SA, Robbins RS, Myers JE, Harriman GA, Braunstein SL, Mitts BJ, Kulkarni SG, **Nash D**. Robust short-term effectiveness of a comprehensive Care Coordination Program (CCP) in New York City (NYC). American Public Health Association Annual Meeting, New Orleans 2014.
26. Mary Irvine, Stephanie Chamberlin, Rebekkah Robbins, Julie Myers, Graham Harriman, Sarah Braunstein, Beau Mitts, Sarah Gorrell Kulkarni, and **Denis Nash**. Robust short-term effectiveness of a Comprehensive HIV Care Coordination Program in New York City. International Association of Providers of AIDS Care (IAPAC) Conference. Miami, 2014. (Oral abstract #363)
27. Tsigereda Gadisa, Olga Tymejczyk, Sarah Gorrell Kulkarni, Susie Hoffman, Robert Remien, Maria Lahuerta, Muluneh Yigzaw, Shalo Daba, Batya Elul, **Denis Nash**, and Zenebe Melaku. #367 HIV Disclosure History among Persons Initiating Antiretroviral Therapy at 6 Ethiopian HIV Clinics, 2012-2013. International Association of Providers of AIDS Care (IAPAC) Conference. Miami, 2014. (Oral abstract #367)
28. Olga Tymejczyk, Susie Hoffman, Sarah Gorrell Kulkarni, Tsigereda Gadisa, Maria Lahuerta, Robert Remien, Batya Elul, Wafaa El-Sadr, Zenebe Melaku, and **Denis Nash**. HIV Care and Treatment Beliefs among Patients Initiating Antiretroviral Therapy in Oromia, Ethiopia. International Association of Providers of AIDS Care (IAPAC) Conference. Miami, 2014. (Oral abstract #368)
29. R Pati, C Beattie, J Park, **D Nash**, and V Sharp. Factors Associated with LTC in a Large HIV Care Center of NYC. International Association of Providers of AIDS Care (IAPAC) Conference. Miami, 2014. (Oral abstract #375).

Denis Nash, PhD, MPH
Curriculum Vitae

30. S. Gorrell Kulkarni, T. Gadisa, S. Hoffman, H. Nuwagaba-Biribonwoha, Y. Wu, B. Elul, Z. Melaku, **D. Nash**. Patterns and motivation for HIV testing and time from HIV diagnosis to ART initiation at six clinics in Ethiopia. International Conference on HIV Treatment and Prevention Adherence, Miami, 2013.
31. Irvine MK, Chamberlin SA, Robbins RS, Myers JE, Harriman GA, Braunstein SL, Mitts BJ, Kulkarni SG, **Nash D**. Robust short-term effectiveness of a comprehensive Care Coordination Program (CCP) in New York City (NYC). International Conference on HIV Treatment and Prevention Adherence, Miami 2014.
32. Tracy Garber, Heidi E. Jones, and **Denis Nash**. HIV testing and mental illness in New York City: Results from the 2009 New York City community health survey. American Public Health Association Meeting, 2014 (Oral Abstract #290263)
33. J. Tesoriero, **D. Nash**, J. Pendergast, K. Piersanti, H. Reukauf, R. Remien, K. Elkington, C. Koenigsmann. Assessing HIV-related stigma and perceptions of medical care in NYS correctional settings: findings from surveys of medical staff, correctional officers and inmates. International AIDS Society Meeting, Melbourne, Australia, 2014 (Abstract # THPE182).
34. Yusuf Ransome, Arpi Terzian, Diane Addison, Sarah Braunstein, Julie Myers and **Denis Nash**. [Expanded HIV testing coverage is associated with decreases in late HIV diagnoses](#), New York City (NYC), 2001-2010. International Association of Providers of AIDS Care (IAPAC) Conference. Miami, 2013. (Oral abstract #182)
35. S. Gorrell Kulkarni, S. Hoffman, T. Gadisa, M. Fantahun, K. Misra, M. Yigzaw, S. Daba, Z. Melaku, **D. Nash**, B. Elul. Barriers to HIV care enrollment, retention, and timely ART initiation: Provider perspectives at 4 Ethiopian HIV clinics. International Conference on HIV Treatment and Prevention Adherence, Miami 2013.
36. S. Hoffman, Y. Wu, W. El-Sadr, Maria Lahuerta, H. Nuwagaba-Biribonwoha, V. Mugisha, M. Hawken, E. Chuva, **D. Nash**, and B. Elul. Levels and determinants of enrolling in HIV care with advanced disease in sub-Saharan Africa. Conference on Retroviruses and Opportunistic Infections, Atlanta, 2013.
37. Irvine, M., Chamberlin, S., Robbins, R., and **Nash, D.** (2013). Care engagement and viral suppression in comprehensive HIV care coordination clients: Baseline characteristics and pre- and post- enrollment outcomes. Poster, CROI, Atlanta, GA.
38. M. Lahuerta, S. Hoffman, B. Elul, Y. Wu, S. Gorrell Kulkarni, R. Remien, H. Nuwagaba-Biribonwoha, J. Lima, W. El-Sadr, **D. Nash**, and the LSTART Team and the Identifying Optimal Models of HIV Care Collaboration. Change over Time in CD4+ Count and Disease Stage at Entry into Care and ART Initiation: 9 Countries in Sub-Saharan Africa. Conference on Retroviruses and Opportunistic Infections, Seattle, 2012.
39. S. Gorrell Kulkarni, S. Hoffman, T. Gadisa, M. Fantahun, K. Misra, M. Yigzaw, S. Daba, Z., Melaku, **D. Nash**, B. Elul. Barriers to HIV care enrollment, retention, and timely ART initiation: Provider perspectives at 4 Ethiopian HIV clinics. International Conference on HIV Treatment and Prevention Adherence, Miami, 2012.
40. E.H. Geng, T.B. Neilands, R. Moore, S.G. Deeks, P. Easterbrook, R. Wood, F. Little, **D. Nash**, J. Nachega, D.M. Zannou, C. Yiannoutsos, R. Thiebaut, S. Reynolds, E. Vittinghoff, J.N. Martin. CD4+ T cell recovery during suppression of HIV replication on antiretroviral therapy: a global comparison of immunologic efficacy. International AIDS Society Meeting, Washington, DC, 2012 (Abstract # LBPE25)

Denis Nash
Curriculum Vitae

41. S. Gorrell Kulkarni, J. Lugalla, G. Antelman, W. Reidy, **D. Nash**, B. Elul. Barriers and enablers to retention in HIV care among patients not yet eligible for ART: A qualitative assessment in rural Tanzania. International Conference on HIV Treatment and Prevention Adherence, Miami 2012.
42. Elul et al. High levels of adherence and viral suppression in a nationally representative sample of adults on ART 6, 12 and 18 months after initiation in Rwanda. 2011 International AIDS Society (IAS) Conference. Rome, Italy.
43. **Denis Nash**. Retention in Care in African Settings. Invited Panel. International Association of Providers of AIDS Care (IAPAC) Conference. Miami, 2011.
44. Vreeman RC, Ayaya SO, Nyandiko WM, Musick BS, Yiannoutsos C, **Nash D**, Wabwire D, Wiehe SE. Adherence to Antiretroviral Therapy Among HIV-Infected Children in East Africa International Epidemiologic Databases to Evaluate AIDS (IeDEA). 2011 International AIDS Society (IAS) Conference. Rome, Italy.
45. R. Pati, M. Lahuerta, M. Okamura, M. Fernanda Alvim, B. Schackman, H. Bang, R. Fernandes, B. Elul, H. Nuwagaba-Biribonwoha, A. Assan, J. Lima, E.J. Abrams, and **D. Nash** for the Identifying Optimal Models of HIV Care in Mozambique Study Group. Factors associated with loss to clinic (LTC) among HIV patients not yet known to be clinically eligible for antiretroviral therapy (ART) in Mozambique. 2011 International AIDS Society (IAS) Conference. Rome, Italy.
46. Saito S, Reid M, Howard A, Elul B, **Nash D**. [TB diagnostic capacity in sub-Saharan African HIV care settings](#). 2011 International AIDS Society (IAS) Conference. Rome, Italy.
47. Howard, S. Saito, **D. Nash**, R. Flam, B. Elul, A. Scardigli, B. Oyeledun, A. Cunningham, D. Hoos, W. El-Sadr and International Center for AIDS Care and Treatment Programs. On-site location of TB Services is associated with TB Screening of HIV-infected patients at enrollment in HIV care programs: 6 Sub-Saharan African countries. Conference on Retroviruses and Opportunistic Infections, Montreal, 2009.
48. H. Nuwagaba-Biribonwoha, A. Cunningham, A. Almeida, M. Tun, S. Saito, B. Elul and **D. Nash**. A web-based Unified Reporting System (URS) to facilitate real time reporting and results feedback. HIV/AIDS Implementers Meeting, Windhoek, 2009.
49. Anema, S.D. Weiser, R.S. Hogg, W. Zhang, J.S.G. Montaner, B. Elul, S. Kelbert, W. El-Sadr and **D. Nash**. Prevalence and correlates of nutrition support services in PEPFAR-supported programs from 9 Sub-Saharan African countries. 5th IAS Conference on HIV Pathogenesis and Treatment, Cape Town, 2009.
50. H. Nuwagaba-Biribonwoha, J. Chale, A. Almeida, J. Chintowa, B. Kasambala, I. Sanga, P. Rugimbanya, A. Kitira, R. Mbatia, A. Cunningham, S. Saito, B. Elul and **D. Nash**. Successful implementation of HIV care and treatment services at primary health centres: improving access to ART in resource limited settings. 5th IAS Conference on HIV Pathogenesis and Treatment, Cape Town, 2009.
51. **D. Nash**, Y. Wu, S. Gandhi, M. Manyasha, R. Ntuny, B. Elul, W. El-Sadr for the International Center for AIDS Care and Treatment Programs (ICAP). Program-level determinants of low CD4 count ART initiation in cohorts of persons aged ≥ 6 years initiating ART in 8 sub-Saharan African countries. 5th IAS Conference on HIV Pathogenesis and Treatment, Cape Town, 2009.
52. **D. Nash**, M. Lamb, M.F. Alvim, M. Okamura, H. Nuwagaba-Biribonwoha, B. Elul, C. Xavier, A. Assan, J. Lima, W. El-Sadr and D. Arakaki-Sanchez. Factors associated with advanced HIV disease at ART initiation among adults in HIV care and treatment programs in Mozambique. 5th IAS Conference on HIV Pathogenesis and Treatment, Cape Town, 2009.

Denis Nash, PhD, MPH
Curriculum Vitae

53. H. Nuwagaba-Biribonwoha, J. Chale, A. Almeida, P. Rugimbanya, A. Kitira, J. Chintowa, B. Kasambala, I. Sanga, R. Mbatia, A. Cunningham, S. Saito, B. Elul and **D. Nash**. Successful expansion of HIV care and treatment services to primary health centres: improving access to ART in resource limited settings. 5th IAS Conference on HIV Pathogenesis and Treatment, Cape Town, 2009.
54. **D. Nash**, C. Korves, S. Saito, S. Sherman, B. Elul, D. Hoos, V. Mugisha, M. Sheriff, W. El-Sadr, and Intl Center for AIDS Care and Treatment Programs (ICAP). Characteristics of facilities and programs delivering HIV care and treatment services are associated with loss to follow-up rates in programs from 7 Sub-Saharan African countries. Conference on Retroviruses and Opportunistic Infections, Boston, 2008.
55. W. El-Sadr, W. Lo, B. Elul, D. Hoos, M. Rabkin, T. Ellerbrock and **D. Nash**. Rates of enrollment across and within sites in rapidly expanding HIV care and treatment programs in 7 Sub-Saharan African countries. HIV/AIDS Implementers Meeting, Kigali, 2007.
56. **D. Nash**, C. Korves, B. Elul, M. Rabkin, J. Lima, D. Macharia, D. Hoos, T. Ellerbrock and W. El-Sadr. Age and sex distribution of patients enrolled in HIV care and treatment programs compared with that of the HIV epidemic in 7 Sub-Saharan African countries. HIV/AIDS Implementers Meeting, Kigali, 2007.
57. W. El-Sadr, B. Elul, W. Lo and **D. Nash**. Temporal trends in CD4 count at initiation of antiretroviral therapy (ART) and 6 month CD4 response among a large population of HIV-infected individuals receiving HIV care and treatment in 7 sub-Saharan African countries. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, 2007.
58. N. Butamanya, K. Mhando, G.F. Chanpong, S. Brasch, J. Ndayongeje, G. Somi, B. Bwijo, R. Swai, B. Semo, M. Hawken, J. Justman, B. Elul, W. El-Sadr and **D. Nash**. Quality of care improvements related to enhanced HIV-patient monitoring and tracing at Sekou Toure regional hospital, Mwanza, Tanzania. XVI International AIDS Conference, Toronto, 2006.
59. R. Swai, B. Semo, M. Hawken, J. Justman, B. Elul, W. El-Sadr and **D. Nash**. Quality of care improvements related to enhanced HIV-patient monitoring and tracing at Sekou Toure regional hospital, Mwanza, Tanzania. XVI International AIDS Conference, Toronto, 2006.
60. P.W. Young, B. Elul, D. Winchell, D. Arakaki-Sanchez, R. Fernandes, M. Rosenthal and **D. Nash**. An assessment of patient and staff satisfaction with services at an HIV/AIDS care and treatment clinic in Nampula, Mozambique. XVI International AIDS Conference, Toronto, 2006.
61. W. El-Sadr, B. Elul, M. Rabkin, M. Hawken, J. Lima, D. Macharia, Z. Melaku, R. Sahabo, J. Justman, E. Abrams, J. Kim, M. Rosenthal, M. Tun, D. Horowitz, A. Berkman and **D. Nash**. Rapid expansion of HIV/AIDS care and treatment programs in 6 Sub-Saharan countries. XVI International AIDS Conference, Toronto, 2006.
62. W. El-Sadr, B. Elul, M. Rabkin, M. Hawken, J. Lima, D. Macharia, Z. Melaku, R. Sahabo, J. Justman, E. Abrams, J. Kim, M. Rosenthal, M. Tun, D. Horowitz, A. Berkman and **D. Nash**. Rapid expansion of HIV/AIDS care and treatment programs in 6 Sub-Saharan countries. XVI International AIDS Conference, Toronto, 2006.
63. **D. Nash**, D. Hoos, M. Rosenthal, B. Musick, G. Chanpong, K. Reed, S. Casey, M. Hawken, D. Macharia, J. Lima, and W. El Sadr. Expansion of HIV/AIDS care and treatment programs in 5 countries in Sub Saharan Africa. Presented at International AIDS Society (IAS) Annual Meeting, 2005, Rio de Janeiro, Brazil.
64. Toro P, Austin J, Abrams E, Katyal M, Day J, El-Sadr W, **Nash D**. Response to Antiretroviral Therapy (ART) in the MTCT-Plus Initiative, a Multi-Country HIV Care and Treatment Program in

Denis Nash
Curriculum Vitae

- Resource-Limited Countries. Presented at International AIDS Society (IAS) Annual Meeting, 2005, Rio de Janeiro, Brazil.
65. WM El-Sadr, EJ Abrams, D Hoos, M Rabkin, J Justman, TW Hardy and **D Nash**. Design of HIV Care and Treatment Programs Impacts on Populations Enrolled. Presented at International AIDS Society (IAS) Annual Meeting, 2005, Rio de Janeiro, Brazil.
 66. EJ Abrams, M Katyal, **D Nash**, P Toro, Jeanne Day and WM El-Sadr. Response to Antiretroviral Therapy in Children Enrolled in the Columbia MTCT-Plus Initiative. Presented at International AIDS Society (IAS) Annual Meeting, 2005, Rio de Janeiro, Brazil.
 67. **Nash D**, Fuller C, Blaney S, Ompad D, Cumberbatch S, Galea S, Vlahov D. The relationship between neighborhood HIV prevalence and other neighborhood level indicators to HCV prevalence in a sample of recently initiated injecting drug users in New York City. Poster presented at the International AIDS Conference, 2005, Bangkok, Thailand.
 68. Torian L, Bennani Y, Wethers J, Schwendemann J, **Nash D**. Use of the Serologic Testing Algorithm for Recent HIV Seroconversion to Assess Specificity of Routine Surveillance to Detection of Incident vs Prevalent HIV: Evaluation of the First 2 Years of Named HIV Reporting, New York City, June 1, 2000 to June 30, 2002. Paper presented at: 11th Annual Conference on Retroviruses and Opportunistic Infections (CROI), 2004; San Francisco, CA.
 69. Ompad D, Fuller C, Galea S, Wu Y, **Nash D**, Benjamin E, Vlahov D. Sexual risk is associated with HIV among injection and non-injection drug users: Implications for intervention strategies. Paper presented at: American Public Health Association (APHA), 2004; Washington, DC.
 70. Ompad D, Fuller C, Galea S, Wu Y, **Nash D**, Benjamin E, Vlahov D. Sexual risk is associated with HIV among injection and non-injection drug users: Implications for intervention strategies. Paper presented at: International AIDS Conference, 2004; Bangkok, Thailand.
 71. **Nash D**, Manning S, Ramaswamy C. Descriptive epidemiology of HIV/AIDS in New York City: Incorporation of newly available population-based surveillance data on HIV (non-AIDS), 2001. Paper presented at: 11th Annual Conference on Retroviruses and Opportunistic Infections (CROI), 2004; San Francisco, CA.
 72. **Nash D**, Gboun M, Sani-Gwarzo N, Mohommed M. The effect of antenatal clinic policies and practices on sentinel surveillance for HIV: Nigeria, 2001. Paper presented at: 4th National Conference on HIV/AIDS in Nigeria, 2004; Abuja, Nigeria.
 73. **Nash D**, Velez-May A. Surveillance for HIV/AIDS in the emerging context of antiretroviral treatment availability in Nigeria. Paper presented at: 4th National Conference on HIV/AIDS in Nigeria, 2004; Abuja, Nigeria.
 74. **Nash D**, Fuller C, Blaney S, Ompad D, Cumberbatch S, Galea S, Vlahov D. The relationship between neighborhood HIV prevalence and other neighborhood level indicators to HCV prevalence in a sample of recently initiated injecting drug users in New York City. Paper presented at: International AIDS Conference, 2004; Bangkok, Thailand.
 75. Mohommed M, Gboun M, Sani-Gwarzo N, **Nash D**. HIV/syphilis seroprevalence in Nigeria: Results of the 2001 National Sentinel Surveillance Survey of women attending antenatal clinic. Paper presented at: 4th National Conference on HIV/AIDS in Nigeria, 2004; Abuja, Nigeria.
 76. Manning S, Ramaswamy C, Hajat A, Thorpe L, Karpati A, Marx M, Mostashari F, Pfeiffer M, **Nash D**. Paper presented at: 11th Annual Conference on Retroviruses and Opportunistic Infections (CROI), 2004; San Francisco, CA.
 77. Manning S, Schillinger J, Ramaswamy C, Shao M, Singh T, Sackoff J, Blank S, **Nash D**. Incidence of sexually transmitted infections among persons previously diagnosed and living with

Denis Nash, PhD, MPH
Curriculum Vitae

- HIV/AIDS in New York City: Preliminary findings from a registry cross-match. Paper presented at: Conference on Sexually Transmitted Diseases, 2004; Philadelphia, PA.
78. Bennani Y, **Nash D**, Schwendemann J, Ramaswamy C, Wethers J, Torian L. Population-based estimates of HIV incidence using the sensitive/less sensitive EIA, New York City, 2001. Paper presented at: 11th Annual Conference on Retroviruses and Opportunistic Infections (CROI), 2004; San Francisco, CA.
 79. Schillinger J, **Nash D**, Selenic D, Shao M, Hajat A, Cobb L, Neylans L, Mathieu J, Mostashari F, Blank S. An ecologic analysis of *Neisseria gonorrhoeae* infection among men who have sex with men in NYC. Paper presented at: International Society for Sexually Transmitted Disease Research (ISSTD), 2003; Toronto.
 80. Manning S, Ramaswamy C, Katyal M, Bennani Y, Quintyne R, Jones L, Figueroa D, Ly S, Forlenza S, Sackoff J, Torian L, **Nash D**. Epidemiologic Data From the First Full Year of Named HIV Surveillance -- New York City, January - December, 2001. Paper presented at: American Public Health Association, 2003; San Francisco.
 81. **Nash D**, Jones L, Ly S, Sackoff J, Singh T, Shum R, Thomas P, Weisfuse I, Forlenza S. Implementation of named surveillance for Human Immunodeficiency Virus (HIV) infection in New York City (NYC): Preliminary data on the first 18 months of HIV reporting. Paper presented at: International AIDS Conference, 2002; Barcelona.
 82. **Nash D**, Labowitz A, Maldin B, Martin D, Mostashari F, Fine A, Roehrig J, Campbell G, Layton M. Follow-Up Study of Persons Infected During the 1999 New York City Area Outbreak of West Nile Viral Disease. Paper presented at: Society for Epidemiologic Research (SER), 2001; Toronto, Canada.
 83. **Nash D**, Fordyce E, Singh T, Forlenza S. Trends in mortality rates among reported AIDS cases in New York City, 1990-1998. Paper presented at: Infectious Disease Society of America (IDSA), 2001; San Francisco, CA.
 84. **Nash D**, Labowitz A, Maldin B, Martin D, Mostashari F, Fine A, Roehrig J, Campbell G, Layton M. A Follow-Up Study of Persons Infected During the 1999 New York City Area Outbreak of West Nile Viral Disease. Paper presented at: Infectious Disease Society of America, 2001. Paper presented at: Infectious Disease Society of America (IDSA), 2001; San Francisco, CA.
 85. **Nash D**, Fordyce E, Singh T, Forlenza S. Trends in mortality among reported AIDS cases, New York City, 1990-1998. Paper presented at: International AIDS Conference, 2000; Durban, South Africa.
 86. Strickland G, **Nash D**, Trevant C, Trevant C, de Souza J, da Silva R, Silbergeld E. Mercury exposures and disease prevalence among garimpeiros (gold miners) in Para, Brasil, 1997. Paper presented at: 5th International Conference on Mercury as a Global Pollutant, 1999; Rio de Janeiro.
 87. **Nash D**, Strickland G, Trevant C, de Souza J, da Silva R, Silbergeld E. Mercury exposure, toxicity, and malaria prevalence among Brazilian Gold miners. Paper presented at: Society of Toxicology (SOT), 1999; New Orleans, LA.
 88. **Nash D**, Silbergeld E, Sherwin R, Magder L, Rubin R, Stolley P. The relationship of blood lead and use of hormone replacement therapy to cognitive function among adult women from NHANES III, 1988-1994. Paper presented at: Society for Epidemiologic Research (SER), 1999; Baltimore, MD.
 89. **Nash D**, Silbergeld E, Sherwin R, Magder L, Rubin R, Stolley P. The relationship of blood lead to blood pressure and hypertension among adult women from NHANES III, 1988-1994. Paper presented at: Society for Epidemiologic Research, 1999; Baltimore, MD.

Denis Nash
Curriculum Vitae

90. **Nash D**, Rhodes J, Silbergeld E. Defining menopausal status in health survey settings: Is there room for improvement? Paper presented at: Conference on Health in the New Millennium, 1999; Washington, DC.
91. **Nash D**, Fine A, Mostashari F, Miller J, Layton M, Gubler D, Roehrig J, Campbell G, Wong S, Smith P. Clinical characteristics of 43 serologically positive, clinical cases of West Nile virus infection in New York City, 1999. Paper presented at: American Society of Tropical Medicine and Hygiene, 1999.
92. **Nash D**, Silbergeld E, Magder L, Stolley P. Menopause, hormone replacement therapy (HRT), and blood lead levels among adult women from NHANES III, 1988-1994. Paper presented at: Society for Epidemiologic Research (SER), 1998; Atlanta, GA.
93. Lasky T, Koski L, Magder L, Ballesteros M, **Nash D**. Flu vaccination and Guillain Barré Syndrome. Paper presented at: Society for Epidemiologic Research (SER), 1997.
94. Cooper C, Eslinger D, **Nash D**, Al-Zarwarhi J, Stolley P. Repeat victims of trauma: who are they and how can we intervene? Paper presented at: American Association of Surgical Trauma, 1997.